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AD:      Autosomal dominant 
ACE:      Angiotensin converting enzyme 
ADPKD:    Autosomal dominant polycystic kidney disease 
AR:      Autosomal recessive 
ARPKD:    Autosomal recessive polycystic kidney disease 
BC1:      Backcross 1 
BN/ssArc
-/-:    Brown Norway 
bpk:      BALK/c polycystic kidney 
CAML:    Calcium ion modulating cyclophilin ligand 
cAMP:     Cyclic adenosylmonophosphate 
CHF:      Congenital hepatic fibrosis 
Cl
!:      Chloride anion 
cM:      CentiMorgan 
cpk:      Congenital polycystic kidney 
DNA:      Deoxyribonucleic acid 
ECM:      Extracellular matrix 
EDTA     Ethylenediaminetetraacetic acid 
EGFR:     Epidermal growth factor receptor 
ESRD:     End stage renal disease 
F2:      Second filial generation 
FC:      Fibrocystin  
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inv:      Inversion of embryonic turning 
jck:      Juvenile cystic kidney 
jcpk:      Juvenile congenital polycystic kidney 
Kat:      Kidney, anemia, testis 
LEW/SsNArc
-/-:  Lewis 
LOD:      Logarithm of odds 
LPK/SsNArc
+/+:  Lewis polycystic kidney 
LRS      Likely Ratio Statistics 
mTOR:    Mammalian target of rapamycin 
Na
+:      Sodium cation 
NaCl:      Sodium chloride 
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PC-2:      Polycystin-2 
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PKD:      Polycystic kidney disease 
PKD-1:    Polycystic kidney disease 1 gene in human 
PKD-2:    Polycystic kidney disease 2 gene in human 
PKD-3:    Polycystic kidney disease 3 gene in human  
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Pkd-1:     Polycystic kidney disease 1 gene in murine models 
Pkd-2:     Polycystic kidney disease 2 gene in murine models 
PKHD-1:    Polycystic kidney and hepatic disease 1 gene in human 
Pkhd-1:  Polycystic  kidney  and  hepatic  disease  1  gene  in  murine 
models 
QTL:      Quantitative trait locus 
RAAS:     Renin-aldosterone-angiotensin system 
RFLP:     Restriction fragment length polymorphism 
RGD:      Rat Genome Database 
RISC:      RNA induced silencing complex 
RNAi:     Ribonucleic acid interference 
SNP:      Single nucleotide polymorphism 
SNS:      Sympathetic nervous system 
SSR:      Simple sequence repeat 
TBE:      Tris-base-Boric acid-EDTA 
TBM:      Tubular basement membrane 
TRP:      Transient receptor protein 
TSC2:     Tubular sclerosis 
TSP:      Total solid protein 
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V2R:      Vasopressin-2-receptor 
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-/-:   Wistar Kyoto 
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Summary 
Polycystic kidney disease (PKD) is a life-threatening disorder that affects millions of 
people all over the world. The disease is usually inherited, but it can also be acquired 
and it leads to development of many cysts in the kidneys, liver, pancreas, brain, 
spleen, ovaries and testes. The major types of inherited PKD are autosomal dominant 
(AD) and autosomal recessive (AR) polycystic kidney disease. ADPKD is caused by 
mutations in PKD-1 (polycystin-1), PKD-2 (polycystin-2) or PKD-3 (polycystin-3) 
and it is mostly diagnosed in adults. ARPKD is caused by mutation in the polycystic 
kidney  and  hepatic  disease  gene  1  (PKHD-1,  fibrocystin)  and  it  is  commonly 
diagnosed in neonates and infants. In murine models of the disease, the Pkd-1, Pkd-2 
and Pkhd-1 genes are the homologs of human PKD genes and mutations in these 
genes cause PKD that resembles the human PKD. The common clinical features of 
PKD in all animal species are: development of bilaterally enlarged cystic kidneys, 
development  of  extra-renal  cysts,  development  of  higher  systolic  blood  pressure, 
development of anemia, and deterioration of the kidney functions, leading to end 
stage renal disease. 
 
In the present study, a spontaneous mutation occurred in the Lewis rat strain and this 
resulted in development of PKD in the mutant rats. Mating experiments between the 
mutant  rats,  now  referred  to  as  Lewis  Polycystic  Kidney  rats  (LPK/SsNArc
+/+), 
produced all progeny with cystic kidneys. Unlike other forms of PKD, the PKD in 
this rat model did not lead to infant deaths and it did not lead to development of 
extrarenal cysts. Furthermore, the inheritance of the disease, the chromosome and  
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the  quantitative  trait  locus  (QTL)  that  harbors  the  mutation  responsible  for  the 
disease were not known. For these reasons, the inheritance of the disease in the 
LPK/SsNArc
+/+ rats was determined. Genetic mapping to identify the region that 
controls the PKD phenotypes using 92 polymorphic simple sequence repeat markers, 
covering the genome of the 20 rat autosomes, was carried out. Linkage analyses 
between marker genotypes and phenotypic trait data in 152 F2 and 139 BC1 progeny 
was performed and the QTL identified. 
 
The PKD was inherited as an ARPKD, controlled by a recessive mutation in a single 
gene (F2: PKD = 42, non-PKD = 110, "
2 = 0.53; BC1: PKD = 63, non-PKD = 76, "
2 
= 0.18, P > 0.05). The PKD rats developed larger cystic kidneys: F2: %K/B weight = 
3.48 ± 0.30, n = 42; BC1: %K/B weight = 4.53 ± 0.20, n = 67, than the non-PKD 
rats, F2: %K/B weight = 0.79 ± 0.01, n = 110; BC1: %K/B weight = 0.85 ± 0.02, n = 
72, (P < 0.001). The PKD rats developed higher systolic blood pressure: F2: SBP = 
160 ± 3 mmHg, n = 42; BC1: SBP = 164 ± 2 mmHg, n = 67, than the non-PKD rats, 
F2: SBP = 117 ± 3 mmHg, n = 110; BC1: SBP = 116 ± 1 mmHg, n = 72, (P < 
0.001). The PKD rats developed anemia: F2: PCV = 0.44 ± 0.01, n = 31; BC1: PCV 
= 0.44 ± 0.01, n = 47, compared to the non-PKD rats, F2: PCV = 0.48 ± 0.00, n = 69; 
BC1: PCV = 0.50 ± 0.00, n = 55, (P < 0.001). The PKD rats were less able to 
concentrate urine: BC1: urine P/C ratio = 1.31 ± 0.15, n = 58 compared to the non-
PKD rats, urine P/C ratio = 0.76 ± 0.07, n = 65, (P < 0.001).  
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In  the  BC1  progeny,  the  PKD  trait  linked  to  marker  D10Rat43  on  chromosome 
10q21,  giving  a  LOD  score  of  7.9  with  D10Rat218,  (P  =  0.00001).  In  the  F2 
progeny, the PKD trait linked to marker 10Rat26 on chromosome 10q21, giving a 
LOD score of 5.1 with D10Rat43, (P = 0.00001). All the other phenotypic traits in 
the  BC1  and  the  F2  progeny  also  linked  to  the  same  QTL,  and  D10Rat43  and 
D10Rat26 are the peak markers, spanning a total genetic distance of 23.76 cM on rat 
chromosome 10q21. 
 
The QTL region that controls the PKD phenotype does not contain the Pkhd-1 gene 
known to be responsible for ARPKD in well-characterized murine models. The QTL 
maps to human chromosome 5q34-5q35 and to mouse chromosomes 11C and 18B1. 
The  location  of  the  QTL  in  10q21  has  excluded  the  LPK/SsNArc
+/+  locus  as  a 
candidate homolog for PKHD-1, which was located on human chromosome 6p21-
p12. It has also excluded the wpk locus, which maps to rat chromosomes 5q13 and 
10q25, and the bpk locus, which maps to mouse chromosome 10, the cpk locus, 
which maps to chromosome 12 and the orpk locus, which maps to chromosome 14, 
as homologs. 
 
The candidate genes located in the QTL are the methionine adenosyltransferase II#, 
kidney injury molecule 1, gamma-aminobutyric acid receptor gamma 2, pituitary 
tumor-transforming gene 1, C1q, and tumor necrosis factor 2, eukaryotic translation 
initiation factor 4 gamma 1 and cyclin J-like. The proteins encoded by these genes 
are not homologous to, do not have common domains with fibrocystin, except for a 
signal peptide domain found between methionine adenosyltransferase II#, kidney  
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injury  molecule  1  and  fibrocystin.  However,  the  genes  are  important  in  signal 
transduction,  cell  growth,  cell  proliferation,  apoptosis  and  cell  differentiation. 
Mutations in these genes were previously linked to cellular aberrations and tumors in 
various human organs. 
 
In conclusion, the results presented in this thesis support the general hypothesis that 
a  recessive  mutation  in  a  single  gene  was  responsible  for  the  development  and 
inheritance of PKD in the LPK/SsNArc
+/+ rats. The ratios: 42:110 in the F2 progeny 
and 67:72 in the BC1 progeny for PKD to non-PKD rats do not significantly deviate 
from Mendelian segregation ratios of 1:3 in the F2 and 1:1 in the BC1, and therefore, 
support the requirement for the inheritance of a recessive mutation controlled by one 
gene. The QTL mapped is novel and it was not previously linked to ARPKD in other 
murine models. It is therefore predicted that a new gene is responsible for ARPKD in 
LPK/SsNArc
+/+ rats or an unknown mechanism is responsible for the development of 
the disease. Chromosome 10q21 is now targeted for fine genetic mapping to identify 
the actual gene that causes ARPKD. Once the gene is identified, sequencing of the 
gene in both the PKD and the non-PKD rats will be carried out to identify the type of 
mutation.  
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CHAPTER I 
General Introduction 
1.1: Introduction 
Polycystic kidney disease (PKD) is a life-threatening disorder that affects millions of 
people across the world (Martinez and Grantham, 1995; Yoder et al., 1997). The 
disease is normally inherited, but it can also be acquired, and it leads to development 
of many cysts in the renal nephrons (Pretorius et al., 1987; Welling and Welling, 
1988). In the present study, the inherited form of PKD is discussed and the major 
types of the disease are autosomal dominant (ADPKD), caused by mutations in the 
PKD-1 or PKD-2 genes, which are located on human chromosomes 16p13.3 and 
4q21-q23,  respectively  (Bertuccio  et  al.,  2009;  Mochizuki  et  al.,  1996),  and 
autosomal  recessive  (ARPKD),  caused  by  mutation  in  the  polycystic  kidney  and 
hepatic disease (PKHD-1) gene, which is located on human chromosome 6p21-p12 
(Zerres et al., 2004). 
 
In rats and mice, the genes that cause PKD are located on different chromosomes 
(Guay-Woodford et al., 1996; Nauta et al., 2000), and these genes are homologous to 
the human PKD genes. The common features of all forms of PKD in all animal 
species are development of bilaterally enlarged cystic kidneys (Lyons et al., 2004),  
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development of extra-renal cysts (Fonck et al., 2001; Qian et al., 1996), development 
of  higher  systolic  blood  pressure  (Phillips  et  al.,  2007),  development  of  anemia 
(Keith et al., 2004; Schillinger, 1993) and deterioration of the kidney functions. In 
human studies, the incidence of ADPKD is 1:500 – 1000 (Bogdanova et al., 2001; 
Chittenden et al., 2002), while that of ARPKD is 1:2000 – 14000 live births (Mucher 
et al., 1998). 
 
In the present study, the inheritance of PKD and identification of the quantitative 
trait  locus  (QTL)  responsible  for  the  disease  in  the  LPK/SsNArc
+/+  rats  will  be 
determined.  This  will  be  carried  out  by  raising  the  second  filial  (F2)  and  the 
backcross (BC1) generations and then determining the number of progeny that has 
developed PKD and the number that has not developed PKD. Deoxyribonucleic acid 
(DNA) will be extracted from the BC1 progeny and mapping analysis will be carried 
out. This will be followed by linkage analyses to identify the QTL that controls the 
disease phenotypes. 
1.2: Mechanism in Development of Cysts in PKD patients 
The precise mechanism in the development of cysts in PKD patients is not clearly 
understood, but in most human studies, proto-oncogenes c-myc, c-fos, c-jun, c-Ha-
ras and c-Ki-ras are found highly expressed in the cystic kidneys  (Martinez and 
Grantham, 1995; Rankin et al., 1992). These genes are also found highly expressed 
in cancer cells, making scientists wonder whether or not PKD is a cancer in disguise 
(Bos, 1989; Grantham, 1990; Harris and Watson, 1997). The same genes are also  
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found highly expressed in cystic kidneys of murine models of the disease (Cowley et 
al.,  1991;  Torres  and  Harris,  2006,  2007;  Torres  et  al.,  2007).  Furthermore,  the 
proteins polycystin-1 (Consortium, 1995), polycystin-2 (Mochizuki et al., 1996), and 
fibrocystin (Menezes et al., 2004) are found highly expressed in the kidneys of PKD 
patients (Harris, 2002). Polycystin-2 is involved in the translocation of calcium ions, 
causing a transient increase of the ions in the renal epithelial cells (Cantiello, 2004). 
Once cysts are formed, fluids accumulate into the cysts’ lumen, leading to kidney 
enlargement, which results in end-stage renal disease (Bogdanova et al., 2001). 
1.3: Diagnosis and Treatment of Polycystic Kidney Disease 
Presently, there are no techniques able to detect the precise time of onset of human 
PKD. However, computerized tomography scanning has been used to ascertain the 
presence of cysts in the kidneys of individuals suspected with PKD (Ishikawa et al., 
2003; Russo, 2000). It is hoped that genetic detection methods will become available 
and be used to test for predisposition of individuals to PKD in early stages of life. 
There are also no definitive therapeutic substances that prevent, or eliminate PKD, 
because the therapeutic targets of the disease are not known. Dietary regulation of 
salts and protein intake (Martinez and Grantham, 1995), kidney dialysis and kidney 
replacement (Gattone, 2005; Ishikawa, 1993) are currently used as modalities to treat 
patients with PKD. The need to silence the expression of the mutated genes that 
cause PKD is proposed here and this includes the application of RNA interference 
(RNAi) methods (Leung and Whittaker, 2005; Stanislawska and Olszewski, 2005).  
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1.4: Animal Models Used in the Study of Polycystic Kidney Disease 
A considerable amount of information on the biological processes of human PKD 
has been obtained from analysis of rodent models of the disease (Yoder et al., 1997). 
Rats and mice are useful models that are commonly used in the study of PKD (Aziz, 
1995; Dracheva et al., 2000). There are different rat and mouse models of PKD, and 
these are described in detail in Chapter II. The use of these animals in the study of 
PKD has made it possible to understand and control the genetic and environmental 
factors that underlie the development, expression and progression of PKD (Rossetti 
and Harris, 2007). 
 
In the present study, a colony from a strain of Lewis (LEW/SsNArc
-/-) rats at the 
Animal Resources Centre of Western Australia developed PKD. Mating experiments 
between the rats with the disease produced litters with PKD (data not published) and 
this colony is now called the Lewis polycystic kidney rat (LPK/SsNArc
+/+). It was 
not clear, however, whether the PKD in the LPK/SsNArc
+/+ rats was inherited as a 
dominant or as a recessive trait and whether one, two or many genes were involved 
in the development of the disease. Furthermore, it was not clear whether the gene 
responsible for PKD in the LPK/SsNArc
+/+ rats was the same gene that causes PKD 
in  other  murine  models.  Similarly,  it  was  not  clear  if  there  were  genetic  loci 
somewhere along the chromosomes that modify the inheritance of the disease and 
influence its phenotypic expression in the LPK/SsNArc
+/+ rats. 
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Therefore, to understand the genetic causes and the inheritance of the PKD in the 
LPK/SsNArc
+/+ rats, mating experiments between male mutant LPK/SsNArc
+/+ rats 
with  PKD  and  female  normal  Brown  Norway  (BN/ssArc
-/-)  and  Wistar  Kyoto 
(WKY/NArc
-/-) rats without PKD to raise second filial (F2) and backcross (BC1) 
generations, respectively, will be carried out. Mapping studies and linkage analyses 
between genotypic and phenotypic trait data to identify the quantitative trait locus 
(QTL) linked to the disease phenotypes will also be carried out. These experimental 
studies and their findings are presented in the chapters that follow. In carrying out 
this study, it was generally hypothesized that the PKD in the LPK/SsNArc
+/+ rats was 
caused by a recessive mutation in a single gene. 
 
It is hoped that the identification of the chromosome, the QTL and the gene that 
causes PKD in the LPK/SsNArc
+/+ rats will provide, at least in part, an insight into 
human PKD and therefore, a better understanding of pathogenesis of the disease. By 
careful  analysis  of  the  phenotypic  trait  data  of  the  crossbred  animals,  it  will  be 
possible  to  predict  the  existence  of  modifier  genetic  loci,  which  will  also  help 
explain the phenotypic trait variation in PKD presentation. A better understanding of 
this experimental model will facilitate future studies aimed at identification of novel 
therapeutic intervention, including possible targeted strategies to prevent progressive 
renal diseases.  
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CHAPTER II 
Literature Review 
2.1: Introduction 
Polycystic kidney disease (PKD) is a devastating, genetically inherited disorder that 
affects millions of people in the world (Harris and Torres, 2009; Torres and Harris, 
2006). However, the disease can also be acquired (Martinez and Grantham, 1995). In 
the present study, emphasis is placed on the genetically inherited PKD, although a 
brief mention of acquired PKD will also be made. Generally, all different forms of 
PKD lead to development of numerous fluid-filled cysts in the kidneys (Lyons et al., 
2004). It has, however, been observed that extra-renal cysts in the liver, pancreas, 
blood vessels, spleen, testes and ovaries are commonplace in humans and animals 
with PKD (Bacallao and Carone, 1997; Fick and Gabow, 1994; Gattone et al., 1996; 
Lager et al., 2001; Masoumi et al., 2008). The cysts in these organs is associated 
with  portal  hypertension  (Shneider  and  Magid,  2005),  intracranial  aneurysms 
(Rossetti et al., 2003), respiratory cyst related abnormalities and infertility (Manno et 
al., 2005, Okada et al., 1999).  
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There are, however, different types of diseases that also lead to the development of 
cysts in the kidneys, and these diseases include nephronophthisis (Caridi et al., 2000; 
Phillips et al., 2004) and medullary cystic kidney disease  (Stavrou et al., 2002). 
Acquired polycystic kidney disease has no known cause, but environmental factors 
and insults to the cells of the renal nephrons are associated with its development 
(Sarasin et al., 1995). Acquired PKD commonly occurs in people who are 60 years 
or older (Cody, 1997), and it is also frequently diagnosed in patients who undergo 
kidney dialysis and those with chronic glomerulonephritis (Ekart and Hojs, 2006). 
 
Nephronophthisis  (NPH)  is  characterized  by  development  of  renal  cysts  in  the 
corticomedullary junction, associated with tubulointerstitial nephritis (Haider et al., 
1998), and it is accompanied by retinitis pigmentosa, hypopituitarism and skeletal 
dysplasia (Di Rocco et al., 1997). These clinical features distinguish NPH from other 
medullary cystic disorders such as Senior-Löken syndrome (Salomon et al., 2009) 
and ARPKD (Fonck et al., 2001; Nauta et al., 2000; Ricker et al., 2000; Zerres et al., 
1998). Currently, there are three variants of NPH, distinguished by the time of onset 
of end stage renal disease (Caridi et al., 2000; Salomon et al., 2009; Tory et al., 
2009). These variants are: infantile, juvenile and adolescent NPH, all characterized 
by  chronic  tubulointerstitial  nephritis,  enlarged  kidneys  and  severe  hypertension 
(Saunier et al., 2005).  
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Infantile  NPH  is  a  chronic  tubulointerstitial  nephritis  characterized  by  cortical 
microcysts (Haider et al., 1998; Salomon et al., 2009). The symptoms of infantile 
NPH appear at the age of four to six years (Salomon et al., 2009) and the kidneys 
quickly progress to ESRD within two years (Phillips et al., 2004; Potter et al., 1980). 
Juvenile NPH is a less common form of NPH (Potter et al., 1980). Adolescent NPH 
is  inherited  as  an  autosomal  recessive  NPH  and  it  is  caused  by  mutation  in  the 
NPHP3 gene. The phenotypic expression of adolescent NPH is similar to juvenile 
NPH (Salomon et al., 2009; Tory et al., 2009). 
 
Genetic analysis of NPH using positional cloning of the candidate genes led to the 
identification  of  mutations  in  eight  different  genes,  designated  NPHP1,  NPHP3, 
NPHP4,  NPHP5,  NPHP6,  NPHP7,  NPHP8  and  NPHP9,  responsible  for  juvenile 
NPH, and NPHP2 responsible for infantile NPH (Table 2-1). Based on the clinical 
features and the genetic mutations known, NPH is therefore a different disease from, 
but has similarities with, PKD (Salomon et al., 2009; Saunier et al., 2005; Tory et al., 
2009). 
 
Medullary  cystic  kidney  disease  (MCKD)  is  inherited  in  an  autosomal  dominant 
manner (Stavrou et al., 2002). The cysts are predominantly found on the medulla, 
and the kidneys progress to renal failure at the fourth decade of human life (Stavrou 
et al., 2002). MCKD and NPH share common clinical and histological features, such 
as tubular basement membrane disintegration, tubular cyst formation, and tubulo-
interstitial inflammation and fibrosis (Caridi et al., 2000).  
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TABLE 2-1: GENETIC HETEROGENEITY OF NPH, SENIOR-LÖKEN, JOUBERT AND 
MECKEL-GRUBER SYNDROMES 
 
 
Locus  Chro  Gene/protein*  Clinical features 
NPHP1/SLSN1  2q13  NPHP1 (nephrocystin-1)  Juvenile nph (mild JBTS, mild RP) 
NPHP2  9q31  NPHP2/INVS (Inversin) 
Infantile  nph  (RP,  liver  fibrosis, 
HT) 
NPHP3/SLSN3  3q22  NPHP3 (nephrocystin-3)  Juvenile nph (liver fibrosis, RP) 
NPHP4/SLSN4  1p36 
NPHP4  (nephrocystin-)  or 
nephroretinin  Juvenile nph (Cogan, RP) 
NPHP5/SLSN5  3q21  NPHP5/IQCB1  Juvenile nph + severe RP 
NPHP6/SLSN6/JB
TS5/MKS4  12q21  NPHP6/CEP290  
Juvenile nph + JBTS + severe RP, 
isolated RP 
NPHP7  16p  NPHP7/GLIS2  Juvenile nph 
NPHP8/JBTS7/MK
S5  16q  NPHP8/RPGRIP1L  Juvenile nph + JBTS (MKS) 
NPHP9  17q11  NPHP9/NEK8  Juvenile and infantile nph 
 
JBTS: Joubert syndrome type B, 
RP: retinitis pigmentosa,  
†Meckel-Gruber syndrome,  
HT: arterial hypertension, 
*The name of the protein is indicated when it is not the same name as the gene, 
(Source: Salomon et al., 2009, Tory et al., 2009).  
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Linkage analysis in families with inherited PKD revealed that there are many genetic 
mutations involved in the development of the disease (Binczak-Kuleta et al., 2006). 
These genetic mutations, however, present with common cellular features including 
cellular  de-differentiation,  extra-cellular  matrix  remodeling  and  cell  membrane 
polarization abnormalities in all PKD patients (Ward et al., 2003). The cumulative 
effects of PKD lead to ESRD and this is of concern worldwide (Park et al., 2000). 
 
End stage renal disease is defined as the loss of kidney functions so that the kidneys 
cannot functionally sustain life (Yeates and Tonelli, 2006, Cody, 1997). However, 
the introduction of dialysis has increased the survival of patients with ESRD, and 
when they receive new and compatible kidneys, they can live longer (Dunnill et al., 
1977).  To  understand  the  phenotypic  inheritance,  expression  and  progression  of 
PKD in the present study, it is important to establish the inheritance of the PKD in 
the  LPK/SsNArc
+/+  rats.  But  for  a  better  understanding  and  appreciation  of  the 
phenotypes of PKD, it is important to have a visual picture of normal and cystic 
kidneys in the LPK/SsNArc
+/+ rats (Figure 2-1). In this figure, the PKD kidneys are 
larger in size than the non-PKD kidneys. Furthermore, the PKD kidneys have lost 
the dark color of the normal, non-PKD kidneys.  
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FIGURE 2-1: THE KIDNYES OF RATS WITHOUT PKD AND WITH PKD 
Left: kidney from a normal BC1 rat; Right: kidney from a PKD BC1 rat; Centre: 
normal nephron; (Source of nephron: Wilson, 2004). 
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2.2: Murine Models of Polycystic Kidney Disease 
When a disease appears in a human population, it is important to establish that the 
disease is genetically inherited for a decision to be made in its clinical management. 
However, to classify a human disease as genetically inherited is not easy, especially 
when the disease is rare in the population and when the phenotype of the disease 
cannot be easily recognized. Moreover, it is common that the inheritance of human 
genetic diseases does not follow simple patterns of Mendelian inheritance. This is 
partly attributed to multiple genetic loci that are involved in disease susceptibility 
(Risch  et  al.,  1993),  and  partly  to  the  interaction  between  genetic  loci  and  the 
environment in which the individual is located (Rossetti and Harris, 2007). However, 
if  genetic  contribution  to  disease  expression  is  the  dominant  factor,  then  the 
occurrence  of  the  disease  should  be  more  highly  reported  in  one  group  than  in 
another group at any given time.  
 
A lot of information about human PKD has been obtained from analysis of rodent 
models of the disease (Yoder et al., 1997). The rat and the mouse are now found to 
provide useful general models in systems biology (Behboudi et al., 2002) and for the 
study of inherited PKD (Guay-Woodford, 2003). Although the mouse is favored 
over the rat for the study of genetically inherited diseases because of availability of 
genetic infrastructure, the rat is a model of choice for biomedical research (Kwitek et 
al., 2004) and genetic study of specific diseases (Brown et al., 1998) because the 
majority  of  physiological  characteristics  of  the  rat  correlate  with  physiological  
 
 
13 
characteristics  of  human  (Gill  et  al.,  1989).  Regardless  of  the  differences  in  the 
physiological characteristics between the rat and the mouse however, both species 
have been used as models in the study of different forms of PKD. 
2.2.1: Rat Models of Polycystic Kidney Disease 
The polycystic kidney (pck) rat is a model for human ARPKD which arose as a 
result of spontaneous mutation in a Crj:CD/SD rat strain (Katsuyama et al., 2000). In 
other studies, however, pck rats developed a disease that resembles human ADPKD 
(Lager et al., 2001). Both the dominant and the recessive diseases are characterized 
by development of cysts in the kidneys and in the liver, increased systolic blood 
pressure  and  increased  urea  nitrogen  levels,  development  of  congenital  hepatic 
fibrosis and anemia (Gunay-Aygun et al., 2006; Onuchic et al., 2002). The gene 
responsible for the dominant trait (Pkd-1) was mapped to chromosome 10q12 (Xu et 
al., 2001). This gene was found to be homologous to the human PKD-1 gene located 
on chromosome 16p13.3 (Reeders et al., 1985) and the mouse Pkd-1 gene located on 
chromosome  17A3.3  (Himmelbauer  et  al.,  1992).  The  gene  responsible  for  the 
recessive trait (Pkhd-1) was mapped to rat chromosome 9 and it was found to be 
homologous to PKHD-1 on human chromosome 6p21-p12 (Guay-Woodford, 2003). 
 
Wistar polycystic kidney (wpk) rats develop PKD that resembles human ARPKD. 
The  homozygote  mutants  develop  nephromegaly,  hypertension,  proteinuria, 
impaired urine-concentrating capacity, and anemia (Nauta et al., 2000; Smith et al., 
2006b). In this model, there is no evidence of biliary tract abnormalities (Smith et  
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al., 2006b). The gene responsible for the phenotype is located on rat chromosome 
5q13  (Nauta  et  al.,  2000)  and  the  human  and  mouse  homologs  are  located  on 
chromosome 8q22.1 and chromosome 4A1, respectively. The protein encoded by the 
gene is called meckelin, important in kidney cilia formation (Smith et al., 2006b). 
 
The Han:SPRD-Cy rat model originated from out bred Han:SPRD-cy/+ Sprague-
Dawley  rats  (Festing,  1979).  The  rat  develops  a  disease  that  resembles  human 
ADPKD and the gene responsible for the disease was mapped on chromosome 5q22, 
and  the  human  homolog  was  mapped o n  chromosome  8  (Kaisaki  et  al.,  2008). 
However, the gene is not homologous to PKD-1 or PKD-2 and therefore it was 
called Pkdr1 (Bihoreau et al., 1997). Different genetic loci responsible for ADPKD 
in this rat model continue to be identified and one locus called Modpkdr1 was also 
identified on chromosome 8 (Bihoreau et al., 2002). 
2.2.2: Mouse Models of Polycystic Kidney Disease 
Many mouse models of PKD in which the phenotype of the mutant resembles human 
PKD  have  been  described  (Guay-Woodford  et  al.,  2000).  However,  the  BALB/c 
polycystic  kidney  (bpk)  mice  develop  ARPKD  that  does  not  resemble  human 
ARPKD  (Ricker  et  al.,  2000).  The  mutation  in  the  bpk  mice  was  mapped  to 
chromosome 10 (Cogswell et al., 2003). This mutation was found to be allelic with 
mutation  in  the  juvenile  congenital  polycystic  kidney  (jcpk)  mice.  However,  the 
presentation of ARPKD in the mouse strains is different in severity (Guay-Woodford  
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et al., 1996). The bpk mutant does not survive for more than four weeks and the jcpk 
mutant does not survive for more than ten days (Chittenden et al., 2002). 
 
The  congenital  polycystic  kidney  (cpk)  mouse  is  a  model  for  human  ARPKD 
(Chittenden et al., 2002; Ricker et al., 2000). In this mouse, the disease penetrance in 
the developing biliary tree is modulated by genetic background. The protein encoded 
by the gene is hydrophilic and contains 145 amino acid residues. This protein is 
called cystin and its expression overlaps with polaris (Hou et al., 2002), which plays 
an important role in the assembly of renal cilia (Yoder et al., 2002a; Yoder et al., 
2002b). 
 
The inversion of embryonic turning (inv) mouse is a transgenic mouse model that 
was created by insertion mutagenesis (Morgan et al., 1998; Shimadera et al., 2007). 
The mouse develops situs inversus and jaundice (Shimadera et al., 2007). In this 
model, the mutants develop cystic kidney disease that resembles NPHP2 in infants 
(Shimadera et al., 2007). The mutants also develop multi-organ defects, including 
renal  cysts,  altered l e f t -right  laterality  and  hepatobiliary  duct  malformations 
transmitted as autosomal recessive traits (Morgan et al., 1998). The affected mice die 
of renal and liver failure within seven days after birth (Phillips et al., 2004). 
 
The  juvenile  cystic  kidney  (jck)  mouse  is  a  model  for  human  ARPKD  (Guay-
Woodford et al., 1996; Smith et al., 2006a). However, the model displays gender 
dimorphism, with more male mice developing the disease than female mice (Smith 
et al., 2006a). The gene mutated is called nek8 and its over-expression is associated  
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with loss of cilia in the renal epithelia. The loss of cilia is accompanied by enhanced 
expression of polycystin in the cilia (Smith et al., 2006a). According to the Rat 
genome database, http://rgd.mcw.edu/, nek8 is located on mouse chromosome 11B5. 
The human homolog is located on chromosome 17q11.1 and the rat  homolog is 
located on chromosome 10q25 (Twigger et al., 2007). 
 
The kidney, anemia, testis (kat) mouse model arose from the inbred RBF/Dn strain 
which spontaneously developed ADPKD (Janaswami et al., 1997). The mutant kat
2J 
arose from the C57BL/6J strain which spontaneously developed ADPKD (Guay-
Woodford, 2003). The disease phenotype in both models resembles human ADPKD, 
but it is also characterized by facial dysmorphism, dwarfism, male sterility, anemia, 
and development of cysts in the choroids plexus (Upadhya et al., 2000). The affected 
mice die prematurely. The genetic locus associated with the disease was mapped on 
mouse chromosome 8 (Janaswami et al., 1997), but the exact location of the gene is 
not known. 
 
The  Oak  Ridge  Polycystic  Kidney  (orpk)  mouse  is  a  model  for  human  ARPKD 
(Nakanishi et al., 2001; Pazour et al., 2002; Sommardahl et al., 2001). The model 
arose  through  integration  of  a  transgene  into  an  intron  of  the  Ift88  gene,  which 
formed  a  hypomorphic  allele  (Ift88Tg737Rpw).  Mutation  of  the  Ift88Tg737Rpw 
gene impairs intra-flagellar transport, a process required for the assembly of motile 
cilia (Lehman et al., 2008).  
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The polycystic kidney (pcy) mouse is a model for human adolescent NPH3 (Olbrich 
et al., 2003; Omran et al., 2001). The disease exhibits a late onset, and presents as a 
recessive renal cystic disease that belongs to the nephronophthisis/medullary cystic 
group of disorders. The gene NPH3 is mapped to chromosome 9F1 and this gene is 
syntenic to a gene on human chromosome 3q21-q22 (Omran et al., 2001). In rat 
models, the gene is located on chromosome 8q32 (Olbrich et al., 2003). 
 
Generally, there are many murine models for human PKD, dominant or recessive 
and  more  will  continue  to  emerge  (Chittenden  et  al.,  2002).  Some  models a re 
generated for academic purposes (Flaherty et al., 1992; Moyer et al., 1994; Rinchik 
et al., 1990), for example, the inv and the orpk (Moyer et al., 1994; Phillips et al., 
2004). In the rats that spontaneously developed PKD, the phenotypes of pck and wpk 
models closely resemble the human PKD phenotypes and in mice, the phenotypes of 
the orpk and bpk closely resemble the human PKD phenotypes (Aziz, 1995; Lager et 
al., 2001; Nauta et al., 2000). All these models of PKD will help us to understand the 
physiological and biochemical processes involved in the development of the disease. 
However, the genetic loci responsible for different forms of PKD will continue to 
vary in the murine models. 
2.3: Enlargement of Cystic Kidneys 
The development of cysts in human kidneys requires at least four events. These 
events  include  germ-line  mutation,  somatic  mutation  (Qian  and  Watnick,  1999), 
proliferation of epithelial cells adjacent to the point of lesion, accumulation of fluids  
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within the cysts’ lumen (Martinez and Grantham, 1995) and prominent restructuring 
of the tubular basement membrane around the cysts and changes in the extracellular 
matrix (Wilson et al., 1992). 
2.3.1: Proliferation of Epithelial Cells Adjacent to the Point of Lesion 
In PKD kidneys, the epithelial cells lining the cysts proliferate at an abnormal rate 
(Li et al., 2004). This is viewed as an innate immune response, to delineate the cysts 
from the surrounding cells so that the proliferation of the cyst does not spread to the 
surrounding cells (Martinez and Grantham, 1995). The cyst proliferation is followed 
by deposition of collagen type IV and vimentin to protect the surrounding cells from 
further damage (Mooney et al., 1999). Fluids accumulate in the cysts and the cysts 
distend. The distension of cysts compresses the surrounding cells so that the cells are 
cut  off  from  the  blood  supply.  The  shunting  away  of  the  blood  supply  prevents 
nutrient supply to the cells, causing localized ischemia and cell death (Martinez and 
Grantham, 1995). 
2.3.2: Fluid Secretion in Normal and Cystic Renal Epithelial Cells 
The mechanism that leads to abnormal fluid secretion into the cysts in PKD kidneys 
can be understood by considering the function of epithelial tubular cells in normal 
kidneys and epithelial tubular cells in cystic kidneys. In normal kidneys, Na
+ ions 
move from the tubular fluid into the cytoplasm through the NaCl transporter proteins 
located in the apical plasma membrane. From the plasma membrane, the Na
+ ions  
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move to the interstitial space through the basolateral Na
+/K
+/ATPase or Na
+ pump. 
This  establishes  a  gradient  between  the  tubular  fluid  and  the  interstitium,  which 
favors  the  movement  of  Cl
–  ions  along  the  electrostatic  gradient  (Martinez  and 
Grantham, 1995). The movement of NaCl from the tubular fluid to the interstitial 
fluid also establishes an osmotic gradient, favoring the movement of water through 
the water channels (Devuyst, 1999a). 
 
In  cystic  renal  tubules,  the  apical  Na
+  channels  are  significantly  decreased  in 
number, but the apical Cl
– channels are significantly increased in number (Martinez 
and Grantham, 1995). In the basolateral membrane, the Na
+/K
+/2Cl
! co-transporter is 
activated so that an electrochemical gradient that favors the passive movement of 
interstitial  Na
+  through  the  para-cellular  channels  into  the  cyst  lumen  is  created 
(Devuyst, 1999a, b). The passive movement of Na
+ ions is followed by electrostatic 
movement  of  Cl
–  ions  and  consequently,  osmotic  movement  of  fluids.  The 
movement of the fluids into the cyst lumen leads to cyst expansion, which in turn 
leads to kidney enlargement (Reuss et al., 1990; Schafer et al., 1994). 
2.3.3: Accumulation of Fluids and Enlargement of the Cysts 
The  accumulation  of  fluids  into  the  cysts  occurs  by  two  separate  mechanisms 
(Lebeau et al., 2002, Li et al., 2004). While the cysts are in direct contact with the 
lumen  of  the  tubule  of  origin,  glomerular  filtrate  collects  within  the  expanding 
diverticulum (Martinez and Grantham, 1995). When the cysts disengage from the  
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parent tubule (Sullivan et al., 1998), fluid is secreted into the cysts’ lumen through 
the transepithelial process (Figure 2-2). 
 
 
 
 
FIGURE 2-2: PKD CYST ENLARGEMENT 
Longitudinal section of a renal tubule showing associated cyst disengaging from the 
tubule  and  fluid  entering  the  cyst  through  transepithelial  fluid  secretion  process 
(Source: Martinez and Grantham, 1995).  
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2.3.4: Restructuring of Tubular Basement Membrane 
The  expansion  of  cysts  leads  to  changes  in  the  structure  of  tubular  basement 
membrane  (TBM)  and  extracellular  matrix  (Martinez  and  Grantham,  1995).  The 
lining of TBM of the tubule, where the cysts arise, thickens and becomes laminated 
(Mooney et al., 1999). An intense accumulation of fibronectin, type I collagen, and 
low molecular weight glycoproteins takes place (Grantham, 1997). In addition, an 
intense synthesis and deposition of heparin sulfate-proteoglycans and chondroitin 
sulfate-proteoglycans (Martinez and Grantham, 1995) in cystic tubular extracellular 
matrix  (ECM)  occurs.  These  changes  are  common  in  all  cystic  kidneys  in  PKD 
patients. 
2.4: Genetic Mutations in Autosomal Dominant Polycystic Kidney Disease 
2.4.1: Two-hit Mechanism to Explain Cyst Formation 
Autosomal dominant PKD arises because of genetic mutations in PKD-1, PKD-2 or 
PKD-3, or mutation of genetic variants at other loci in the same chromosome or 
different chromosomes. For example, mutation of TSC2, a tumor suppressor gene, 
located adjacent to PKD-1 in rat chromosome 10 leads to development of renal cysts 
(Harris, 1997; Kleymenova et al., 2001; Martignoni et al., 2002). The expression of 
ADPKD has been explained using the two-hit mechanism (Qian and Watnick, 1999).  
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In the two-hit model (Figure 2-3), a germ-line mutation exists in a single allele, but 
this requires somatic mutation in the cell that carries the germ-line mutation for 
initiation  of  cyst  development  and  therefore,  PKD  manifestation  (Yeung  et  al., 
1993). 
 
Research has shown that genetic mutations that follow the two-hit mechanism have 
led to development of several tumor types (Pazzaglia et al., 2006; Taniguchi et al., 
2009). According to Torres and Harris (2006) however, incomplete inactivation of 
PKD-1  and  PKD-2  alleles,  a  process  called  haploinsufficiency  and  dominant 
negative  mechanisms,  may  also  contribute  to  the  cystic  phenotype  in  ADPKD. 
Torres and Harris (2006) described haploinsufficiency as a phenomenon that exists 
in a genetic locus whereby there is only one copy of the wild-type allele. This copy 
cannot generate the normal phenotype because of a reduction in gene dosage. In the 
dominant-negative effect, the mutant molecule forms a complex with, and disrupts 
the functions of the wild-type counterpart. 
 
In human studies, PKD-1 is located on the short arm of chromosome 16p13.3 and 
mutations in this gene account for 85% of all ADPKD cases worldwide (Reeders et 
al., 1985). The gene spans 52kb of DNA, comprising 46 exons (Consortium, 1995), 
and it encodes for a 14kb mRNA (Sullivan et al., 1998). A missense mutation in 
PKD-1,  combined  with  a  3-nucleotide  deletion,  produces  an  in-frame  shift  of  a 
single codon (Xu et al., 2007) and this leads to development of ADPKD. Ten to 15% 
of ADPKD cases worldwide (Chauvet et al., 2002) are caused by mutations in PKD-
2, which is located on the long arm of human chromosome 4q21-q23 (Harris and  
 
 
23 
Watson, 1997, Kimberling et al., 1993). Studies have also shown that PKD-2 defines 
a genetic segment of about 9 cM (Kimberling et al., 1993). 
 
 
 
FIGURE 2-3: THE TWO-HIT MODEL IN ADPKD 
Germ-line mutation occurs and it is followed by somatic mutation in the normal 
allele as indicated by the star. The cell undergoes clonal expansion and forms cysts, 
(Source: Qian and Watnick, 1999).  
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2.4.2: Patients with Polycystic Kidney Disease in Australia 
In Australia, the number of patients with PKD as a proportion of patients admitted to 
hospitals for renal disease is large (Harris, 2007, Andreasyan and Hoy, 2007). In 
1999 for example, 120 out of 1750 (6.86%) were PKD patients. In 2000, 2001, 2002, 
and 2003, there were 110/1755 (6.27%), 108/1911 (5.65%), 107/1898 (5.64%) and 
110/1953 (5.63%) respectively, averaging 6.01% patients with PKD per year, and 
kidneys of 50% of these patients reach ESRD (ANZDATA, 2006; Harris, 2007). 
 
In the kidneys of patients with ADPKD, renal parenchyma cells are displaced by 
cysts so that the physiological functions of the kidneys are not regulated (Chittenden 
et al., 2002). Individuals with mutation in PKD-1 are severely affected, and kidney 
deterioration progresses faster than in individuals with mutation in PKD-2 (Torra et 
al., 1998). Furthermore, it has been established that ADPKD accounts for 5 percent 
of patients in hemodialysis units worldwide (Sutters and Germino, 2003). 
 
Although ADPKD is known to manifest in the kidneys, it is a systemic disorder and 
affected individuals develop cysts in the liver, pancreas, brains, spleen, heart, ovaries 
and testes as well (Qian and Watnick, 1999, Torres and Harris, 2006). The cysts in 
the liver lead to portal hypertension, and this is the leading cause of death in patients 
with cystohepatic disease (Arikan et al., 2004). The development of cysts in the 
pancreas destroys the Islet of Langerhans so that the $- and #- cells that produce 
glucagon  and  insulin  hormones,  respectively,  are  destroyed.  This  leads  to  
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perturbation of glucose levels in blood circulation so that diabetes mellitus manifests 
(Duclos et al., 2006; Sumara et al., 2009). 
 
The clinical presentation of ADPKD is, however, heterogeneous (Qian and Watnick, 
1999). This is caused by mutations in different genes (PKD-1, PKD-2 and PKD-3) 
that synergistically contribute to expression of PKD phenotype (Harris and Torres, 
2009;  Kleymenova  et  al.,  2001).  The  type  of  mutation,  whether  it  is  a  deletion, 
insertion  or  substitution  also  influences  the  expression  of  the  PKD  phenotype. 
Mutations in different functional domains of PKD-1 or PKD-2 or a mutation in a 
gene that regulates the function of PKD-1 or PKD-2 or indeed a mutation of a gene 
that regulates cellular processes such as cell proliferation and signal transduction 
also lead to development of ADPKD with varying degree of phenotypic expression 
(Li et al., 2004; Rodriguez-Pena et al., 2005). 
 
It was found that the co-deletion of both the contiguous tuberous sclerosis (TSC2) 
and PKD-1 genes gives rise to phenotypic differences in the clinical presentation of 
ADPKD (Culty et al., 2006; Harris, 1997; Martignoni et al., 2002; Yadaden et al., 
2007). In addition, the genetic background on which germ-line mutation occurs also 
determines  the  degree  of  clinical  variability  in  PKD  presentation.  Environmental 
factors,  such  as  nutrition,  were  found  to  modify  the  phenotypic  expression  of  a 
specific mutant allele, but this is not clearly understood (Harris and Torres, 2009; 
Rossetti and Harris, 2007).  
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2.4.3: Involvement of Polycystin-1 and Polycystin-2 on Cell Membranes 
The PKD-1 and PKD-2 genes encode for polycystin-1 (PC-1) and polycystin-2 (PC-
2), respectively. PC-1 is a large glycoprotein (4303 amino acids) with between 7 to 
11 helices that traverse the epithelial membrane (Figure 2-4). It has a molecular 
weight of 485 kDa (Harris and Torres, 2009; Huan and van Adelsberg, 1999), and 
approximately 200 amino acid intracellular C- terminal domain and a 300 amino 
acid extra-cellular N- terminal domain (Xu et al., 2007). PC-1 is highly expressed in 
developing human kidneys and in low amounts in adult human kidneys, but it is 
found highly expressed in human cystic kidneys (Sullivan et al., 1998). PC-1 is also 
found in cilia and it contributes to their structural integrity and function (Xu et al., 
2007). 
 
PC-2 is a membrane-associated protein which consists of 968 amino acid residues 
(Sutters and Germino, 2003). It has a molecular weight of 110 kDa (Huan and van 
Adelsberg, 1999). PC-2 is highly expressed in the plasma membrane, endoplasmic 
reticulum and the cilia, and it traverses the membrane six times with both the C- and 
N- terminal domains in the cytoplasm (Figure 2-5). It functions as an intracellular 
Ca
2+ ion release channel (Li et al., 2009; Tsiokas et al., 2007). It is also important in 
signal transduction, and this is potentiated when PC-2 forms a complex with PC-1 
(Xu et al., 2007). The structure of PC-2 suggests that it belongs to the transient 
receptor potential protein super family of ion channels (Tsiokas et al., 2007).  
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FIGURE 2-4: POLYCYSTIN-1 TRAVERSING THE MEMBRANE 
The intra-membrane domains of PC-1 span the plasma membrane to shuttle Na
+, 
Ca
2+ and Cl
- ions across the membrane (Source: Torres and Harris, 2006).  
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FIGURE 2-5: POLYCYSTIN-2 TRAVERSING THE MEMBRANE 
PC-2 traverses the plasma membrane with the N– and C– termini located within the 
cytoplasm. The intra-membrane domains span the membrane forming channels to 
shuttle Na
+, Ca
2+ and Cl
– ions across the membrane (Modified from: Xu et al., 2007).  
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Transient receptor potential (TRP) proteins belong to a group of voltage-dependent 
cation-permeable  channels  expressed  in  many  mammalian  tissues  including  the 
kidneys and the liver (Hsu et al., 2007). TRP proteins respond to stimuli from inside 
and outside the cells (Clapham, 2003) and they transmit these stimuli across the 
membranes (Yu et al., 2009). TRP channels are also involved in the functions of the 
kidneys,  liver,  blood  vessels  and  the  heart  and  this  involvement  means  that  the 
dysfunction  of  TRP  can  also  result  in  systemic  diseases  (Hsu  et  al.,  2007; 
Woudenberg-Vrenken et al., 2009). 
 
TRP proteins are grouped into six subfamilies on the basis of their sequence identity 
(Woudenberg-Vrenken  et  al.,  2009).  According  to  Pedersen  et  al.  (2005),  TRP 
proteins  are  grouped  into  Canonical  (TRPC1–C7),  Vanilloid  (TRPV1–V6), 
Melastatin  (TRPM1–M8),  Ankyrin  (TRPA1),  Polycystin  (TRPP1–P3)  and 
Mucolipin (TRPML1–ML3). The common feature of these channels is that they span 
the plasma membrane six times (Montell et al., 2002; Pedersen et al., 2005). These 
channels are expressed in different parts of the kidney and their activity is regulated 
by Ca
2+ ions (Schumann et al., 2009). The glomeruli, for example, express TRPC1, 
TRPC3 and TRPC6, the renal tubules express TRPC1, TRPC3, TRPC6, TRPV4–6, 
TRPM6 and TRPP2 and the tubular cilia express TRPP1 and TRPP2 (Hsu et al., 
2007).  
 
 
30 
2.4.4: Expression of Polycystin-1 and Polycystin-2 
During kidney development, the expression of PC-1 is tightly regulated, and targeted 
disruption of this tight regulation is thought to result in cyst development in the 
kidneys (Chauvet et al., 2002; Sutters and Germino, 2003). During embryogenesis, 
however, PKD-1 is highly expressed in the kidneys, brain, liver, pancreas and the 
heart (Chauvet et al., 2002) and according to Wilson (2001), the higher amounts of 
PC-1 are important in the development and differentiation of normal kidneys. The 
interaction of the C-terminal domain of PC-1 with the C-terminal domain of PC-2 
(Figure 2-6) leads to up-regulation of several transcriptional pathways (Low et al., 
2006; Wilson, 2001). This interaction, coupled with similarity of ADPKD caused by 
mutations in either PKD-1 or PKD-2, suggests that these molecules act together, 
although their biochemical pathway is unknown (Qian et al., 1997).  
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FIGURE 2-6: THE INTERACTION OF PC-1 AND PC-2 
Polycystin-1 and polycystin-2 interact through binding of their cytoplasmic carboxyl 
termini.  LRR:  leucine  rich  repeat;  LDL-A:  low-density  lipoprotein-A  (Modified 
from: Sutters & Germino, 2003).  
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2.4.5: Development of Cysts in ADPKD 
In ADPKD the cysts arise from all segments of the renal nephrons (Wilson, 2004a, 
b), and they progressively enlarge and disengage from the tubule due to increased 
forces of distortion caused by accumulation of fluids (Figure 2-7). Two or more 
adjacent cysts may coalesce to form bigger cysts (Figure 2-8). In human PKD, it is 
reported that cysts develop in less than 5% of kidney nephrons (Xu et al., 2007) and 
this explains why human kidneys can continue to carry out homeostatic functions 
after cystogenesis. However, the reason why only 5% of the nephrons develop cysts 
is unknown, considering that all tubular cells are thought to carry the same germ-line 
mutation. 
 
During cystogenesis, monocytes congregate on the site where the cysts arise (Figure 
2-9). This implies that cell death in the renal nephrons occurs earlier and monocytes 
congregate there to localize the lesion, a typical innate immune response (Martinez 
and Grantham, 1995). The congregation of the monocytes in the site of cystogenesis 
is followed by an abnormal proliferation of adjacent cells to generate a wall. The 
wall  delineates  the  lesion  from  the  surrounding  cells.  Once  the  wall  has  been 
generated, deposition of collagen type IV and vimentin takes place (Mooney et al., 
1999).  
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FIGURE 2-7: ADPKD IN THE HUMAN RENAL NEPHRON 
In ADPKD cysts develop at all points along the renal nephron (Source: Wilson, 
2004).  
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FIGURE 2-8: A CORONAL SECTION OF KIDNEY FROM A PKD RAT 
There are numerous cysts, which coalesce to form larger cysts.  
 
 
35 
 
 
 
 
 
 
FIGURE 2-9: A CROSS SECTION OF KIDNEY CORTEX 
A cross-section of kidney cortex showing a renal cyst in a PKD (Han:SPRD) rat. The 
proximal tubule on the left has developed a cyst and it has lost the cilia in the brush 
borders that normally project into the lumen of the tubule. On the right is a renal 
tubule that has not developed any cysts (Source: Martinez & Grantham, 1995).  
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2.5: Autosomal Recessive Polycystic Kidney Disease 
Autosomal recessive PKD is a severe form of PKD that primarily presents in infants 
(Onuchic et al., 2002). The disease is caused by mutations in the PKHD-1 gene and 
it is characterized by development of cysts in the collecting ducts (Figure 2-10). In 
the liver, the cysts lead to congenital hepatic fibrosis (CHF), biliary dysgenesis and 
dilation of intrahepatic bile ducts (Ward et al., 2003, Gunay-Aygun et al., 2006). The 
PKHD-1 gene consists of 86 exons, which are assembled into alternative spliced 
transcripts,  and  the  longest  transcript  consists  of  67  exons,  which  encodes  for 
fibrocystin (Losekoot et al., 2005). 
 
In a study of 39 Dutch families with ARPKD, extensive mutation analysis by direct 
sequencing of the 67 exons of the longest transcript revealed 11 nonsense mutations, 
15 indels, five splice site mutations, and 39 missense mutations (Losekoot et al., 
2005). The mutations were localized in the region 6p21.1-p12 (Zerres et al., 1994). 
Through  mutation  analysis,  therefore,  it  is  possible  to  use  genetic  methods  for 
diagnosis of ARPKD (Gaspar et al., 2006). Previously, Blyth and colleagues (1971) 
reported  that  the  presentation  of  ARPKD  was  divided  into  perinatal,  neonatal, 
infantile and juvenile nephropathy. However, the subtle differences between these 
categories are not easily distinguishable (Fonck et al., 2001). It is not clear, however, 
whether mutations in different functional domains of PKHD-1 or genetic modifier 
loci are the cause of this clinical variability.  
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FIGURE 2-10: ARPKD IN THE COLLECTING DUCTS OF THE HUMAN NEPHRON 
In ARPKD, the cysts develop in the collecting ducts (Source: Wilson, 2004).  
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Perinatal  ARPKD  causes  severe  renal  disease,  congestive  heart  failure,  and 
respiratory distress syndrome (Nishi et al., 1991). Neonatal ARPKD patients develop 
progressive renal disease and most of the patients die from pulmonary insufficiency. 
However, the survival rate of infants with ARPKD has now increased because of 
improved  neonatal  care  and  the  use  of  antihypertensive  drugs  (Capisonda  et  al., 
2003). Infantile ARPKD is a less severe form of ARPKD but it leads to gradual and 
progressive hepatic fibrosis (Desmet, 2005; Zerres et al., 1996). Clinical signs of 
Juvenile ARPKD are minimal renal disease and congestive heart failure (Gunay-
Aygun et al., 2006). 
 
Because of improved care, patients with ARPKD can now live longer (Fonck et al., 
2001), and between 56 – 67% of children who survive the neonatal period can live 
for up to 15 years without needing dialysis (Roy et al., 1997). Because 56 – 67% of 
patients can survive for 15 years, it indicates that renal heterogeneity exist in the 
expression of ARPKD among children. There is however a paucity of evidence to 
indicate whether or not the children can escape renal failure after 15 years (Fonck et 
al., 2001). Although there is individual variability in the expression and the rate of 
kidney deterioration in ARPKD, genetic studies indicate that PHKD-1 is the only 
gene responsible for human ARPKD (Chittenden et al., 2002; Nauta et al., 2000).  
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2.5.1: Structure and Function of Fibrocystin Protein 
The  protein  product  of  PKD-1,  fibrocystin  (Figure  2-11),  is  predicted  to  contain 
4074 amino acids (Ward et al., 2002; Ward et al., 2003). It has a molecular weight of 
447 kDa (Ward et al., 2003). Fibrocystin functions as part of the polycystin complex 
and it is involved in calcium flux signaling (Tsiokas et al., 2007) and the functions of 
cilia (Menezes et al., 2004). Fibrocystin also interacts with calcium ion modulating 
cyclophilin ligand (CAML) and this suggests that fibrocystin is involved in Ca
2+
 
homeostasis (Tsiokas et al., 2007). Fibrocystin is also involved in cell transduction 
and a variety of other biological functions, including sperm fertilization in different 
animal species (Delmas, 2004). It was found that dysfunction of fibrocystin leads to 
molecular dysfunction of cilia of the respiratory tract (Driscoll et al., 2008), and this 
causes respiratory distress syndrome, which leads to sudden infant death (Ugwu et 
al., 2006).  
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FIGURE 2-11: MOLECULAR STRUCTURE OF FIBROCYSTIN 
Fibrocystin interacts with the cell membrane. It has a long extra-cellular N-terminus 
and a single trans-membrane domain and a short intracellular C-terminus (Source: 
Ward et al., 2002).  
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2.5.2: Molecular Structure of Cilia and Arrangement of Axoneme 
In general, cilia are hair-like structures that emerge as single projections from the 
basal body (Wheatley, 1995). A single cilium consists of nine peripheral microtubule 
doublets arranged around two central microtubules, called a 9 + 2 axoneme. Each of 
the  doublets  consists  of  an  A  and  a  B  tubule  (Figure  2-12).  The  central  pair  of 
microtubules extends the length of the axoneme. Some cilia, however, do not have 
the central pair of microtubules and they are called 9 + 0 axonemes. 
 
Based on this structural arrangement, the cilia are now placed into four subgroups: 
motile 9 + 2 cilia, for example the respiratory cilia; motile 9 + 0 cilia such as the 
nodal cilia; sensory 9 + 2 cilia such as the vestibular cilia and sensory 9 + 0 cilia 
such as the renal cilia and the photoreceptor connective cilia (Ibanez-Tallon et al., 
2003).  The  movement  of  the  renal  cilia  during  fluid  flow  is  associated  with  the 
translocation of Ca
2+ ions into the interstitial space (Kaimori et al., 2007). The cilia 
serve as versatile mechanosensors and chemosensors (Rodat-Despoix and Delmas, 
2009). In PKD individuals, the cilia are lost and so the ability to translocate Ca
2+ 
ions into the interstitial space is also lost (Martinez and Grantham, 1995).  
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FIGURE 2-12: A CROSS SECTION OF CILIA WITH 9 + 2 AND 9 + 0 STRUCTURE 
In PKD development, the cilia lose the 9 + 2 and gain the 9 + 0 structure (Source: 
Ibanez-Tallon et al., 2003).  
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The microtubule contains many protein complexes that connect the radial spokes, 
nexin links, central sheath and dynein arms (Afzelius et al., 1995). The dynein arms 
are attached to the peripheral microtubules and generate motion by ATP-dependent 
reactions  (Satir  and  Christensen,  2007).  The  central  apparatus  and  radial  spokes 
provide  structural  connection  for  transmission  of  regulatory  signals  to  the  arms 
(Ibanez-Tallon et al., 2003). The coordinated action of the dynein arms and the radial 
spokes generates bending of cilia and flagella (Afzelius et al., 1995). Among the 
many normal, non-motile cilia on cells throughout the body, some may be missing 
the central pair of microtubules, the dynein arms or both (Pan et al., 2005). 
 
Motile cilia and flagella beat in a synchronized fashion and this is important in cell 
motility,  transport  of  mucus  and  cells  like  the  ova  (Ibanez-Tallon  et  al.,  2003). 
Dysfunction of motile cilia in different parts of the body is associated with a number 
of disorders (Pan et al., 2005; Veland et al., 2009), generally referred to as primary 
cilia dyskinesia (PCD) or immotile cilia syndrome (Afzelius, 1976; Greenstone et 
al., 1988). As an example, the cilia of the upper and lower airways are motile and 
clear mucus, but in PCD, the cilia become immotile or absent and result in reduced 
mucus clearance in the airways (Ibanez-Tallon et al., 2003). PCD is common in 
individuals with PKD and it leads to difficulty in breathing, resulting in apnea, and 
in infants it causes sudden death (Driscoll et al., 2008).  
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2.5.3: Polycystic Kidney Disease and Cilia-related Infertility 
Some males with PKD become infertile because the sperms are immotile due to loss 
of the central microtubule (Afzelius et al., 1995; Okada et al., 1999). The sperm can 
also become immotile due to dysfunction of dynein arms (Afzelius and Eliasson, 
1983). In females, however, infertility arises because of dysfunction of the cilia in 
the fallopian tube, and therefore, cannot propel the oocytes to the vicinity where 
fertilization occurs (Afzelius and Eliasson, 1983; Kotsis et al., 2007). As such, the 
dysfunction of the dynein arms and loss of central microtubule in cilia due to PKD 
cause infertility in both males and females (Afzelius and Eliasson, 1983, Okada et 
al., 1999). 
2.6: Co-morbidity of Polycystic Kidney Disease 
The progression of PKD kidneys to ESRD is accompanied by an increasing burden 
of  co-morbidity  and  mortality  as  kidney  function  deteriorates  (2006,  Yeates  and 
Tonelli, 2006, Keith et al., 2004). This is reflected in both the number of patients 
who die before their kidneys reach ESRD and the high prevalence of additional 
chronic conditions such as coronary artery disease and peripheral vascular disease in 
individuals whose kidneys have reached ESRD (Fonck et al., 2001, Go et al., 2004). 
Although  advances  in  dialysis  and  renal  transplant  therapies  have  been  made, 
patients  with  PKD  whose  kidneys  have  reached  ESRD  have  a  reduced  lifespan 
compared to the age and sex matched general population (Khan et al., 2002).  
 
 
45 
Currently, there are no techniques available to detect the precise time of onset of 
PKD  or  to  predict  whether  an  individual  is  predisposed  to  PKD.  The  use  of 
ultrasound,  magnetic  resonance  imaging  and  computed  tomography  scanning  has 
simply increased the diagnosis of cysts in kidneys of suspected individuals (Russo, 
2000). Genetic detection techniques need to be developed and these would be the 
method of choice to predict whether an individual is likely to develop PKD (Zerres 
et al., 2004). 
 
Furthermore, there are no effective therapeutic substances to prevent, slow down, or 
eliminate PKD. The only methods available for the treatment of patients with PKD 
are  palliative  treatments,  dietary  control,  kidney  dialysis  and,  ultimately,  kidney 
replacement (Martinez and Grantham, 1995; Reed and Cowley, 2007). However, 
there are limitations to these methods of treatment. Because PKD is associated with 
other  diseases  including  hypertension,  diabetes  and  infertility,  treatment  of  these 
diseases is always carried out first (Gunay-Aygun et al., 2006). 
2.6.1: Polycystic Kidney Disease and Hypertension 
Polycystic kidney disease is always associated with hypertension, aneurysms, ciliary 
dyskinesia (Greenstone et al., 1988) and in some cases, infertility (Ibanez-Tallon et 
al., 2003). Hypertension is defined as a persistently higher systolic blood pressure, 
ranging between 150 – 200 mmHg. Unfortunately, the etiology of hypertension in 
PKD  patients  is  not  established.  According  to  hemodynamic  laws,  arterial  blood 
pressure (BP) is directly related to the product of blood flow or cardiac output (CO)  
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and  the  total  peripheral  vascular  resistance  (PVR):  BP  =  CO  x  PVR.  In  PKD 
individuals, it is not known whether CO, PVR, or both, are affected so that there is 
an increase in systolic blood pressure. 
 
In normal individuals, blood pressure is maintained within a narrow range through 
regulation  of  the  cardiac  output  and  peripheral  vascular  resistance.  In  PKD 
individuals however, some as yet unknown factors come to play so that the tight 
regulation  is  not  maintained.  However,  the  renin-aldosterone-angiotensin  system 
(RAAS) and increased activity of sympathetic nervous systems (SNS) have been 
implicated in the development of the higher systolic blood pressure (Chapman et al., 
1990; Cody, 1997; Wyss, 1993). 
 
In PKD patients, the progressive enlargement of cysts in the kidneys distorts the 
architecture of the tubules, glomeruli, and renal vasculature (Lawson et al., 2006) as 
the cysts push against the cells of the juxtaglomerular apparatus. The cysts also alter 
the normal renal blood flow, leading to localized ischemia. These structural changes 
underline  the  rise  in  systolic  blood  pressure  and,  therefore,  contribute  to 
hypertension  in  different  ways:  by  activating  the  renin-aldosterone-angiotensin 
system,  increasing  the  activity  of  the  sympathetic  nervous  system,  and  altering 
sodium ion control in the renal tubule. 
 
The juxtaglomerular cells act as baroreceptors and they are sensitive to changes in 
blood pressure. The cells also secrete prorenin, which splits to release renin. Renin is 
an enzyme that acts on angiotensinogen to release angiotensin I, a 10 amino acid  
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peptide with a mild vasoconstrictor activity. Angiotensin converting enzyme (ACE) 
from the lungs splits angiotensin I to angiotensin II, an eight amino acid peptide. 
Angiotensin II is a strong vasoconstrictor (Chapman et al., 1990) and also acts on the 
kidneys to retain both salt and water. The retention of salt and water leads to increase 
in  plasma  volume,  which  results  in  pathogenesis  of  hypertension.  However,  the 
measurement  of  markers  to  predict  increase  in  systolic  blood  pressure  and  the 
influence of RAAS in PKD patients has shown inconclusive results (Lawson et al., 
2006). Cody (1997), for example, it has been shown that the activation of RAAS 
plays an important role in vascular adaptive processes. 
 
The sympathetic nervous system (SNS) is an important regulator of systemic blood 
pressure,  RAAS  activity,  intra-renal  vascular  tone  and  renal  tubular  sodium  re-
absorption (Lawson et al., 2006). The mechanisms that increase the activity of the 
SNS are not clear, but imbalances in neurotransmitters and neuromodulators directly 
or  indirectly  contribute  to  the  release  of  norepinephrine,  which  contributes  to 
sympathetic activity. There is also a complex feedback loop from the kidneys to the 
central nervous system, which in itself, regulates sympathetic activity (Tuncel et al., 
2002). 
2.6.2: Polycystic Kidney Disease and Anemia 
All PKD patients and animal models develop anemia (2006; Janaswami et al., 1997; 
Masoumi  et  al.,  2008),  which  results  from  deterioration  of  kidney  functions  and 
distortion  of  the  renal  parenchyma  cells  by  the  cysts.  Renal  parenchyma  cells  
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synthesize erythropoietin, a hormone necessary for the maturation of red blood cells 
(Erslev, 1991; Schafer et al., 1994). The measurement of hematocrit is therefore an 
important facet in the assessment of anemia resulting from the development of cysts 
in the kidneys. 
2.6.3: Polycystic Kidney Disease and Kidney Deterioration 
In all PKD animals and humans, the kidneys progressively deteriorate as the cysts 
continue to enlarge (Schillinger, 1993; Zerres et al., 1984). The deterioration of the 
kidneys is reflected in the decrease in homeostatic functions, which can be estimated 
by  measuring  the  amounts  of  plasma  urea,  proteins  and  creatinine  and  urine 
creatinine, protein and protein/creatinine ratio. The measurement of the amounts of 
these osmolites in the plasma is also used to estimate the glomerular filtration rate 
and therefore, kidney function (Flamant et al., 2009). These biochemical osmolites 
will be measured in this study to assess the function of the kidneys in PKD rats. 
2.7: Treatment of Patients with Polycystic Kidney Disease 
The treatment and management of PKD is to address the causes and to ensure that 
progression of the disease is slowed down. However, the presentation of PKD has a 
significant intra-familial clinical variability (Qian and Germino, 1997). In breeding 
experiments using rat models, it has been established that genes at secondary genetic 
loci play an important role in modification of the phenotype of the primary mutant 
genotype (Guay-Woodford et al., 1996; Nauta et al., 2000). It was also found that  
 
 
49 
family  members  who  shared  the  same  mutant  genotype  have  different  alleles  at 
modifying loci (Qian and Germino, 1997), and these alleles are the cause of the 
clinical variability. However, the presence of modifying loci is unlikely to explain all 
aspects of phenotypic variability in all PKD patients. 
 
The most widely used methods in the treatment of patients with PKD are: changing 
lifestyle to control risk factors, regulating consumption of foods which are toxic to 
the kidneys and, ultimately, carrying out renal replacement, which includes dialysis 
and kidney transplant. Angiotensin converting enzyme (ACE) inhibitors (Masoumi 
et  al.,  2008),  lipid  lowering  medications,  vasopressin  2  receptor  antagonists,  and 
epidermal  growth  factor  receptor  (EGFR)  inhibitors  are  currently  used  in  the 
treatment of all types of PKD (Wang et al., 2005). In this study, direct interference 
with the mutated mRNA in PKD rats is proposed. In recent years, RNA interference 
has become useful in treatment of genetic diseases (Zheng et al., 2009a). 
2.7.1: Renal Replacement Therapy in Patients with PKD 
Renal replacement therapy is the modality frequently used for treatment of patients 
with kidney problems, and the therapy includes dialysis and kidney transplant (Villar 
et al., 2007). Kidney dialysis is an artificial way of filtering the patient’s blood to 
remove metabolic waste and this is carried out in two ways: externally, a process 
called hemodialysis, and internally, a process called peritoneal dialysis (Reed and 
Cowley,  2007).  In  Australia,  hemodialysis  is  frequently  used  in  renal  therapy  
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(Rogers et al., 2006). This is performed two to three times a week. As such, dialysis 
is cumbersome and therefore, kidney transplant is a better option (Moist et al., 2007). 
2.7.2: Dialysis and Infection in Patients with End Stage Renal Disease 
Studies  have  shown  that  dialysis  is  accompanied  by  bacterial,  fungal  and  viral 
infections, and this accounts for a number of deaths of patients on dialysis (Justesen 
et al., 2007; Moist et al., 2007). Furthermore, dialysis is repeated at least twice a 
week  and  it  is  continued  for  life  (Brattich,  2006).  All  dialysis  patients  become 
anemic and require erythropoietin supplements to boost red blood cell production 
(Goldstein et al., 2007, Warady and Ho, 2003). As a result, the life expectancy of 
individuals  with  PKD  that  has  progressed  to  ESRD  and  who  are  on  dialysis  is 
significantly reduced (Moist et al., 2007). 
2.7.3: Kidney Transplant in Patients with End Stage Renal Disease 
Kidney transplant is the replacement of diseased kidneys with better kidneys from a 
dead person, or a living donor, and this is the treatment option of choice for patients 
with PKD (Goldstein et al., 2007). The problem associated with kidney transplant is 
the lack of donors, and the risk of immunological rejection of the donor kidney by 
the recipient. Transplant patients also need to take several expensive medicines for 
the  rest  of  their  lives;  they  are  more  frequently  hospitalized  than  the  general 
population.  The  administration  of  immunosuppressive  drugs  to  inhibit  kidney 
rejection during transplant also compromises the immune defensive mechanisms of  
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the  patient,  leading  to  infections  that  may  become  difficult  to  treat  (Horl  et  al., 
2002). 
 
The number of patients who need of kidney transplant is greater than the number of 
donors. In Australia, it has been reported that the average waiting time for kidney 
transplant is two and half years (Moist et al., 2007). Moreover, indigenous people in 
Australia are reported to be less likely to receive kidney transplant than the non-
indigenous (Hoy et al., 1998; Rogers et al., 2006). Furthermore, the cost of kidney 
transplant is high and therefore, patients with low incomes may not be able to afford 
it  (Ward,  2009).  In  developed  nations  including  Australia,  however,  medical 
insurance can subsidize the cost of kidney transplant, but tissue rejection and donor 
availability limit the practice (Smith et al., 1989). 
 
In  Australia,  the  management  of  renal  disease  consumes  5.7%  of  the  healthcare 
budget, but this budget excludes money spent on renal replacement therapy for those 
with ESRD (Chadban et al., 2003). Hjelm et al (2003) reported that, in the last few 
decades, the number of patients with ESRD has doubled in Europe and the USA. 
Following this trend, the burden of renal disease will proportionately increase with 
both the increase in age of the population and the increase in prevalence of diabetes 
mellitus (Hjelm et al., 2003).  
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2.7.4: Vasopressin-2-receptor Antagonists in the Treatment of PKD 
A common problem associated with cystic kidneys is their inability to concentrate 
urine (Chadban et al., 2003). The inability of the cystic kidneys to concentrate urine 
is associated with increased expression of vasopressin-2-receptor (Torres and Harris, 
2006; Wang et al., 2005). The increased expression of vasopressin-2-receptor (V2R) 
is an attempt by the cystic kidneys to concentrate urine. But the V2R is a Gs-linked 
protein  receptor  that  activates  adenylate  cyclase  to  generate  cyclic  adenosyl-
monophosphate (cAMP). Cyclic AMP plays an important role in cell proliferation 
and therefore, PKD progression (Wang et al., 2005). 
 
Mechanical  stimulation  of  the  cells  of  the  kidneys  by  primary  cilia  lead  to  the 
formation of the PC-1 and PC-2 complex, which mediates Ca
2+ entry into the cells 
(Siroky et al., 2006). The entry of Ca
2+ ions into the cells triggers the release of Ca
2+ 
ions from the endoplasmic reticulum (Tsiokas et al., 2007). Furthermore, fibrocystin 
(FC) regulates the homeostasis of Ca
2+ ion concentration by interacting with PC-2 
and Ca
2+ modulating cyclophilin ligand (CAML). When this pathway is disrupted, it 
leads to elevation of cAMP, up-regulation and apical mis-localization of epidermal 
growth factor receptor (EGFR) and up-regulation of V2R (Torres and Harris, 2006). 
The use of V2R antagonists therefore, at least in part, provides a way to prevent the 
progression of PKD (Figure 2-13).  
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FIGURE 2-13: CELLULAR CHANGES ASSOCIATED WITH PKD 
Components  and  pathways  that  are  upregulated  and  down  regulated  in  PKD  are 
shown. Potential therapeutic targets that disrupt major PKD pathways are shown in 
red.  PKA:  Protein  kinase  A;  Src:  membrane-associated  tyrosine-specific  kinase; 
V2RA:  vasopressin  2  receptor  antagonist;  Src  inh:  Src  inhibitors;  EGFR-TKI: 
epidermal  growth  factor  receptor  tyrosine  kinase  inhibitor  (Source:  Harris  and 
Torres, 2009).  
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2.7.5: Mammalian Target of Rapamycin Inhibitors 
Rapamycin, also called Sirolimus, is used to suppress immunity to prevent acute 
graft rejection during transplant (Valantine, 2007). It was, however, found to inhibit 
enlargement  of  kidney  cysts  (Wahl  et  al.,  2006;  Wuthrich  and  Serra,  2009). 
Rapamycin is highly selective and it inhibits serine-threonine kinase, the mammalian 
target of rapamycin (mTOR), which regulates cell cycle (Zheng et al., 2009a; Zheng 
et al., 2009b). Rapamycin also arrests G1-cell cycle, reduces cell growth and reduces 
the  rate  of  cell  proliferation.  Because  of  this,  rapamycin  is  used  to  prevent  the 
progression of different tumor types (Marinov et al., 2007). 
 
Mammalian target of rapamycin (mTOR) is a protein kinase enzyme that coordinates 
nutrient  availability  and  cell  proliferation  (Abraham  and  Gibbons,  2007)  and 
modulates  human  immune  responses  (Zimmerman  and  Kahan,  1997).  It  is  an 
important target for cancer therapy (Lang et al., 2007). When mTOR is blocked 
using  mTOR  inhibitors,  such  as  rapamycin,  the  signal  that  mediates  T-cell 
proliferation is also blocked. Unfortunately, the inhibition of mTOR also results in 
decrease in antibody production by blocking B-cell proliferation and maturation into 
antibody producing cells (Masri et al., 2007).  
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2.7.6: Ribonucleic Acid Interference 
Some researchers have suggested that PKD shares common cellular features with 
cancer (Grantham, 1990; Qian et al., 2001). Currently, cancer poses a tremendous 
therapeutic challenge, and requires an immediate development of novel therapeutic 
substances, which arrest the expression of cancer causing genes, a process called 
gene interference (He et al., 2009; Leung and Whittaker, 2005; Wu, 2009). For these 
therapeutic substances to be effective in treatment, they must have the ability to 
suppress  transcription  or  initiate  RNA  sequence-specific  degradation,  a  process 
called RNA interference (Agrawal et al., 2003). 
 
RNA  interference  (RNAi)  involves  sequence-specific  post-transcriptional  gene 
silencing  by  double-stranded  RNA  (Zheng  et  al.,  2009c).  Double-stranded  RNA 
(dsRNA) is processed into short dsRNA to trigger a cascade of biochemical events, 
which requires ribonuclease III (RNase III)-like proteins called Dicer and a multi-
protein complex called RNA-induced silencing complex (RISC) to degrade mRNAs 
(Agrawal  et  al.,  2003;  Grimm,  2009;  Stanislawska  and  Olszewski,  2005).  Since 
RNAi  is  becoming  an  excellent  strategy  to  degrade  mRNA  involved  in  disease 
development (Yue et al., 2009), it is tempting to apply the technology to arrest gene 
expression in living animals. Currently, RNAi is a potentially powerful tool for the 
fight against undesirable gene expression in human diseases (Agrawal et al., 2003).  
 
 
56 
2.8: Inheritance of PKD in the Lewis Polycystic Kidney Rats 
The Mendelian traits that are controlled by mutation in one gene may be inherited as 
dominant or recessive traits. The dominant trait is always expressed in the presence 
of a mutation in a single allele. The recessive trait, however, is expressed when two 
alleles that carry the same mutation come together during independent assortment of 
the homologous chromosomes. However, it has been established that the phenotypic 
expression of traits is influenced by the environment, and/or the presence of other 
genes in close proximity or distal to the gene of interest (Rossetti and Harris, 2007; 
Wilson, 2004b). But the inheritance of traits influenced by more than one gene, may 
be difficult to explain using simple Mendelian genetics. 
 
In the determination of the inheritance of PKD in the mutant LPK/SsNArc
+/+ rats, 
the Brown Norway (BN/ssArc
-/-) and the Wistar Kyoto (WKY/NArc
-/-) female rat 
strains are used to raise second filial and back cross generations, respectively. These 
rat strains are genetically distant from each other and they provide a useful diagnosis 
of whether there are genetic loci in the BN/ssArc
-/- or WKY/NArc
-/- that can modify 
the inheritance of the PKD in the LPK/SsNArc
+/+ rats. Once the mode inheritance of 
the PKD from the LPK/SsNArc
+/+ rats has been established, genetic mapping of the 
entire genome will be carried out to localize the quantitative trait locus (QTL) that 
controls the PKD phenotypes in the LPK/SsNArc
+/+ rats.  
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There are, however, phenotypic differences in the inheritance and presentation of 
PKD in the LPK/SsNArc
+/+ and other models studied. First, there are no extrarenal 
cysts and second, the disease does not lead to infant deaths. This shows that the gene 
responsible for PKD in the LPK/SsNArc
+/+ is different or an unknown mechanism is 
responsible for the development of the disease. Because of this, it is not plausible to 
genotype the known genes with the aim of eliminating them as possible cause of the 
disease. The cost of doing this will be very high and if it is established that the genes 
are not the cause of the disease, the research will be a waste of time and money. 
Instead, genetic mapping and linkage analysis in the backcross 1 population will be 
carried out to identify the quantitative trait locus (QTL) that harbors the mutation 
responsible for the disease phenotypes. 
2.9: Genetic Mapping and Linkage Analysis of the PKD Locus 
In all PKD studies, the inheritance of PKD is associated with variation in phenotypic 
traits, which includes development of cysts in the kidneys, increased systolic blood 
pressure, anemia and variation in plasma and urine protein, creatinine and urea. It is 
not well established, however, whether variation in the phenotypic traits is a result of 
mutations in different genes or it is the consequence of distortion and deterioration in 
kidney  functions.  To  identify  the  genetic  loci  that  influence  the  variation  in  the 
phenotypic traits, correlation studies between the phenotypes and the genotypes are 
carried out.  
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Using genetic markers to map the chromosomes and linkage analyses to find an 
association  between  genotypic  and  phenotypic  trait  variation,  it  is  possible  to 
identify  the  chromosomal  region  that  contains  the  QTL  that  has  measurable 
phenotypic trait variation owing to genetic influences (Abiola et al., 2003; Tanksley, 
1993). A QTL may be defined as a region in a genome or a genetic locus, which 
controls variation in phenotypic traits of interest (Abiola et al., 2003; Doerge, 2002) 
and mapping of a QTL is the method used to identify this region in the chromosome 
(Abiola et al., 2003; Caulfield et al., 2003; Hao et al., 2009). Once the QTL region is 
identified, more markers are used to reduce the genetic distance between the peak 
markers associated with the QTL (Bihoreau et al., 1997; Kreutz et al., 1995). 
 
According to Lander and Schork (1994), a QTL detected in rodent models of disease 
often predicts the location of a QTL in human disease. Yet, the identification of the 
actual QTL as opposed to the identification of the chromosomal region containing 
the QTL is not easy, especially in genetic analysis of complex traits, such as PKD 
(Lander and Schork, 1994). 
 
Genetic mapping of loci that contain the genes controlling these varying phenotypic 
traits requires the use of polymorphic markers to map the loci (Janaswami et al., 
1997; Manly et al., 2001). There are different types of markers used in mapping, for 
example,  single  nucleotide  polymorphism  (SNP)  and  restriction  fragment  length 
polymorphism  (RFLP).  In  this  study,  however,  simple  sequence  repeat  (SSR) 
markers are used. In mapping the QTL, the markers used must show strong allelic 
identity by descent in grandparents, parents and siblings. The markers must also  
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show allele fragment sizes that are different in the parental DNA (Risch et al., 1993) 
for an unambiguous assignment of the allele fragments to either parent A, parent B 
or the heterozygote (H) recombination. If there is reduction in polymorphism in an 
SSR marker, then that SSR marker may be associated with locus susceptibility to the 
trait under investigation (Steen et al., 1999). 
 
Genetic mapping is carried out by determining the genotype of markers distributed 
across the genome of the segregating population such as the backcross or inter-cross 
(Neuhaus and Beier, 1998). According to Bihoreau and colleagues (1997) genetic 
mapping  results  in  identification  of  genetic  loci  that  are  linked  to  disorders  that 
follow Mendelian pattern of inheritance. The identification of susceptibility loci for 
the traits is not only important in mapping the traits, but also in defining the pattern 
of inheritance and disease etiology (Risch, 1990a). 
 
When a marker genotype segregates with the phenotypic trait in the diseased rats and 
this genotype differs in the normal rats, this is evidence that the disease susceptibility 
locus is linked to the marker. However, to detect a locus with this genotype depends 
on the contribution the marker makes to the total variation in the trait locus (Risch, 
1990b). The randomness of the allele distribution for each marker is then statistically 
evaluated, and the trait locus is generated by analyzing more markers in the vicinity 
of the assigned sub-chromosomal region (Neuhaus and Beier, 1998).  
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In the present study, if the PKD locus is recessive, then the chromosomal interval in 
which  the  mutation  resides  must  be  homozygous  for  the  PKD  parental  allele 
somewhere along its length. If the mutant carries a non-recombinant chromosomal 
interval from the non-PKD parent, the interval is heterozygous along its length and 
that rat cannot present with PKD. In genetic mapping of QTL, whether simple or 
complex, those regions of the chromosomes that are shared by the diseased rats and 
differ between the diseased and the normal rats must be found. To identify this QTL, 
three steps are carried out: scan the entire genome with a dense collection of genetic 
markers,  calculate  the  appropriate  linkage  statistics  at  each  position  along  the 
genome and identify the regions which statistically show a significant deviation from 
what is expected under independent assortment (Lander and Kruglyak, 1995). The 
marker genotype is then used to determine the logarithm of odds (LOD) score for 
each chromosome. 
2.9.1: Logarithm of Odds (LOD) Score 
The LOD score is defined as: LOD = Log10 [(1 - %)
N% 
R/(0.5)
N+R], where % is the 
recombinant fraction and N and R refer to the number of observed non-recombinant 
and  recombinant  individuals,  respectively.  In  the  use  of  LOD  score,  the  relative 
likelihood that a set of data would be obtained if a pair of genes is linked rather than 
if  they  segregate  randomly  is  calculated  for  different  recombination  frequencies 
varying between 0, loci completely linked, and 0.5, no evidence of linkage (Ehm et 
al., 1996). In QTL mapping procedure, the significance of each potential association 
between genotypic and phenotypic traits is measured by a likelihood ratio statistic  
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(LRS). LRS and LOD score, commonly used in human genetics, are essentially the 
same statistic, but according to Manly (2001), the LRS is statistically convenient 
because its distribution is asymptotically a "
2 distribution. Two or more genes that 
segregate  together  are  inherited  together,  and  when  they  are  involved  in  the 
expression  of  a  phenotypic  trait,  then  they  are  linked.  To  establish  the  linkage 
between  these  genes  is  important  and  for  this  to  be  meaningful,  a  chromosomal 
region or QTL associated with the phenotype needs to be identified (Angquist and 
Hossjer, 2005). 
 
In this study, if the QTL associated with the disease phenotypes is identified, then it 
will be possible to predict the locus in the rat genome that is responsible for the PKD 
phenotype  (Churchill  and  Doerge,  1994).  Linkage  between  a  phenotype  and  a 
genotype is firmly accepted as established when the total LOD score reaches a value 
of 3 or more, giving a probability that this occurrence by chance is in less than 1 in a 
1000. A LOD score between 3 and - 2 is accepted as an indication of absence of 
linkage  and  a  demonstration  of  complete  independent  segregation  (Lander  and 
Kruglyak, 1995). 
 
When  linkage  is  established,  the  recombinant  fraction  between  the  two  loci 
concerned is taken as the % value corresponding to the highest LOD score, referred 
to as maximum likelihood ratio statistic (LRS) value of % (Anisimova and Gascuel, 
2006; Guindon and Gascuel, 2003). In reality, however, linkage is unambiguously 
established if the parental genotypes are known with certainty and if the segregation 
ratios are not disturbed by incomplete penetrance (Morton, 1955).  
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2.10: The Study Plan 
2.10.1: Crossbreeding to Determine the Inheritance of PKD 
Mating experiments between the Lewis polycystic kidney (LPK/SsNArc
+/+) rats with 
PKD and Brown Norway (BN/ssArc
-/-) rats without PKD to determine the mode of 
inheritance  of  PKD  will  be  performed.  If  a  recessive  mutation  in  a  single  gene 
controls the disease phenotypes, then all the first filial (F1) generation will be normal 
(Katsuyama et al., 2000). The F1 littermates will be mated to produce the second 
filial (F2) generation and a ratio of 1:3 for PKD:non-PKD rats will be predicted. The 
phenotype  of  the  F2  rats  with  respect  to  PKD  trait,  body  weight,  systolic  blood 
pressure, plasma urea, creatinine and proteins, kidney weight will be measured, and 
histological determination of cysts in kidneys and liver will be carried out. The liver, 
kidney and tail tips will be stored for DNA extraction for future linkage analyses. 
The phenotypic data from the F2 rats will be compared to the phenotypic data from 
the LPK/SsNArc
-/- and LPK/SsNArc
+/+ rats. This is critical in the determination of 
the modifier effect of the background strain.  
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2.10.2: Backcross Studies for Mapping and Linkage Analysis 
In humans, PKD arises as a result of mutation in any of the disease loci in PKD-1, 
PKD-2 and PKHD-1. In rats, Pkhd-1 was mapped to chromosomes 5 and 9 (Guay-
Woodford, 2003; Nauta et al., 2000), while Pkd-1 and Pkd-2 were mapped to other 
chromosomes, as explained above. Eliminating these genes and other genes that are 
associated with dominant and recessive PKD in murine models by sequencing the 
genes in the LPK/SsNArc
+/+ rats is cumbersome and expensive. In addition, it has 
already  been  established  through  mating  of  the  mutant  rats  that  the  PKD  in  the 
LPK/SsNArc
+/+ rats does not lead to development of extrarenal cysts and it does not 
lead to infant deaths. This suggests that the mutated gene responsible for PKD in the 
LPK/SsNArc
+/+ rats is different, or a mechanism yet to be discovered, is responsible 
for its development. 
 
Therefore, a backcross generation will be raised and mapping and linkage analyses 
between  genotypic  and  phenotypic  trait  data  will  be  carried  out.  Segregation 
distortion of genetic markers near the corresponding rat homologs of these genes 
will also be tested. We will genotype all the rat autosomes, but a special focus will 
be placed on chromosomes 5 and 9, because the genes that cause PKD were mapped 
to both chromosomes in other murine models (Nauta et al., 2000; Ward et al., 2002). 
According to Lander and Kruglyak (1995), the analysis of PKD can be carried out 
with as few as 20 affected backcross rats.  
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If chromosomes 5 and 9 are excluded for being responsible for the development of 
the disease in the present study, it will then suggest that the mutated gene in this rat 
model is novel, and the DNA from the backcross rats will be used in a genome-wide 
scan to map the gene concerned, using well-defined criteria (Figure 2-14). Mating 
experiments  will  be  performed  between  male  LPK/SsNArc
+/+  and  female  Wistar 
Kyoto (WKY/NArc
-/-) rats to raise F1 rats. If a recessive mutation in a single gene 
controls  the  disease  in  the  LPK/SsNArc
+/+  rats,  then  all  the  F1  progeny  will  be 
normal.  The  female  F1  rats  will  be  mated  with  the  male  LPK/SsNArc
+/+  rats  to 
produce backcross 1 (BC1) progeny and a ratio of 1:1 for PKD:non-PKD rats will be 
expected. 
 
If the markers near the corresponding rat homologs of known PKD genes are not 
linked to the gene mutated in the LPK/SsNArc
+/+ rats, then a novel gene is predicted 
to confer the mutant phenotype observed. In this case, DNA from the initial 20 BC1 
rats will be tested using markers distributed across the 20 rat autosomes. There are 
over  240  known  markers  whose  genotype  differ  between  the  LEW/SsNArc
-/- 
(background  strain  to  LPK/SsNArc
+/+)  and  the  WKY/NArc
-/-  (Steen,  2000).  In 
genetic mapping, markers that vary between the progenitor strains by greater than 12 
base pairs, and are located at approximately 20 cM intervals will be selected. 
 
The PCR products will be separated on 8% high-resolution polyacrylamide gels, 
stained with ethidium bromide and visualized under UV illumination. Genotypes of 
the BC1 will be assigned as homozygous LPK/SsNArc
+/+ (A), WKY/NArc
-/- (B) or 
heterozygous  LPK/SsNArc
+/+/WKY/NArc
-/-  (H)  by  reference  to  the  known  allele  
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sizes and to control parental and F1 DNAs. The genotypic data will be entered into a 
database. Linkage of markers with a putative LPK/SsNArc
+/+ locus will be predicted 
by the presence of a significant excess of homozygotes in the affected progeny. The 
significance of this linkage will be further assessed by calculating the Chi Square 
values in the F2 and BC1 progeny and the values converted to the logarithm of the 
odds to the base 10, (LOD) score by dividing by 4.6. A LOD score of 3 or more will 
indicate genome-wide significant evidence for linkage between the QTL region and 
the  phenotypes  of  PKD  (Lander  and  Kruglyak,  1995).  Such  analysis  will  be 
confirmed using the Map Manager program (Manly et al., 2001). 
2.10.3: Gene Identification in the Lewis Polycystic Kidney Rat 
Once the QTL region controlling the PKD phenotypes is mapped to a chromosomal 
location,  the  candidate  genes  in  the  QTL  region  will  be  identified.  This  will  be 
confirmed by using the genotype of the F2 progeny in linkage analyses in future 
studies. If markers show linkage to a known gene or homolog, then primers that 
amplify  the  exons  of  such  genes  will  be  designed.  Exons  of  LPK/SsNArc
+/+, 
WKY/NArc
-/-  rats  and  parental  LEW/SsNArc
-/-  strains  will  be  amplified  and 
sequenced.  In  the  absence  of  known  mutations,  which  could  account  for  the 
phenotype, other genes will be mapped. A further 100 BC1 rats will be genotyped 
using an increasingly densely spaced panel of SSR markers that lie within 40 cM of 
the peak of linkage. In this way, it will be possible to map the gene to between two 
markers separated by 1 cM. Map resolution can be gained by genotyping more BC1 
rats and inspection of the genome assembly may reveal candidate genes that can be  
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sequenced and compared directly. Sequence changes in the candidate gene between 
LPK/SsNArc
+/+  and  parental  LEW/SsNArc
-/-  rats  will  indicate  that  this  gene  is 
responsible for the mutant phenotype. 
 
1. Disease phenotype (PKD) 
2. Establish a genetic basis for the PKD (Mode of inheritance) 
3. Map a susceptibility locus to a defined QTL 
4. Fine mapping of susceptibility locus 
5. Identify candidate genes in the QTL 
6. Carry out sequencing of the candidate genes in the PKD and the non-PKD rats 
7. Identify the types of mutation in the candidate genes 
8. Test effects of mutation on function 
9. Validate resistance by allele transgenesis 
 
FIGURE 2-14: PATHWAY TO IDENTIFY THE PKD GENE IN THE LPK/SSNARC
+/+ RAT 
The pathway for defining the susceptibility genetic locus that causes PKD in the 
LPK/SsNArc
+/+ rats is not easy, but it may be simplified to this model (Modified 
from Morahan and Morel, 2002).  
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2.11: The Hypothesis 
When a genetic disease appears in a human population, it is important to understand 
its mode of inheritance and to establish its genetic origin. The use of experimental 
models with the same disease to understand its inheritance is therefore paramount. 
Following Gregor Mendel’s experiments on the inheritance of traits, and his method 
of setting a hypothesis, it has become imperative to develop experiments that are in 
accordance with Mendelian genetics. For this reason, in the present study, it was 
generally  hypothesized  that  mutation  in  a  single  gene  was  responsible  for  the 
development and expression of PKD in the LPK/SsNArc
+/+ rats. 
2.12: The Aim and Objectives 
2.12.1: The Aim of the Study 
The  aim  of  this  study  is  to  characterize  polycystic  kidney  disease  in  the  Lewis 
polycystic kidney rats.  
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2.12.2: The Objectives of the Study 
1  To determine the mode of inheritance of polycystic kidney disease in the 
Lewis polycystic kidney rats by raising F2 and BC1 progeny. 
2  To determine the genetic locus linked to the PKD phenotypes in the Lewis 
polycystic kidney rats by mapping the 20 rat autosomes. 
3  To determine if there are genetic modifier loci that influence the expression 
of PKD in the Lewis polycystic kidney rats.  
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CHAPTER III 
Determination of Inheritance of Polycystic Kidney Disease 
3.1: Introduction 
Genetic studies of human diseases require understanding of inheritance of visible, 
genetically controlled characteristics. According to Risch et al. (1993), one way of 
understanding the inheritance of human genetic diseases is to study analogous traits 
in experimental models. In this study, the LPK/SsNArc
+/+ rats that spontaneously 
developed PKD are used to determine the inheritance of the disease and to determine 
whether one, two or many genes are involved in the development of the disease. 
Furthermore, the LPK/SsNArc
+/+ rats are used to understand if genetic modifier loci 
influence the phenotypic expression of the PKD. 
 
The advantage of using the LPK/SsNArc
+/+ rats is that genetic background and the 
environmental factors that influence the phenotype of the disease can be controlled 
(Rossetti and Harris, 2007). In this study, the mutant LPK/SsNArc
+/+ rats are used in 
the genetic background of BN/ssArc
-/- and WKY/NArc
-/-, both are genetically distant 
from the LPK/SsNArc
+/+ strain and do not carry the mutation. It is hoped that the 
study will establish whether the genetic background of the two rat strains has any 
significant influence in the inheritance and expression of PKD in the LPK/SsNArc
+/+  
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rats. In the determination of inheritance of PKD in the LPK/SsNArc
+/+ rats, and in 
accordance  with  Mendelian  principles  of  genetics,  it  was  hypothesized  that a  
recessive mutation in one gene was responsible for the development of PKD. Based 
on this hypothesis, it was expected that the phenotypic presentation of PKD in the 
progeny would follow simple Mendelian segregation ratios of 1:3 in the F2 and 1:1 
in the BC1, for PKD to non-PKD rats. 
3.2: Materials and Methods 
3.2.1: Breeding of Animals 
Breeding of LPK/SsNArc
+/+, BN/ssArc
-/- and WKY/NArc
-/- rats is carried out at the 
Animal Resources Centre of Western Australia in accordance with the requirements 
of the Animal Welfare Act of 2002, Western Australia. Mating experiments for the 
study were carried out with the approval of the Animal and Ethics Committee of 
Murdoch University, registration number AEC 1156.  
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3.2.2: Rat Strains to Determine the Inheritance of PKD 
Polycystic kidney disease studied here developed as a result of spontaneous mutation 
in an inbred Lewis rat strain, LEW/SsNArc
-/-, at the Animal Resources Centre of 
Western Australia. The Animal Resources Centre received the LEW/SsNArc
-/- rat 
strain from  the  Department  of  Health  and  Human  Services,  National  Institute  of 
Health, USA, in 1990. To maintain the PKD trait in this new colony of the PKD rats, 
now referred to as the Lewis polycystic kidney (LPK/SsNArc
+/+) rats at the Animal 
Resources  Centre,  mating  was  performed  between  brothers  and  sisters  with  the 
disease. Currently more than ten generations of the mutant rats have been raised and 
it has been established that all offspring from each intercross developed bilateral 
enlarged cystic kidneys (data not published). 
 
The Brown Norway rat strain, BN/ssArc
-/-, was received by the Animal Resources 
Centre  from  Harlan,  Indianapolis  in  2003.  To  maintain  the  strain  at  the  Animal 
Resources Centre, mating between brothers and sisters was carried out. There was no 
evidence of development of PKD in any member of the strain. 
 
The Wistar Kyoto rat strain, WKY/NArc
-/-, was received by the Animal Resources 
Centre from the School of Medicine, Flinders University, South Australia as F12 in 
1983. Flinders University received this strain from the National Institute of Health 
(NIH), USA, as F14 in 1976. The NIH received the animals from non-inbred stock  
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from the Kyoto School of Medicine, Japan in 1971. The strain is maintained by full-
sib mating. 
 
The pure breeds, LEW/SsNArc
-/-, LPK/SsNArc
+/+, BN/ssArc
-/- and WKY/NArc
-/- are 
kept as single colonies at the Animal Resources Centre. BN/ssArc
-/- and WKY/NArc
-
/- were chosen for this study to determine if their genetic background is a factor in 
the inheritance of the disease. The rat strains drank the same water and were fed on 
the same cubes, fortified with vitamins and minerals to meet the nutrient requirement 
of the rats after the diet was autoclaved. The rats were housed in a quarantined area 
with enough space to dispel the possibility that congestion influences the expression 
of PKD. 
3.2.3: Experiment to Raise Second Filial (F2) Generation 
Homozygote mutant LPK/SsNArc
+/+ male and homozygote non-mutant BN/ssArc
-/- 
female rats (3 pairs) were mated. Each pair produced 2 litters of heterozygote F1, a 
total of 6 litters. The F1 progeny were mated as brothers and sisters (16 pairs). Each 
pair produced 2 litters of F2, a total of 152 progeny.  
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3.2.4: Experiment to Confirm the Mode of Inheritance 
Homozygote mutant LPK/SsNArc
+/+ male and homozygote non-mutant WKY/NArc
-
/- female rats (3 pairs) were mated. Each pair produced 3 litters of F1 progeny. The 
F1  females  were  mated  with  the  LPK/SsNArc
+/+  male  rats  (13  pairs).  Each  pair 
produced 2 litters of BC1, a total of 139 progeny. 
3.2.5: Recording of Phenotypic Traits 
The rats were earmarked as previously described (Short and Woodnott, 1969). From 
one week after birth until euthanasia, the rats were palpated weekly to determine 
which rat had developed enlarged kidneys and which had not. 
3.2.5.1: Measurement of Systolic Blood Pressure 
Systolic  blood  pressure  (SBP)  of  F2  and  BC1  progeny  was  measured  at  twelve 
weeks of age, by the tail-cuff method, using an NIBP Controller (ADI Instruments, 
Castle Hill, NSW, Australia). At least three measurements were made per animal and 
the average value was used in statistical analysis. 
3.2.5.2: Urine Collection and Analysis 
Urine  was  collected  from  each  BC1  rats  between  10:00AM  and  4:00PM  using 
metabolic cages. No urine was collected from the F2 progeny. To 20µl of urine 
samples, blank and standard solution, 1000µl of Pyrogallol red was added. This was  
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mixed and incubated at 37° C for 5 minutes. The absorbance of the samples (Asample) 
and the standard (Astandard) was measured against the reagent blank at 600 nm using a 
spectrophotometer. Protein concentration was calculated according to instructions of 
the manufacturers (RANDOX Laboratories Ltd, UK). 
Protein concentration (g/L) = Asample x [Standard]/Astandard. 
Where: [Standard] is the concentration of the standard solution in g/L, 
Asample is the absorbance of the sample, 
Astandard is the absorbance of the standard solution. 
 
Urine creatinine was determined as follows: To 20µl of urine sample (diluted 1 in 20 
with distilled water) was added sodium hydroxide and picric acid, as per instructions 
provided by the manufacturers (RANDOX Instrument). Creatinine, in the presence 
of sodium hydroxide solution, reacts with picric acid to form a colored complex. The 
rate of formation of the complex was measured using a colorimetric method. Urine 
protein/creatinine ratio was calculated according to instructions of the manufacturer 
(RANDOX Laboratories Ltd, UK). 
Protein/creatinine ratio = 8840[Protein]/[Creatinine]. 
Where: [Protein] is the concentration of protein in g/L, 
[Creatinine] is the concentration of creatinine in g/L. 
3.2.5.3: Blood, Kidney and Liver Collection 
The  rats  were  euthanized  using  carbon  dioxide  and  oxygen  gas  mixture,  in  the 
proportions  of  80:20.  After  euthanasia,  the  rats  were  weighed.  Blood  (2ml)  was 
collected  by  cardiac  puncture  into  Lithium-Heparin  tubes.  The  rats  were  opened  
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along the linear Alba, and kidneys and sections of liver were removed. Each kidney 
was  weighed  and  both  kidneys  and  sections  of  the  liver  were  fixed  in  4% 
formaldehyde  solution.  Sections  of  the  liver  were  stored  at  -80°C  for  DNA 
extraction. 
3.2.5.4: Blood Analysis 
The packed cell volume/hematocrit (PCV) was determined by the microhematocrit 
technique  using  a  Haeraeus  Biofuge  hemo  centrifuge.  Plasma  total  solid  protein 
(TSP)  was  estimated  on  EDTA  using  a  Refractometer  according  to  the 
manufacturers’ instructions (RANDOX Laboratories Ltd, UK). 
 
Plasma creatinine was determined in the same way as urine creatinine, except that no 
dilution  of  samples  was  carried  out.  Plasma  urea  was  measured  on  the  Randox 
Daytona,  the  reaction  catalyzed  by  urease  enzyme  (RANDOX  Laboratories  Ltd, 
UK).  The  ammonia  produced  combined  with  $-oxoglutarate  and  hydrogenated 
nicotinamide  adenine  dinucleotide  (NADH)  in  the  presence  of  glutamate-
dehydrogenase to yield glutamate and NAD
+. The NAD
+ produced was measured in 
µmol/L using an ultraviolet method. 
3.2.5.5: Histological Analysis of Sections 
Histological  analysis  of  the  kidney  and  liver  tissues  was  carried  out  at  the 
Department of Histology, Murdoch University. Briefly, the kidney and liver tissues 
were  paraffin  embedded  and  sectioned  (4µM  thickness)  using  a  microtome.  The  
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sections were fixed on glass slides, stained with hematoxylin and eosin and viewed 
with light microscope and the images digitalized using a digital camera (Olympus). 
3.2.5.6: Statistical Analysis 
Statistical  analysis  of  the  phenotypic  trait  data  was  carried  out  using  Statistical 
Package  for  Social  Sciences  (SPSS16),  Chicago,  Ill.,  USA.  One-way  analysis  of 
variance (ANOVA) and multiple comparison tests with Post hoc analyses of the 
combined male and female data sets were performed and significance was taken at P 
< 0.05, unless otherwise stated. 
3.3: Results 
The phenotypic trait data shown in all graphs for Lewis and LPK/SsNArc
+/+ rats 
(animals  kept  in  the  same  conditions  as  in  the  present  study)  were  previously 
collected and kindly provided by Dr. Phillips (data not published). These phenotypic 
trait data were used in statistical analysis together with the phenotypic trait data 
collected from the present study. The gross and microscopic anatomy of the kidneys 
(Figures 3-1 and 3-2) revealed that 28% of the F2 and 48% of the BC1 progeny 
developed PKD (Table 3-1). The cysts were found in the kidneys and not in the liver 
of the PKD rats (Figures 3-2 to 3-4). The non-PKD rats did not develop any cysts. 
The ratios of PKD:non-PKD rats are in agreement with Mendelian segregation ratios 
for inheritance of traits resulting from a recessive mutation in a single gene.  
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The bars in all the graphs (Figures 3-4 to 3-16) are the values for mean ± SEM of the 
phenotypic trait data. Increase in kidney size due to accumulation of fluids in the 
cysts, and presented here as percentage kidney/body weight, is directly correlated to 
increase  in  systolic  blood  pressure,  decrease  in  hematocrit  and  increase  in  urine 
specific gravity (Figures 3-7, 3-9 and 3-17). The PKD rats developed higher systolic 
blood pressure than the non-PKD rats. But, there were no significant differences 
(except for the mean body weight, Figure 3-5) in the mean values of phenotypic trait 
data between male and female rats or between F2 and BC1 rats with PKD or without 
PKD. The rats with PKD lost kidney homeostatic functions and their kidneys were 
less able to concentrate urine, as shown by the amounts of urine proteins, urea and 
creatinine. The kidneys of the PKD rats progressed to end stage renal disease and by 
the 12
th week of life, they were at the point of death. As such, they were sacrificed. 
 
TABLE 3-1: THE CHI SQUARE STATISTICS 
 
Progeny  N  Non-PKD  O  E  %  Ratio  "
2  P 
F2  152  110  42  38  28  1:3  0.531  > 0.05 
BC1  139  72  67  69.5  48  1:1  0.180  > 0.05 
 
!
2:  Chi Square values 
O:  Observed number of rats with PKD 
E:  Expected number of rats with PKD 
F2:  Second filial generation 
BC1:  Backcross 1 generation  
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3.3.1: Gross and Microscopic Anatomy 
 
 
 
FIGURE 3-1: GROSS AND MICROSCOPIC ANATOMY OF NON-PKD KIDNEYS 
Gross (3-1A) and microscopic (3-1B) anatomy of a non-PKD BC1 rat, 
Magnification x400.  
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FIGURE 3-2: GROSS AND MICROSCOPIC ANATOMY OF PKD KIDNEYS 
Gross (3-2A) and microscopic (3-2B) anatomy of kidneys of a PKD BC1 rat, 
Magnification x400.  
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FIGURE 3-3: MICROSCOPIC ANATOMY OF LIVER FROM PKD AND NON-PKD RATS 
Liver sections of a non-PKD (3-3A) and a PKD (3-3B) rat, 
The asterisks show the artery (left) and the vein (right), 
Magnification x400  
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3.3.2: Body and Kidney Weights 
FIGURE 3-4: MEAN BODY WEIGHT OF PKD AND NON-PKD RATS 
3-4A: Combined mean body weight; 3-4B: Mean body weight of male and female 
rats. The number of rats in each category is indicated along the bars and the data are 
presented as mean ± SEM, **P < 0.001, ***P < 0.0001.  
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FIGURE 3-5: PERCENTAGE RELATIVE KIDNEY/BODY WEIGHT 
3-6A:  Combined  mean  percentage  kidney/body  weight;  3-6B:  Mean  percentage 
kidney/body weight of male and female rats (no significant differences). Data are 
presented as mean ± SEM, and the number of rats in each group is indicated, *** P < 
0.0001.  
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3.3.3: Systolic Blood Pressure 
FIGURE 3-6: MEAN SYSTOLIC BLOOD PRESSURE OF PKD AND NON-PKD RATS 
3-7A: Combined mean systolic blood pressure; 3-7B: Mean systolic blood pressure 
of male and female rats (no significant differences). The number of rats in each 
category is indicated along the bars and the data are presented as mean ± SEM. ***P 
< 0.0001.  
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FIGURE 3-7: SYSTOLIC BLOOD PRESSURE AND PERCENTAGE KIDNEY/BODY WEIGHT 
The  linear  relationship  between  systolic  blood  pressure  and  percentage  relative 
kidney/body weight of PKD and non-PKD rats, R
2 = 0.66, P < 0.01.  
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3.3.4: Blood Sample Analysis 
FIGURE 3-8: PACKED CELL VOLUME IN PKD AND NON-PKD RATS 
3-9A: Combined mean packed cell volume; 3-9B: Mean packed cell volume of male 
and female rats (no significant differences). The data are presented as mean ± SEM. 
The number of rats in each category is indicated along the bars, *P < 0.05, ** P < 
0.001, *** P < 0.0001.  
 
 
86 
 
 
 
 
 
 
 
 
FIGURE 3-9: CORRELATION BETWEEN PCV AND PERCENTAGE K/B WEIGHT 
The  linear  relationship  between  packed  cell  volume  and  percentage  kidney/body 
weight in PKD and non-PKD BC1 rats, R
2 = 0.59, P < 0.01.  
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FIGURE 3-10: PLASMA TOTAL SOLID PROTEIN IN PKD AND NON-PKD RATS  
3-11A: Combined mean plasma total solid proteins; 3-11B: Mean plasma total solid 
proteins of male and female rats (no significant differences). The number of rats in 
each group is indicated along the bars and the data are presented as mean ± SEM, 
**P < 0.001.  
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FIGURE 3-11: PLASMA CREATININE OF PKD AND NON-PKD RATS  
3-12A: Combined mean plasma creatinine; 3-12B: Mean plasma creatinine of male 
and female rats (no significant differences). The number of rats in each group is 
indicated along the bars and the data are presented as mean ± SEM, *P < 0.05, ***P 
< 0.0001.  
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FIGURE 3-12: PLASMA UREA OF PKD AND NON-PKD RATS 
3-13A: Combined mean of plasma urea; 3-13B: Mean of plasma urea of male and 
female  rats  (no  significant  differences).  The  number  of  rats  in  each  group  is 
indicated in brackets and the data are presented as mean ± SEM, ***P < 0.0001.  
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3.3.5: Urine Sample Analysis 
FIGURE 3-13: URINE PROTEIN OF PKD AND NON-PKD RATS 
3-14A: Combined mean of urine proteins; 3-14B: Mean of urine proteins of male 
and female rats (no significant differences). The number of rats in each group is 
indicated along the bars and the data are presented as mean ± SEM, ***P < 0.001.  
 
 
91 
 
 
 
FIGURE 3-14: URINE CREATININE IN PKD AND NON-PKD RATS 
3-15A: Combined mean of urine creatinine; 3-15B: Mean of urine creatinine of male 
and female rats (no significant differences). The number of rats in each group is 
indicated along the bars and the data are presented as mean ± SEM, ***P < 0.001.  
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FIGURE 3-15: URINE PROTEIN/CREATININE RATIO IN PKD AND NON-PKD RATS 
3-15A:  Combined  mean  of  urine  protein/creatinine  ratio;  3-15B:  Mean  of  urine 
protein/creatinine  ratio  of  male  and  female  rats  (no  significant  differences).  The 
number of rats in each group is indicated along the bars and the data are presented as 
mean ± SEM, ***P < 0.0001.  
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FIGURE 3-16: URINE SPECIFIC GRAVITY OF PKD AND NON-PKD RATS 
3-16A: Combined mean of urine specific gravity; 3-16B: Mean of urine specific 
gravity of male and female rats (no significant differences). The number of rats in 
each category is indicated along the bars and the data are presented as the mean ± 
SEM, ***P < 0.0001.  
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FIGURE 3-17: CORRELATION BETWEEN SPECIFIC GRAVITY AND PERCENTAGE K/B 
WEIGHT 
The linear relationship between urine specific gravity and percentage kidney/body 
weight in PKD and non-PKD BC1 rats, R
2 = 0.32, P < 0.01.  
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3.4: Discussion 
In the present study, there is strong evidence that the inheritance of PKD in the 
LPK/SsNArc
+/+ rats follows simple Mendelian segregation ratios for traits controlled 
by a recessive mutation in a single gene. This is consistent with several reports that 
recessive mutation in one gene was the cause of ARPKD (Capisonda et al., 2003; 
Harris, 2002; Mucher et al., 1998; Onuchic et al., 2002; Ward et al., 2002). However, 
although  genetic  studies  of  ARPKD  in  other  murine  models  clearly  show  that 
mutations in multiple loci result in various forms of the disease (Lager et al., 2001; 
Rossetti and Harris, 2007), the current study shows that a recessive mutation in one 
genetic locus is the cause of ARPKD in the LPK/SsNArc
+/+ rats. 
 
The PKD in the LPK/SsNArc
+/+ rats was expressed in the kidneys and resulted in 
bilateral  enlargement  of  the  kidneys.  Correlation  studies  between  systolic  blood 
pressure, packed cell volume and urine specific gravity with percentage kidney/body 
weight established a strong direct correlation, and demonstrated that the cysts in the 
kidneys were the cause of the increase in systolic blood pressure in all the PKD rats, 
development  of  anemia  in  all  the  PKD  rats,  loss  of  kidney  homeostasis  and 
deterioration of the kidney functions in the PKD rats. Although the limited sample 
size of the LPK/SsNArc
+/+ and the Lewis rats leaves open any conclusions regarding 
genetic modification of phenotypic traits, it supports the hypothesis that a recessive 
mutation in one genetic locus is the cause of the statistical differences in the mean 
values of the PKD phenotypes.  
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In the two mating experiments, none of the F1 progeny developed cystic kidneys. 
The lack of cysts in the kidneys of the F1 progeny indicates a recessive mutation in a 
single locus, which caused the development of ARPKD in the Lewis rats. It is also 
possible that several recessive mutations in different genetic loci were involved, but 
these  loci  interacted  with  each  other,  so  that  it w a s   unlikely  that  any  of  the  F1 
progeny developed the disease. The ratios of PKD to non-PKD in the F2 (42:110) 
and BC1 (67:72) progeny are consistent with Mendelian segregation ratios for the 
inheritance of traits controlled by a recessive mutation in a single gene (Ehm et al., 
1996). If a dominant mutation were responsible for the disease, a bigger percentage, 
if not all of the F1 progeny would develop PKD and the ratios of PKD:non-PKD 
would be altered. Yet, the influence of genetic modifier loci that affect the disease 
progression in the rat population is not ruled out. 
 
In the study of ARPKD in humans and in murine models, both genetic background 
and environment factors influenced the disease phenotype (1999; Mrug et al., 2005; 
Rossetti  and  Harris,  2007).  According  to  Qian  and  Watnick  (1999),  mutation  in 
genes that are in close proximity or distal to the gene carrying the PKD trait on the 
same or on a different chromosome also influenced the expression and progression 
of the disease. In the Han:SPRD rats, for example, mutation in modpkdr1 influenced 
the  expression  of  ARPKD  (Bihoreau  et  al.,  2002;  Guay-Woodford  et  al.,  1996; 
Kleymenova et al., 2001; Qian and Watnick, 1999; Upadhya et al., 1999).  
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In the present study, the effect of the environment on the expression of ARPKD was 
invariant, but the genetic background varied. The invariant environment was created 
by the conditions of the breeding facility whereby all the rats received the same 
amount of light, ate the same food and drank the same water. In addition, equal 
number of rats was kept in each cage with the same dimensions. The variation in 
genetic background was, however, created by the use of different female rat strains 
(BN/ssArc
-/- and WKY/NArc
-/-). Regardless of the different genetic backgrounds of 
the female rats, there were no statistical significant differences in the mean values of 
the phenotypic trait data between male and female rats with or without PKD across 
the rat population, and this suggests lack of significant genetic modifier effect. 
 
The phenotypes of ARPKD in LPK/SsNArc
+/+ rats are similar to the phenotypes of 
ARPKD in humans (Harris, 2009; Zerres et al., 2004). In both the LPK/SsNArc
+/+ 
rats and humans, homozygote individuals present with enlarged cystic kidneys, as 
previously reported (Harris and Torres, 2009; Losekoot et al., 2005; Onuchic et al., 
2002). The cysts develop early in fetal life and in humans, enlarged kidneys can be 
observed in utero using ultrasound scans (Martinez and Grantham, 1995). In the 
LPK/SsNArc
+/+ rats, enlarged kidneys can be palpated in the first week of birth, 
which implies that the cysts could be detected in utero using ultrasound. In humans, 
all ARPKD patients develop higher systolic blood pressure and anemia (Deget et al., 
1995; Schillinger, 1993), and this was consistent in all the rats with ARPKD in this 
study.  
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In human studies, infants with ARPKD suffer from pulmonary hypoplasia and most 
of them die early in life (Nauta et al., 2000). In mice, the jcpk and bpk mutants die 
within the first four weeks after birth (Chittenden et al., 2002). In the present study, 
there was no incident of infant death. Furthermore, in human studies, individuals 
with ARPKD develop extra-renal cysts in the liver and other organs (Gabow et al., 
1984; Gabow et al., 1990; Zhang et al., 2004). None of the rats with ARPKD in this 
study  developed  extra-renal  cysts.  The  lack  of  extra-renal  cysts  in  the  rats  with 
ARPKD  in  the  present  study  is  not  due  to  the  influence  of  genetic  modifier  or 
background effect, as proposed for wpk rats (Nauta et al., 2000; Smith et al., 2006b), 
but it may be due to mutation of a gene which is different from Pkhd-1. 
 
The  combined  body  weight  of  the  rats  varied  across  the  rat  population,  but  a 
significant  difference  was  observed  in  the  mean  body  weight  between  male  and 
female rats in both F2 and BC1 progeny. There was also a significant difference in 
the combined percentage kidney/body weight in both the PKD and the non-PKD 
rats, but no significant difference was observed between male and female rats. The 
significant differences observed between the PKD and the non-PKD suggests that 
the PKD rats were severely affected by the development of cysts in the kidneys. 
 
Higher systolic blood pressure is a common finding in human and murine models 
with ARPKD and it contributes to morbidity and mortality of the murine models 
(Phillips et al., 2007). In the present study, all the rats with PKD developed higher 
systolic blood pressure. However, there was no significant difference in the mean 
values  of  systolic  blood  pressure  between  male  and  female  rats  with  or  without  
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ARPKD. The lack of significant difference in systolic blood pressure suggests that 
the varied genetic background (as provided by the female rats) did not have any 
significant  effect  in  modulation  of  systolic  blood  pressure.  The  finding  also 
demonstrates that an increase in systolic blood pressure was a direct consequence of 
cysts in the kidneys, as previously described (Fall and Prisant, 2005; Kaplan et al., 
1988),  and  as  shown  here  by  correlation  analysis.  Given  that  the  scores  cluster 
uniformly  around  the  regression  line,  the  assumption  of  homoscedasticity  is  not 
violated, which demonstrates that increase in systolic blood pressure in the PKD rats 
is the result of the development of cysts in the kidneys and the accumulation of 
fluids in to the cysts. It was observed that higher systolic blood pressure in the PKD 
rats preceded end stage renal disease. 
 
The mechanism in the development of higher systolic blood pressure associated with 
ARPKD is not well established in studies in human and murine models. However, 
stimulation of the renin-angiotensin-aldosterone system (RAAS) and an increase in 
sympathetic activity during PKD progression have been suggested to cause increase 
systolic blood pressure (Chapman et al., 1990; Cody, 1997) in all PKD individuals. 
The development of higher systolic blood pressure in the LPK/SsNArc
+/+ rats with 
PKD may be interpreted as a mechanism to compensate for poor renal perfusion. 
 
The  direct  positive  correlation  between  systolic  blood  pressure  and  percentage 
kidney/body weight implies that increase in cyst dimensions due to accumulation of 
fluid into the cyst lumen is followed by proportionate increase in systolic blood 
pressure. Whether the increase in systolic blood pressure is a result of sympathetic  
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activity, which is to compensate for poor renal perfusion is not known. Therefore, 
further research needs to be done to establish the underlying mechanisms that lead to 
increase  in  systolic  blood  pressure  during  the  development  of  ARPKD  in  the 
LPK/SsNArc
+/+ rats. 
 
Measurement of hematocrit is necessary to predict development of anemia, which 
results from reduction in red blood cell mass or hemoglobin concentration in the 
blood (Jain and Kamat, 2009). In this study, the measurement of hematocrit was 
necessary to define the effect of cysts in the kidneys. It was found that all rats with 
ARPKD had lower hematocrit levels than their age-matched counterparts without 
ARPKD. It was observed that the liver of the PKD rats was lighter in color than that 
of the non-PKD counterparts, which signified severe anemia. However, there were 
no significant differences in hematocrit levels between male and female rats with 
PKD, and this demonstrates lack of genetic modifier loci that influenced hematocrit 
production. 
 
Kidneys produce erythropoietin, a hormone important in red blood cell maturation, 
and its absence leads to development of anemia (Sulkowska et al., 2006). In normal 
kidneys, once erythropoietin hormone is produced, it is transported in blood to the 
bone marrow and it binds to the receptors on the committed erythroid progenitor 
cells (Erslev, 1991). It is then internalized so that the survival, proliferation and 
maturation of the marrow progenitor cells are stimulated (Ackleh et al., 2006). This 
leads to production and maturation of erythrocytes. Decrease in hematocrit in rats 
with ARPKD shows that peritubular interstitial cells of the kidneys were severely  
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affected by the cysts in the kidneys. This also means that the pathway that leads to 
red blood cell maturation in the LPK/SsNArc
+/+ rats is affected the same as in the 
pcy mouse with PKD (Janaswami et al., 1997). 
 
The  proportionate  decrease  in  hematocrit  levels  with  increase  in  percentage 
kidney/body  weight  implies  that  the  cysts  in  the  kidneys  are  the  cause  of  the 
decrease  in  hematocrit  levels.  It  is  not  clear,  however,  whether  the  decrease  in 
hematocrit  in  the  LPK/SsNArc
+/+  rats  is  caused  by  a  decrease  in  functional 
hematopoietic stem cells that produce erythropoietin or by erythropoietin deficiency 
due to renal insufficiency. As such, a study to measure the levels of erythropoietin in 
both the PKD and the non-PKD rats is needed to understand the effects of cyst 
development on erythropoietin production. 
 
Determination of plasma protein, creatinine and urea is important in diagnosis of 
renal diseases (Price et al., 2005). There was a decrease in plasma total solid protein 
in  the  PKD  rats.  The  decrease  in  plasma  proteins  is  caused  by  poor  protein  re-
absorption from the glomerular filtrate due to reduction in glomerular filtration rate. 
However, there were no differences in plasma proteins between male and female rats 
or F2 and BC1 progeny with or without PKD. Decrease in levels of these osmolites 
suggests that the renal nephrons are severely affected by the cysts, rendering the 
kidneys unable to carry out homeostasis (Yoder et al., 1997). Although less that 5% 
of the renal nephrons per kidney are reported affected in humans with PKD (Xu et 
al., 2007), in the LPK/SsNArc
+/+ rats, the percentage of affected renal nephrons is 
not known.  
 
 
102 
The levels of plasma creatinine and urea were higher in all PKD rats. Detection of 
higher  amounts  of  creatinine  and  urea  in  plasma  is  always  used  to  estimate 
glomerular filtration rate (Flamant et al., 2009). However, there was no difference in 
the levels between male and female or F2 and BC1 rats with or without PKD. The 
higher amounts of plasma creatinine and urea indicate that the cysts affected the 
homeostatic function of the kidneys. Therefore, this study has shown that the cysts in 
the kidneys affected the glomerular filtration rate in all the rats with ARPKD. 
 
Higher amounts of protein in urine is diagnostic and confirmation of renal disease 
(Ruggenenti et al., 1998). All the rats with ARPKD had higher protein content in 
their urine. The LPK/SsNArc
+/+ rats, in particular, had higher content of proteins in 
the  urine  than  the  Lewis  counterpart.  This  trend  was  also  observed  in  urine 
creatinine, urine protein/creatinine ratio and urine specific gravity. In addition, urine 
specific gravity was directly, but negatively correlated to the percentage kidney/body 
weight and this signifies that the cysts in the kidneys are the cause of decrease in 
kidney  homeostatic  functions.  There  were  no  significant  differences  observed  in 
urine proteins, urine creatinine, urine protein/creatinine ratio and specific gravity 
between  male  and  female  rats  with  or  without  PKD.  This  mutation  controls  the 
phenotype of ARPKD in the LPK/SsNArc
+/+ rats and it is the main genetic mutation 
responsible for variation in the phenotypic traits.  
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In  conclusion,  the  inheritance  of  PKD  has  been  determined  and  it  has  been 
established that a recessive mutation in a single gene is responsible for the disease 
phenotypes. This finding supports the general hypothesis, which states that mutation 
in a single gene was responsible for the PKD phenotypes in the LPK/SsNArc
+/+ rats. 
The PKD is characterized by development of bilaterally enlarged cystic kidneys and 
increased systolic blood pressure and anemia. Unlike other forms of the disease, 
which cause development of cysts in the kidneys and extra-renal organs and also 
cause  sudden  infant  deaths  in  human  and  murine  models,  the  PKD  in  the 
LPK/SsNArc
+/+ rats does not lead to formation of extra-renal cysts and it does not 
cause infant deaths. Based on the phenotypic expression of PKD in both the F2 and 
the BC1 progeny, it is proposed that the PKD inherited from the LPK/SsNArc
+/+ rats 
is a result of a recessive mutation in a gene that has not previously been identified, 
and  it i s ,  therefore,  a  variant  of  ARPKD.  Therefore,  the  LPK/SsNArc
+/+  rat  has 
become a useful model that contributes to the understanding of novel genetic causes 
of ARPKD.  
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CHAPTER IV 
Determination of Quantitative Trait Locus Associated with ARPKD 
4.1: Introduction 
It has been established that the PKD in the LPK/SsNArc
+/+ rats was inherited as an 
ARPKD and that a recessive mutation in a single genetic locus controls the disease 
phenotypes. However, the chromosomal region containing this genetic mutation is 
not known. Therefore, mapping and linkage analyses are carried out to determine the 
QTL  that  has  direct  control  over  the  phenotype  of  the  PKD  and  to  identify  the 
candidate genes that may be responsible for the disease. By identifying the QTL, it 
will  become  easier  to  understand  the  etiology  of  ARPKD  and  to  identify  the 
homologs of the QTL in human and mouse genomes. The QTL will show whether it 
contains Pkhd-1 or Nek8 genes, mutation of which are known to cause ARPKD in 
other murine models of the disease. In the identification of the QTL that controls the 
phenotype of the disease, it was hypothesized that the segregation of the mean values 
of the phenotypic trait data was independent of the segregation of the genotypes of 
the markers used in genetic mapping.  
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In identifying the PKD locus, the chromosomal interval in which the PKD mutation 
resides must be homozygous in the LPK/SsNArc
+/+ parental strain somewhere along 
the length of the chromosome, since the LPK/SsNArc
+/+ rat is the mutant strain with 
two copies of the mutated allele at the same locus. According to Risch et al. (1993), 
if any of the markers is linked to the locus that carries the mutation, which increases 
PKD susceptibility in any chromosome, then the BC1 progeny should show at that 
locus  an  increasing  frequency  of  homozygosity  for  the  PKD  allele  over  the 
frequency of 48% (Table 3-1). If the rats carry a non-recombinant chromosomal 
interval however, then this  interval  is  heterozygous  along  its  length  and  the  rats 
cannot present with PKD. However, if this locus contains a large deletion, a loss of 
heterozygosity with the given marker will be evident (Bonsdorff et al., 2009; Qian 
and Germino, 1997; Qian and Watnick, 1999). 
4.2: Materials and Methods 
4.2.1: The SSR Markers Chosen to Map the Trait Locus 
The simple sequence repeat (SSR) markers used to map the trait locus were chosen 
from  the  rat  genome  database,  http://rgd.mcw.edu/  (Twigger  et  al.,  2007).  The 
position of the markers on each chromosome is shown in Figure 4-1 for chromosome 
1, but the genetic distance for each marker on each chromosome varied. The markers 
used to map all the other chromosomes are presented in Table 4-1 and the predicted 
fragment sizes in base pairs, the motif and the total length of chromosomes are also 
shown.  
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FIGURE 4-1: CHROMOSOME 1 AND SSR MARKERS CHOSEN 
The  position  of  the  SSR  markers  used  to  map  chromosome  1  of  a  total  genetic 
distance of 149.25 cM and their genetic distance (cM).  
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TABLE 4-1: THE SSR MARKERS USED TO MAP CHROMOSOMES 1 TO 20 
The SSR markers, rat genome database identity (ID), the chromosomes and their 
total length in cM, the name of the marker, the motif of the markers, the distance of 
each marker from the top of the chromosome in cM, the predicted fragment size in 
base pairs for each marker and the start and stop position of each marker in the 
chromosomes. 
 
ID  Chr  Length (cM)  Name  Motif  cM  Size  Start  Stop 
39666  1  149.25  D1Rat246  (CA)n  0.04  227  2436832  2437062 
40798  1    D1Rat256  (GT)n  28.34  207  53871755  53872145 
37930  1    D1Rat183  (GT)n  65.46  226  131123181  131123541 
39264  1    D1Rat194  (GT)n  134.55  124  246528823  246528943 
36896  2  112.4798  D2Rat9  (CA)n  12.71  130  33495861  33496242 
38266  2    D2Rat136  (CA)n  43.34  215  121385356  121385565 
40898  2    D2Rat228  (GT)n  70.05  134  181071573  181071715 
35340  2    D2Rat70  (GT)n  112.48  172  254933191  254933362 
35981  3  94.2199  D3Rat56  (GT)n  2.47  180  3577905  3578102 
41476  3    D3Rat193  (CA)n  3.49  147  10016016  10016172 
40968  3    D3Rat194  (GT)n  3.53  199  10311363  10311552 
42639  3    D3Rat231  (GT)n  3.57  224  9925540  9925751 
40854  3    D3Rat192  (GT)n  4.62  235  12470687  12470922 
37166  3    D3Rat110  (CA)n  32.82  121  42729639  42729760 
38316  3    D3Rat68  (CA)n  76.61  199  153994739  153995233 
38244  3    D3Rat132  (CA)n  91.49  208  165064454  165064659 
36305  4  102.2399  D4Rat4  (CA)n  0.04  182  3237190  3237361 
41182  4    D4Rat168  (CA)n  37.41  142  77155286  77155422 
40642  4    D4Rat195  (GT)n  65.69  215  143875115  143875322 
38580  4    D4Rat140  (GA)n  98.81  146  182740817  182741162 
40250  5  105.6599  D5Rat125  (GT)n  9.22  234  17702961  17703194 
38548  5    D5Rat82  (CA)n  26.04  240  45822600  45822846 
39248  5    D5Rat72  (CA)n  63.77  226  120983238  120983466 
38574  5    D5Rat111  (CA)n  103.85  225  30418090  30418319 
35963  6  85.1598  D6Rat46  (GT)n  1.15  144  13286615  13286759 
39972  6    D6Rat132  (GT)n  39.81  221  52753065  52753434 
37376  6    D6Rat87  (GT)n  56.75  173  98742972  98743161 
39052  6    D6Rat101  (CA)n  81.77  120  135964407  135964844 
35382  7  88.5699  D7Rat36  (CA)n  0.04  180  1526177  1526344 
35237  7    D7Rat35  (GT)n  3.9  125  20307479  20307622 
38322  7    D7Rat63  (CA)n  4.6  246  14454482  14454831 
35068  7    D7Rat32  (CA)n  11.42  143  21790655  21790795 
40050  7    D7Rat152  (GT)n  17.91  131  25926004  25926410 
39016  7    D7Rat103  (CA)n  25.4  200  44462790  44463229  
 
 
108 
36932  7    D7Rat17  (CA)n  57.96  135  100258077  100258647 
36193  7    D7Rat3  (GT)n  86.23  128  137404381  137404493 
36039  8  85.2699  D8Rat58  (CA)n  0.00  174  3039648  3039822 
38690  8    D8Rat98  (GT)n  38.06  214  53665152  53665540 
41310  8    D8Rat130  (CA)n  57.27  174  98986085  98986263 
37976  8    D8Rat69  (CA)n  83.04  148  125922482  125922636 
35695  9  79.5198  D9Rat44  (CA)n  1.33  176  2948882  2949051 
37416  9    D9Rat70  (GT)n  23.24  190  21667066  21667255 
41600  9    D9Rat110  (CA)n  64.74  174  94217517  94217673 
37268  9    D9Rat75  (CA)n  76.1  212  104531509  104531801 
37464  10  95.4399  D10Rat95  (GT)n  0.04  217  6380753  6381051 
41524  10    D10Rat180  (CA)n  4.5  170  19148316  19148638 
38756  10    D10Rat218  (CA)n  4.6  137  9092033  9092176 
35001  10    D10Rat43  (TG)n  24.27  150  23428127  23428280 
36319  10    D10Rat26  (TG)n  51.03  167  101292502  101292630 
35627  10    D10Rat12  (TG)n  76.13  170  99198838  99198997 
34941  10    D10Rat7  (CA)n  87  173  105886241  105886414 
35665  10    D10Rat4  (GT)n  95.44  164  107033560  107033716 
37070  11  41.6299  D11Rat28  (GT)n  2.55  246  13185810  13186049 
39084  11    D11Rat93  (CA)n  29.84  240  67930910  67931151 
40938  11    D11Rat56  (GT)n  35.73  195  77880883  77881082 
38800  11    D11Rat43  (GT)n  41.63  234  85039892  85040103 
40394  12  54.0099  D12Rat89  (GT)n  2.13  139  2957061  2957210 
37272  12    D12Rat28  (GT)n  20.46  120  16312645  16312771 
37830  12    D12Rat36  (GT)n  42.14  200  33216127  33216334 
38410  12    D12Rat53  (GT)n  51.79  134  43863148  43863270 
40188  13  44.1698  D13Rat108  (CA)n  0.29  219  21828843  21829056 
38990  13    D13Rat58  (GT)n  26.04  249  71116479  71116738 
40656  13    D13Rat131  (GT)n  33.98  147  80755428  80755583 
39262  13    D13Rat86  (CA)n  40.75  209  91410706  91411049 
36890  14  712399  D14Rat2  (GT)n  0.00  160  2350091  2350247 
40852  14    D14Rat90  (CA)n  34.67  111  73956596  73956701 
41138  14    D14Rat94  (GT)n  49.47  235  89192602  89192873 
39030  14    D14Rat38  (GT)n  63.96  200  99079814  99080020 
36516  15  66.5498  D15Rat1  (GT)n  1.63  280  8988164  8988442 
36189  15    D15Rat17  (GT)n  33.51  178  45042674  45042874 
40252  15    D15Rat101  (GT)n  53.95  157  38968338  38968494 
41308  15    D15Rat107  (CA)n  65.4  151  55591156  55591299 
40498  16  45.5099  D16Rat107  (GT)n  2.32  133  7776021  7776427 
38428  16    D16Rat53  (GT)n  28.33  133  66606252  66606369 
39010  16    D16Rat34  (GT)n  33.98  238  72653395  72653827 
36608  16    D16Rat48  (CA)n  45.51  150  79850041  79850195 
36051  17  47.5999  D17Rat1  (CA)n  3.67  166  5583326  5583494 
36011  17    D17Rat17  (GACA)n  28.16  168  42344830  42344987 
37998  17    D17Rat96  (GT)n  37.14  205  78253719  78254071 
41084  17    D17Rat131  (CA)n  47.54  201  93347783  93347990 
41120  18  52.3799  D18Rat112  (GT)n  2.48  223  6489051  6489519 
39444  18    D18Rat96  (GT.GA)n  16  247  41105037  41105280 
34975  18    D18Rat13  (TTTC)n  38.79  149  61728726  61728877 
39278  18    D18Rat44  (GT)n  52.38  210  86863206  86863411  
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37042  19  48.1398  D19Rat19  (CT)n  2.24  140  7813537  7813671 
35881  19    D19Rat11  (GT)n  22.52  128  31605037  31605157 
40110  19    D19Rat64  (GT)n  38.05  243  46434967  46435202 
43138  19    D19Rat5  (GT)n  46.36  157  54509577  54509737 
37490  20  48.2299  D20Rat21  (GA)n  0.00  170  1674648  1675005 
35327  20    D20Rat10  (GT)n  23.96  156  33642621  33642779 
38304  20    D20Rat19  (GT)n  37.79  178  45070473  45070798 
37792  20    D20Rat29  (CA)n  43.54  241  48055659  48055886 
 
4.2.2: DNA Extraction and PCR Analysis 
The extraction of deoxyribonucleic acid (DNA) from liver tissue was carried out 
according to the instructions provided in the Standard Tissue Kit Protocol
& (QIAamp 
DNA Mini Kit from Qiagen). The DNA was quantified using a NanoDrop', ND-
1000 (BIOLAB). 
 
The polymerase chain reaction (PCR) was performed in a total volume of 10 µl 
containing 10% (w/v) Cresol Red solution; PCR buffer [6.7mM Tris-HCl, pH 8.8, 
1.66 mM (NH4)2SO4, 0.045% Triton X-100, 0.02 mg/ml gelatin]; 0.25 mM of total 
dNTPs; 10 pM each of forward and reverse primers; 1U Taq polymerase; 1.5 mM 
MgCl2,  and  20  ng/"l  genomic  DNA  template  in  the  reaction  mixture.  The 
amplification of the DNA was performed using touchdown conditions, with initial 
denaturation at 94°C for 3 minutes, followed by 8 cycles of 94°C for 30 seconds, 
63°C for 30 seconds and 72°C for 30 seconds, and the temperature decreased to 
55°C,  one  cycle/1°C.  A  further  30  cycles  of  94°C  for  30  seconds,  55°C  for  30 
seconds and 72°C for 30 seconds were carried out. A final extension at 72°C for 5 
minutes was allowed.  
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The  PCR  products w ere  separated  using  8%  polyacrylamide  (acrylamide/bis-
acrylamide solutions 40% w/v) gels and electrophoresis was carried out for 20 hours 
using  1X  Tris-base-Boric  acid-EDTA  (TBE)  buffer.  The  potential  difference  for 
electrophoresis  was  set  at  4  volts/cm  and  the  gels w ere  stained  with  Ethidium 
Bromide  solution  from  Sigma  (E1510;  10  mg/ml).  The  image  of  the  gel  was 
visualized using ultraviolet light on a transilluminator. 
4.2.3: Scoring of Genotypes and Linkage Analysis 
The genotypes of the progeny were independently scored by two people either as 
homozygote parent A (LPK/SsNArc
+/+/LPK/SsNArc
+/+) or the heterozygote parent H 
(LPK/SsNArc
+/+/WKY//NArc
-/-)  in  the  BC1  and  either  as  homozygote  parent  A, 
homozygote  parent  B  (BN/ssArc
-/-/BNssArc
-/-)  or  the  heterozygote  parent  H 
(LPK/SsNArc
+/+/BN/ssArc
-/-) in the F2. Where there was no agreement in the score, 
the  fragment  was  not  scored.  Linkage  analysis  between  genotypic  and  the 
phenotypic trait data to identify the QTL that controls the disease phenotype in the 
LPK/SsNArc
+/+ rats was carried out using Map Manager QTX20b software. The 
interaction between loci to identify epistatic interaction between loci was also carried 
out using the Map Manager QTX20b software (Manly et al., 2001). 
 
Each BC1 mutant that developed PKD (67/139) carried the paternal genotype A and 
each other rat that did not develop PKD (72/139) carried the maternal genotype H. 
This genotype was called the LPK//SsNArc
+/+ genotype. So all the mutant rats were 
assigned the A genotype and all the non-mutant rats were assigned the H genotype.  
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Regression  analyses  and  interval  mapping  were  carried  out  to  determine  the 
association between phenotypic and genotypic trait data, according to the methods of 
Manly et al., 2001. The LPK/SsNArc
+/+ genotype was then taken out from the scores 
of genotypic data and regression analyses and interval mapping were again carried 
out. The program grouped the genotypes into linked groups and the LOD scores 
were calculated. A minimum LOD score of 3.6 was used to declare the presence of a 
QTL  (Lander  and  Kruglyak,  1995)  and  the  additive  effects  for  each  QTL  were 
calculated (Abiola et al., 2003; Manly et al., 2001). The markers that showed LOD 
scores  greater  than  3  in  the  BC1  genotype  were  used  in  mapping  and  linkage 
analyses of the 152 F2 DNA samples. 
4.2.4: Identification of Candidate Genes Controlling Phenotypic Traits 
When the QTL associated with the LPK/SsNArc
+/+ phenotypic traits was located, the 
candidate genes found in the QTL were identified by studying the DNA sequence of 
the rat genome in the QTL (chromosome 10q21), a total of 35.1Mb. This genetic 
distance contains the peak markers, D10Rat43 and D10Rat26. 
4.3: Results 
In this Chapter, analysis of data from the BC1 progeny is carried out and reported. 
Data  from  the  F2  are  not  presented,  as  these  do  not  produce  results  that  are 
significantly different from the results obtained from the BC1. The phenotypic and  
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genotypic trait data for F2 progeny are currently used to identify the gene and the 
recessive mutation responsible for ARPKD in the LPK/SsNArc
+/+. 
 
In linkage analyses, all phenotypic traits in BC1 linked to LPK/SsNArc
+/+ genotype, 
and the results are presented in Table 4-2; Figures 4-4A to 4-12A. In these figures, 
the black solid vertical line represents the chromosome; the black and red solid curve 
are the likelihood ratio statistics (LRS) and regression coefficient, respectively; the 
green vertical lines are critical estimates of the LRS. The bars are the percentage of 
individual rats carrying the genotype that correlate with the phenotype at that locus. 
 
The phenotypic traits linked to the genotype of either marker D10Rat43 or marker 
D10Rat26. The results are shown in Tables 4-3 and Figures 4-4B to 4-12B. The gel 
showing the genotypes of 24 BC1 including parental DNA using marker D10Rat43 
(Figure 4-2) and the genotype of F2 including parental DNA using marker D10Rat26 
(Figure 4-3) are shown. In these gels, the genotypes are scored either as A, B or H. 
However,  all  the  genotypes  for  the  BC1  DNA  samples  used  in  this  study  are 
presented  in  Appendix  A.  The  interval  mapping  between  the  genotypic  and  the 
phenotypic trait data for BC1 progeny are shown (Figures 4-4B to 4-12B). In these 
figures, the genotypes of the peak markers (D10Rat43 and D10Rat26) are associated 
with  the  phenotypic  traits  controlled  by  the  QTL.  Epistatic  interaction  between 
D10Rat26 locus and loci on chromosomes 3, 5, 7, 11, 12, 14, and 17 on chromosome 
10q21 was found and this is shown in Table 4-4. The QTL controlling the PKD 
phenotype in both F2 (LOD = 5.1, P = 0.00001) and BC1 (LOD = 7.9, P = 0.00001) 
is shown in Figure 4-13. The candidate genes identified in the QTL region are the  
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methionine  adenosyltransferase  II# ( Mat2b),  kidney  injury  molecule  1  (KIM1), 
gamma  aminobutyric  acid  A  receptor  gamma  2  (Gabrg2),  pituitary  tumor 
transforming gene 1 (Pttg1), C1q, and tumor necrosis factor 2 (C1qtnf2), eukaryotic 
translation initiation factor 4 gamma 1 (Eif4g1) and cyclin J-like (Ccnjl) and these 
are shown in Table 4-5. 
4.3.1: Gel Map and Scores 
 
 
 
FIGURE 4-2: GENOTYPE FOR MARKER D10RAT43 IN 22 BC1 DNA 
Lane 1: 50bp molecular weight marker, Lane 2: parent A (LPK/SsNArc
+/+), Lane 3: 
parent B (WKY/NArc
-/-); Lanes 4 – 25:  BC1 DNA. Parent B was included to show 
the segregation of alleles in parent A, parent B and H (LPK/SsNArc
+/+/WKY/NArc
-/-
). Parent H is the female F1 progeny.  
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FIGURE 4-3: GENOTYPE FOR MARKER D10RAT26 IN 22 F2 DNA 
Lane 1: 50bp molecular weight marker; Lane 2: parent A (LPK/SsNArc
+/+); Lane 3: 
parent B (BN/ssArc
-/-); Lanes 4 – 25: F2, where H is the heterozygote genotype, 
LPK/SsNArc
+/+/BN/ssArc
-/-.  
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4.3.2: Interval Mapping 
 
 
FIGURE 4-4: INTERVAL MAPPING BETWEEN THE PKD TRAIT AND THE BC1 GENOTYPE 
A: The interval mapping between PKD phenotype and the marker genotypes located 
in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype included. B: The interval 
mapping between PKD phenotype and the marker genotypes located in the QTL 
with  the  LPK/SsNArc
+/+/SsNArc
+/+  genotype  excluded.  The  black  line  shows  the 
LRS and the red line is the regression coefficient. The vertical lines (from left to 
right) show estimates for critical LRS statistic values for PKD phenotype: significant 
(8.4), very significant (13.5) and highly significant (21.3), P = 0.05.  
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FIGURE 4-5: INTERVAL MAPPING BETWWEEN SYSTOLIC BLOOD PRESSURE AND THE 
BC1 GENOTYPE 
A: The interval mapping between systolic blood pressure and the marker genotypes 
located in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype included. B: The 
interval mapping between PKD phenotype and the marker genotypes located in the 
QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype excluded. The black line shows 
the LRS and the red line is the regression coefficient. The vertical lines (from left to 
right) show estimates for critical LRS statistic values for PKD phenotype: significant 
(5.8), very significant (10.8) and highly significant (18.6), P = 0.05.  
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FIGURE 4-6: INTERVAL MAPPING BETWEEN PERCENTAGE KIDNEY/BODY WEIGHT AND 
BC1 GENOTYPE 
A: The interval mapping between percentage kidney/body weight and the marker 
genotypes located in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype included. 
B: The interval mapping between PKD phenotype and the marker genotypes located 
in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype excluded. The black line 
shows the LRS and the red line is the regression coefficient. The vertical lines (from 
left to right) show estimates for critical LRS statistic values for PKD phenotype: 
significant (5.7), very significant (10.8) and highly significant (18.6), P = 0.05.  
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FIGURE 4-7: INTERVAL MAPPING BETWEEN PACKED CELL VOLUME AND THE BC1 
GENOTYPE 
A: The interval mapping between packed cell volume and the marker genotypes 
located in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype included. B: The 
interval mapping between PKD phenotype and the marker genotypes located in the 
QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype excluded. The black line shows 
the LRS and the red line is the regression coefficient. The vertical lines (from left to 
right) show estimates for critical LRS statistic values for PKD phenotype: significant 
(5.0), very significant (10.0) and highly significant (17.8), P = 0.05.  
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FIGURE 4-8: INTERVAL MAPPING BETWEEN PLASMA TOTAL SOLID PROTEINS AND THE 
BC1 GENOTYPE 
A:  The  interval  mapping  between  plasma  total  solid  proteins  and  the  marker 
genotypes located in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype included. 
B: The interval mapping between PKD phenotype and the marker genotypes located 
in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype excluded. The black line 
shows the LRS and the red line is the regression coefficient. The vertical lines (from 
left to right) show estimates for critical LRS statistic values for PKD phenotype: 
significant (5.3), very significant (10.3) and highly significant (18.1), P = 0.05.  
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FIGURE 4-9: INTERVAL MAPPING BETWEEN PLASMA UREA AND THE BC1 GENOTYPE 
A: The interval mapping between plasma urea and the marker genotypes located in 
the  QTL  with  the  LPK/SsNArc
+/+/SsNArc
+/+  genotype  included.  B:  The  interval 
mapping between PKD phenotype and the marker genotypes located in the QTL 
with  the  LPK/SsNArc
+/+/SsNArc
+/+  genotype  excluded.  The  black  line  shows  the 
LRS and the red line is the regression coefficient. The vertical lines (from left to 
right) show estimates for critical LRS statistic values for PKD phenotype: significant 
(5.0), very significant (10.0) and highly significant (17.8), P = 0.05.  
 
 
121 
 
 
 
 
FIGURE 4-10: INTERVAL MAPPING BETWEEN PLASMA CREATININE AND BC1 GENOTYPE 
A:  The  interval  mapping  between  plasma  creatinine  and  the  marker  genotypes 
located in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype included. B: The 
interval mapping between PKD phenotype and the marker genotypes located in the 
QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype excluded. The black line shows 
the LRS and the red line is the regression coefficient. The vertical lines (from left to 
right) show estimates for critical LRS statistic values for PKD phenotype: significant 
(4.4), very significant (9.4) and highly significant (17.5), P = 0.05.  
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FIGURE 4-11: INTERVAL MAPPING BETWEE URINE SPECIFIC GRAVITYAND BC1 
GENOTYPE 
A: The interval mapping between urine specific gravity and the marker genotypes 
located in the QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype included. B: The 
interval mapping between PKD phenotype and the marker genotypes located in the 
QTL with the LPK/SsNArc
+/+/SsNArc
+/+ genotype excluded. The black line shows 
the LRS and the red line is the regression coefficient. The vertical lines (from left to 
right) show estimates for critical LRS statistic values for PKD phenotype: significant 
(5.4), very significant (10.4) and highly significant (18.2), P = 0.05.  
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FIGURE 4-12: INTERVAL MAPPING BETWEEN URINE PROTEIN/CREATININE RATIO AND 
THE BC1 GENOTYPE 
A:  The  interval  mapping  between  urine  protein/creatinine  ratio  and  the  marker 
genotypes located in the QTL with the LPK/SsNArc
+/+ genotype included. B: The 
interval mapping between PKD phenotype and the marker genotypes located in the 
QTL with the LPK/SsNArc
+/+ genotype excluded. The black line shows the LRS and 
the red line is the regression coefficient. The vertical lines (from left to right) show 
estimates for critical LRS statistic values for PKD phenotype: significant (5.4), very 
significant (10.4) and highly significant (18.2), P = 0.05.  
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4.3.3: Linkage Analysis and Epistatic Interaction 
TABLE 4-2: LINKAGE ANALYSIS AND LOD SCORE IN BC1 WITH LPK/SSNARC
+/+ LOCUS 
GENOTYPE 
 
Trait  Chr  Locus  Statistic  %  P  CI 
Additive 
value  Marker Interval  LOD 
PKD  10  D10Rat43  16.8  12  0.00004  33  0.35 
D10Rat218-
D10Rat43  7.9 
  ?  LPK/SsNArc
+/+  101.7  52  0.00001  7  0.77 
D10Rat43-
LPK/SsNArc+/+  2.9 
  10  D10Rat26  12.9  9  0.00032  43  0.35 
LPK/SsNArc+/+-
D10Rat26  5.9 
SBP  10  D10Rat43  9.7  7  0.00189  57  15.22 
D10Rat218-
D10Rat43  7.9 
  ?  LPK/SsNArc
+/+  66.9  38  0.00001  10  38.51 
D10Rat43-
LPK/SsNArc+/+  2.9 
  10  D10Rat26  8.9  6  0.00287  62  16.78 
LPK/SsNArc+/+-
D10Rat26  5.9 
%K/BW  10  D10Rat43  8.2  9  0.00418  68  -1.33 
D10Rat218-
D10Rat43  7.9 
  ?  LPK/SsNArc
+/+  80.8  44  0.00001  9  3.03 
D10Rat43-
LPK/SsNArc+/+  2.9 
  10  D10Rat26  17  12  0.00004  33  1.68 
LPK/SsNArc+/+-
D10Rat26  5.9 
USG  10  D10Rat43  22.9  25  0.00001  27  -0.01 
D10rat218-
D10Rat43  7.9 
  ?  LPK/SsNArc
+/+  23.4  19  0.00001  25  -0.01 
D10Rat43-
LPK/SsNArc+/+  2.9 
  2  D10Rat26  7.1  9  0.0076  78  0.01 
LPK/SsNArc+/+-
D10Rat26  5.9 
P/C Ratio  ?  LPK/SsNArc
+/+  16.8  13  0.00044  34  0.75 
D10Rat43-
LPK/SsNArc+/+  2.9 
  10  D10Rat26  7.1  6  0.00776  77  0.53 
LPK/SsNArc+/+-
D10Rat26  5.9 
PCV  ?  LPK/SsNArc
+/+  44.7  35  0.00001  15  -0.06 
D10Rat43-
LPK/SsNArc+/+  2.9 
  10  D10Rat26  11.9  11  0.00057  47  -0.03 
LPK/SsNArc+/+-
D10Rat26  5.9 
TSP  10  D10Rat43  7.2  7  0.00718  76  -3.25 
D10Rat218-
D10Rat43  7.9 
  ?  LPK/SsNArc
+/+  17.1  15  0.00004  34  -4.63 
D10Rat43-
LPK/SsNArc+/+  2.9 
  10  D10Rat26  7.2  7  0.00718  76  -3.25 
LPK/SsNArc+/+-
D10Rat26  5.9 
Urea  10  D10Rat43  4.6  3  0.03112  116  1.4 
D10Rat218-
D10Rat43  7.9 
  ?  LPK/SsNArc
+/+  47.4  41  0.00001  14  5.11  D10Rat43- 2.9  
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LPK/SsNArc+/+ 
  10  D10Rat26  6.4  7  0.01066  84  2.19 
LPK/SsNArc+/+-
D10Rat26  5.9 
Creatinine  10  D10Rar43  7.3  8  0.00695  76  7.37 
D10Rat218-
LPK/SsNArc+/+  3 
  ?  LPK/SsNArc
+/+  10.5  11  0.00119  53  8.76 
LPK/SsNArc+/+-
D10Rat26  5.9 
   9  D9Rat44  6.9  8  0.00839  79  7.27 
D9Rat44-
D10Rat26  1.6 
 
Statistic: The likelihood ratio statistic (LRS) for association of the trait with the 
locus, 
%: The amount of the total trait variance, which would be explained by the QTL at 
this locus, as a percentage, 
P-value: The probability of an association this strong happening by chance, 
CI: An estimation of the size of a 95% confidence interval for a QTL, 
Additive: The additive regression coefficient for the association, 
LOD Score: Logarithm of odds score.  
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TABLE 4-3: LINKAGE ANALYSIS IN BC1 WITHOUT LPK/SSNARC
+/+ LOCUS GENOTYPE 
 
Trait  Chr  Locus  Stat  %  P  CI 
Add 
value  Marker Interval  LOD 
PKD  10  D10Rat43  16.8  12  0.00004  33  0.35 
D10Rat218-
D10Rat43  7.9 
  10  D10Rat26  16.1  16  0.00006  36  0.41 
D10Rat43-
D10Rat26  5.1 
SBP  10  D10Rat43  9.7  37  0.00189  57  15.22 
D10Rat218-
D10Rat43  7.9 
  10  D10Rat26  10.0  10  0.00158  56  20.30 
D10Rat43-
D10Rat26  5.1 
%K/BW  10  D10Rat43  6.0  34  0.01435  90  0.88 
D10Rat218-
D10Rat43  7.9 
  10  D10Rat26  15.4  15  0.00009  37  1.84 
D10Rat43-
D10Rat26  5.1 
P/C Ratio  10  D10Rat43  4.8  34  0.02771  112  0.42 
D10Rat218-
D10Rat43  17.6 
  10  D10Rat26  4.6  4  0.03216  118  0.39 
D10Rat43-
D10Rat26  13.2 
USG  10  D10Rat26  7.0  9  0.00760  78  0.01 
D10Rat26-
D10Rat43  5.4 
PCV  10  D10Rat26  8.5  41  0.00361  66  -0.03 
D10Rat26-
D10Rat43  5.1 
TSP  10  D10Rat26  8.0  11  0.00480  70  -4.02 
D10Rat26-
D10Rat43  5.1 
Urea  10  D10Rat26  8.2  6  0.00410  66  1.87 
D10Rat26-
D9Rat44  1.6 
Creatinine  10  D10Rat26  7.3  8  0.00695  76  7.37 
D10Rat26-
D9Rat44  8.8 
 
Statistic: Likelihood ratio statistic (LRS) for association of the trait with the locus, 
%: The amount of the total trait variance, which would be explained by the QTL at 
this locus, as a percentage, 
P-value: The probability of an association this strong happening by chance, 
CI: An estimation of the size of a 95% confidence interval for a QTL, 
Additive: The additive regression coefficient for the association, 
LOD Score: Logarithm of odds score.  
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TABLE 4-4: EPISTATIC INTERACTION BETWEEN LOCI 
The Chi Square Statistic was considered significant at P = 10
-5. 
 
Trait  Chr  Locus1  Chr  Locus2  LRS  IX  Main1 
 
Main2 
PKD  3  D3Rat132  10  D10Rat26  26.9  9.60  1.1 
 
15.5 
  7  D7Rat36  10  D10Rat26  35.8  11.7  4.9 
 
15.5 
  7  D7Rat35  10  D10Rat26  23.4  7.10  4.4 
 
15.5 
SBP  5  D5Rat111  10  D10Rat26  26.5  14.9  0.1 
 
11.3 
  11  D11Rat43  10  D10Rat26  27.7  16.7  0.1 
 
10.5 
% 
K/BW  7  D7Rat36  10  D10Rat26  35.0  7.70  7.1 
 
15.4 
  11  D11Rat43  10  D10Rat26  31.9  13.6  0.6 
 
16.8 
  12  D12Rat89  10  D10Rat26  26.1  10.3  0.8 
 
15.4 
  14  D14Rat90  10  D10Rat26  28.5  9.60  2.7 
 
15.4 
  17  D17Rat96  10  D10Rat26  28.4  12.4  0.8 
 
15.4 
 
LRS: Total likelihood ratio statistics for interaction between locus1 and locus2, 
IX: Interaction LRS, 
Main1: LRS for locus 1 main effect, 
Main2: LRS for locus 2 main effect.  
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4.3.4: The QTL that Controls the PKD Phenotypes 
 
FIGURE 4-13: CHROMOSOME 10 AND QTL CONTAINING THE LPK/SSNARC
+/+ LOCUS 
The QTLs and LOD scores for BC1 and F2 progeny. The two peak markers linked to 
the PKD phenotype in the two crosses are D10Rat43 and D10Rat26, and they are 
23.76 cM apart. The makers are located in chromosome10q21.  
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4.3.5: The Candidate Genes in the QTL Region 
TABLE 4-5: THE CANDIDATE GENES AND PROTEINS ASSOCIATED WITH THE 
LPK/SSNARC
+/+ LOCUS 
 
Protein  Gene  Gene ID 
Methionine adenosyltransferase II#  Mat2b  683630 
Kidney injury molecule 1  KIM1  689968 
Gamma-aminobutyric acid A receptor gamma 2  Gabrg2  29709 
Pituitary tumor-transforming 1  Pttg1  64193 
C1q and tumor necrosis related factor 2  C1qtnf2  497886 
Eukaryotic translation initiation factor 4 gamma 1  Eif4g1  497887 
Cyclin J-like  Ccnjl  303050 
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4.4: Discussion 
The quantitative trait locus (QTL) that controls the expression of ARPKD in the 
LPK/SsNArc
+/+ rats is mapped to rat chromosome 10q21, giving a total LOD score 
of  7.9  between  markers  D10Rat43  and  D10Rat26.  This  LOD  score  provides  a 
significant evidence for linkage and shows that mutation in this QTL is responsible 
for  the  development  and  expression  of  ARPKD  in  the  LPK/SsNArc
+/+  rats.  The 
candidate  genes  located  in  the  QTL  are:  the  methionine  adenosyltransferase  II#, 
kidney injury molecule 1, gamma-aminobutyric acid A receptor gamma 2, pituitary 
tumor-transforming  1,  C1q,  and  tumor  necrosis  related  factor  2,  eukaryotic 
translation initiation factor 4 gamma 1 and cyclin J-like. 
 
In mapping the QTL that controls the PKD trait, assigning allele fragments to the 
parents was not biased. The accuracy in data preparation for analysis was considered 
more important than the ease of computation. Furthermore, it did not escape the 
author’s mind that variation in quantitative traits is influenced by multiple genetic 
loci and the environment, and according to Zeng (1994), the control of the genetic 
and  environmental  factors  was  a  key  to  increasing  the  precision  of  mapping. 
Although linkage to D10Rat43 and D10Rat26 in both F2 and BC1 rats was found, 
the data from the BC1 rats are presented in this study.  
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The LOD score of 7.9 in the BC1 indicates a strong linkage between the mean values 
of the phenotypic traits and the genotype of the markers located in the QTL. The 
linkage  strongly  suggests  that  the  means  of  the  phenotypic  trait  values  were 
dependent on the genotypes of the markers located in this QTL, and according to 
Doerge (2002), the segregation of the phenotype was dependent on the segregation 
of markers located in the QTL. The linkage of all the phenotypic traits to the same 
QTL  demonstrates  the  causal  relationship  that  exists  among  traits  resulting  from 
mutation in a single genetic locus, which is responsible for ARPKD. 
 
The QTL spans a total genetic distance of 23.76 cM on chromosome 10q21. This 
chromosomal section contains many genes, some of which are not yet characterized. 
The mapping of the QTL to chromosome 10q21 provides an important step in the 
identification of regulatory elements that may be involved in pathogenesis of PKD 
and regulation of other genes, mutation of which can result in cellular aberration. 
The regulatory elements will include those found in the non-coding regions of the 
QTL. 
 
In the BC1 progeny, it was expected that when an informative marker link to the 
locus that controlled the disease phenotype or when the segregation of the mean 
values of the phenotypic traits was dependant on the segregation of the informative 
marker, then the alleles of the BC1 genotype would show, at this locus, an increasing 
frequency of homozygosity for the alleles inherited from LPK/SsNArc
+/+ rats over 
the frequency of 48% (Chapter III). According to Risch et al. (1993), however, this 
percentage frequency depends on the disease penetrance and expressivity and also on  
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the distance of the marker from the disease locus. Furthermore, if this percentage 
frequency is to be maintained, the parental genotypes must be known with certainty 
and  the  method  of  ascertainment  of  the  phenotypic  ratios  and  the  selection  of 
families are properly followed (Morton, 1955). It was found that less that 48% of the 
BC1 progeny carried the LPK/SsNArc
+/+ genotype and this percentage varied for 
every marker. The variation in the percentage frequency arose because of varying 
number of informative alleles for every informative marker. 
 
In previous studies, the loci that controlled the phenotype of ARPKD in pck and wpk 
rats  were  mapped  to  chromosomes  5  and  9  respectively (Nauta  et  al.,  2000).  In 
humans, the ARPKD locus was mapped to chromosome 6 (Zerres et al., 1994). In 
this study, the QTL that controls the PKD phenotypes is mapped to chromosome 
10q21. This QTL does not contain the Pkd-1 gene, which was previously mapped to 
chromosome 10q12 and caused ADPKD in a different rat strain (Katsuyama et al., 
2000; Xu et al., 2001). The QTL does not contain Pkhd-1 responsible for ARPKD in 
other murine models (Guay-Woodford et al., 2000; Harris and Rossetti, 2004). This 
finding suggests that the gene responsible for ARPKD in the LPK/SsNArc
+/+ rats is 
novel  and  it  is  different  from  Pkhd-1,  but  the  mutation  results  in  similarities  in 
disease expression among animal species.  
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Studies in humans, rats and mice have shown that mutation in the candidate genes 
located  in  the  QTL  region  caused  cellular  aberrations,  such  as  uncontrolled  cell 
growth, cell dedifferentiation and cancer development in different organs and tissues 
(Martinez-Chantar et al., 2003; Ramani et al., 2008). Mutation in the Mat2b gene, for 
example, caused liver cancer in mice (Calvisi et al., 2007) and the human homolog, 
MAT2!, is highly expressed in the liver and the kidneys (Horikawa and Tsukada, 
1992). Increase expression of human MAT2! in the kidneys is associated with cell 
dedifferentiation and malignant degeneration (Mato et al., 2002), and in the liver, it 
is associated with liver cirrhosis (Calvisi et al., 2007; Halim et al., 1999; Martinez-
Chantar et al., 2003). Although it is not clear at this stage which gene in the QTL 
region is mutated and caused ARPKD in the LPK/SsNArc
+/+ rats, the phenotype of 
ARPKD  resembles  the  phenotype  of  ARPKD  caused  by  mutation  in  the  Pkhd-1 
(Masyuk et al., 2004). For example, development of renal cysts, increase in systolic 
blood pressure and development of anemia in the LPK/SsNArc
+/+ rats resemble the 
same symptoms in other murine models or humans with ARPKD. 
 
Kidney injury molecule 1 (KIM1) is found within the QTL region and according to 
Kotsis et al. (2007), KIM1 is highly expressed in injured and cancerous kidneys. 
However, it is not clear whether the high expression of KIM1 is a result of mutation 
or it is the consequence of kidney injury. Yet, the gene plays an important role in 
DNA binding, cell adhesion and regulation of transcription (Prozialeck et al., 2009) 
and therefore, its mutation could cause cellular dysfunction, which suggests loss of 
normal gene function. Pituitary tumor-transforming gene 1 (PTTG1), also found in 
the QTL region, regulates both the G1/S and G2/M phases during cell division (Tong  
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et al., 2008; Tong et al., 2007). The gene is highly expressed in several cancer types 
and PTTG1 protein interacts with Aurora kinase A to initiate tumors in many human 
cells and organs (Prozialeck et al., 2009; Tong et al., 2008). 
 
Although  it  has  been  established  that  mutation  in  one  gene  is  responsible  for 
ARPKD  in  the  LPK/SsNArc
+/+  rats  (Chapter  III)  and  the  QTL  is  located  on  rat 
chromosome 10q21, it is not known which gene in the QTL region is mutated. In 
murine  models,  multiple  mutations  in  Pkhd-1  were  associated  with  renal  cystic 
kidneys (Bergmann et al., 2005; Janaswami et al., 1997). In other murine models of 
ARPKD, mutations in modifier loci in close proximity or distal to the Pkhd-1 were 
also associated with modification of the disease phenotypes. In the orpk, kat
2J and 
the pck mutants, for example, mutations in modifier loci were found to influence the 
kidney  phenotype  during  the  development  of  ARPKD  (Gattone  et  al.,  1996; 
Sommardahl et al., 2001; Upadhya et al., 1999). 
 
Although there was no evidence in breeding studies and phenotypic trait variation 
(Chapter  III)  to  suggest  that  there  were  multiple  genetic  loci  involved  in  the 
development  of  ARPKD  in  the  LPK/SsNArc
+/+  rats,  the  epistatic  effect  between 
QTLs was not ruled out. An epistatic interaction between marker D10Rat26 locus in 
chromosome  10q21  and  loci  in  chromosomes  3,  5,  7,  11,  12,  14  and  17  was 
established. However, the interaction did not produce significant phenotypic trait 
variation between male and female or between F2 and BC1 rats with PKD. Previous 
genetic studies of ARPKD in murine models showed that the variability of a disease 
phenotype could not be explained by mutation at a single locus, but mutations at  
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multiple  loci  that  exerted  synergistic  effects  to  modify  disease  penetrance  and 
expressivity (Badano et al., 2006; Janaswami et al., 1997). In this study, the epistatic 
interaction  between  trait  loci  did  not  alter  the  phenotypes  of  PKD  in  the 
LPK/SsNArc
+/+ rats. This means that mutation in one gene located in the QTL region 
is the major cause of the PKD phenotypes in the LPK/SsNArc
+/+ rats. 
 
Although it is predicted that mutation in one gene is the cause of ARPKD in the 
LPK/SsNArc
+/+ rats, and this explains the lack of significant modification of the 
disease phenotypes, it is proposed that a new QTL mapping framework whereby 
interval test can separate and isolate effects of individual QTL when testing and 
mapping for QTLs be carried out. This will improve the precision of mapping and 
isolate those QTLs that specifically modify the PKD phenotype, because the PKD in 
the LPK/SsNArc
+/+ rats is highly heritable and genetic variation can be controlled. 
 
In conclusion, mapping studies and linkage analyses have shown that mutation in the 
gene that causes ARPKD in the LPK/SsNArc
+/+ rats is located on rat chromosome 
10q21. The findings support the specific alternative hypothesis, which states that the 
segregation  of  the  means  of  the  phenotypic  trait  values  was  dependent  on  the 
segregation of the genotypes of the markers located on the QTL region. Mutations in 
the candidate genes located in the QTL region were previously implicated in the 
development of tumors in different human organs (Ramani et al., 2008; Yang et al., 
2008). While recent evidence in the study of renal diseases suggests that different 
forms of renal carcinoma such as collecting duct and medullary carcinoma lead to 
renal dysfunction (Okon, 2008), the present study does not confirm or refute that  
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ARPKD inherited in the LPK/SsNArc
+/+ rats is a tumor of the kidneys. The results in 
this Chapter do not give a reason to accept the hypothesis that the segregation of the 
mean values of the phenotypic trait data was independent of the segregation of the 
genotypes  of  the  markers  used  in  genetic  mapping,  but  rather  the  alternative 
hypothesis that the segregation was dependent on the genotype of markers used in 
mapping the QTL. Work is currently in progress to precisely identify the gene that 
causes ARPKD in the LPK/SsNArc
+/+ rats using the genotype of F2 progeny.  
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CHAPTER V 
Analysis of Proteins Encoded by the Candidate Genes in the QTL 
5.1: Introduction 
The QTL responsible for the development of ARPKD in the LPK/SsNArc
+/+ rats has 
been mapped to chromosome 10q21. This QTL does not contain Pkhd-1 or Nek8 
genes, mutation of which is known to cause ARPKD in other murine models (Smith 
et al., 2006a; Zhang et al., 2004). Furthermore, it is not known whether or not the 
proteins encoded by the candidate genes located in the QTL region share sequence 
similarity  with  or  have  common  functional  domains  with  or  share  evolutionary 
ancestry with fibrocystin, the protein encoded by Pkhd-1. 
 
The  common  method  used  to  compare  two  or  more  proteins  with  the  aim  of 
determining their sequence similarity is the basic sequence alignment (Altschul et 
al.,  1990).  The  method  is  based  on  global  or  local  pairwise  sequence  alignment 
(Needleman and Wunsch, 1970; Smith and Waterman, 1981). In the alignment of 
more than two sequences, however, the method used is progressive alignment (Feng 
and Doolittle, 1987). This method uses programs like the ClustalW (Thompson et 
al., 1994), MUSCLE (Edgar, 2004) and T-Coffee (Notredame et al., 2000). These 
methods of sequence alignment allow the identification of biological information  
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contained  in  the  sequences  (Goodman,  2002).  Of  the  two  methods,  progressive 
alignment is preferred and used in this study because it aligns more than two protein 
sequences. Therefore, multiple sequence alignment of these proteins to determine 
their sequence similarity and identification of conserved amino acid sequences were 
carried  out.  Phylogenetic  analysis  of  the  protein  sequences  to  predict  their 
evolutionary relationships was also performed. In carrying out these analyses, it was 
hypothesized that there were no sequence similarity between the proteins encoded by 
the candidate genes and fibrocystin, the protein invariably ubiquitous in ARPKD. 
5.2: Materials and Methods 
The QTL that controls the PKD phenotype in the LPK/SsNArc
+/+ rats was used to 
map  and  identify  homologous  loci  in  human  and  mouse  genomes  using 
http://blast.ncbi.nlm.nih.gov/Blast.cgi. The proteins encoded by the candidate genes 
in  the  QTL  region  (Table  4-5)  were  retrieved  from  the  protein  database, 
http://www.ncbi.nlm.nih.gov/sites/entrez. Fibrocystin proteins (Table 5-1) encoded 
by Pkhd-1 in rats and mice models of ARPKD were retrieved from the Rat Genome 
Database, http://rgd.mcw.edu/. 
 
Common protein domains and functions were identified using PROSITE (Sigrist et 
al., 2010), SMART (Schultz et al., 1998), Psort and InterPro programs (Dorr and 
Denton, 2009). Complete sequence alignment of the proteins was carried out using 
CLUSTALW (Thompson et al., 1994). Gblocks (Dereeper et al., 2008) was used to 
refine and eliminate poorly aligned sequences to produce sequences that are used for  
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construction  of  phylogenetic  trees  (Talavera  and  Castresana,  2007).  Molecular 
phylogenetic analysis of the proteins was carried out using molecular evolutionary 
genetics analysis version 4.0 (MEGA4) software (Tamura et al., 2007; Thompson et 
al.,  1994).  The  phylogenetic  trees  were  constructed  using  the  Neighbor-Joining 
method (Saitou and Nei, 1987). 
 
TABLE 5-1: FIBROCYSTIN PROTEINS FROM THE RAT AND MOUSE 
 
ID  Symbol  Chro  Start  Stop  Accession No. 
Animal 
species  †Proteins 
1308476  Pkhd1  9  188339903  19365387  XP_236972 
R. 
norvegicus  FibrocystinARn 
          XP_001070557    FibrocystinBRn 
1318267  Pkhd1  1  20047860  20608138  NP_694819 
M. 
musculus  FibrocystinAMm 
          EDL14373    FibrocystinBMm 
          EDL14374    FibrocystinCMm 
          EDL14375    FibrocystinDMm 
          EDL14376    FibrocystinEMm 
 
†: Protein sequences used in alignment and phylogenetic analysis 
Rattus norvegicus (Rn); Mus musculus (Mm) 
Fibrocystin has isoforms denoted here as: A, B, C, D or E 
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5.3: Results 
The QTL region that controls the PKD phenotype in the LPK/SsNArc
+/+ rats maps to 
human chromosome 5q34-q35 and mouse chromosomes 11C and 18B1 (Figure 5-1). 
Multiple  sequence  alignment  of  the  proteins  encoded  by  the  potential  candidate 
genes  located  in  the  QTL  region,  two  fibrocystin  proteins  from  rats,  and  five 
fibrocystin proteins from mice, shows that the proteins are only 3% similar (Figure 
5-2), suggesting that these proteins are not structurally homologous. Phylogenetic 
analysis of the proteins to determine their evolutionary relationships showed that the 
proteins  encoded  by  the  candidate  genes  do  not  have  a  common  ancestry  with 
fibrocystin (Figure 5-3). However, signal peptide was found to be the only common 
functional domain in the proteins encoded by methionine adenosyltransferase II# 
and  kidney  injury  molecule  1  and  fibrocystin  (Table  5-2).  Although  there  is  no 
complete  structural  homology  and  signal  peptide  is  the  only  common  functional 
domain between the protein sequences and fibrocystin, this does not rule out the 
possibility that there could be regions within the genes that are structurally different 
but share common cellular functions and when these regions are mutated, they would 
confer common disease processes and pathways that result in phenotypic similarity 
in the expression of diseases.  
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5.3.1: Mapping Analysis 
 
 
FIGURE 5-1: MAPPING QTL TO HUMAN AND MOUSE CHROMOSOMES 
The QTL that controls the phenotype of ARPKD in the LPK/SsNArc
+/+ rats maps to 
human chromosome 5q34q35 and mouse chromosomes 11C and 18B1.  
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5.3.2: Multiple Sequence Alignment 
                    10        20        30        40        50        60 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   IPCDISPLFVDLPVVTTRSLPSEAPEGLYSLEIRSGQLLGSPCARLLDNCTFKFSKEQTP 
FibrocystinBRn   IPCDISPLFVDLPVVTTRSLPSEAPEGLYSLEIRSGQLLGSPCARLLDNCTFKFSKEQTP 
FibrocystinAMm   IPCDVSPAFVDLPVVTTRSLPSEADAGPYSLEMRSGQVLGTPCPGSLDSCTFKFSKDQTP 
FibrocystinEMm   IPCDVSPAFVDLPVVTTRSLPSEADAGPYSLEMRSGQVLGTPCPGSLDSCTFKFSKDQTP 
FibrocystinBMm   IPCDVSPAFVDLPVVTTRSLPSEADAGPYSLEMRSGQVLGTPCPGSLDSCTFKFSKDQTP 
FibrocystinDMm   IPCDVSPAFVDLPVVTTRSLPSEADAGPYSLEMRSGQVLGTPCPGSLDSCTFKFSKDQTP 
FibrocystinCMm   IPCDVSPAFVDLPVVTTRSLPSEADAGPYSLEMRSGQVLGTPCPGSLDSCTFKFSKDQTP 
KIM1Rn           IYQTSSRYQINAQLLQTIEDTYESDSGLYCCRVEMKTLTTSLQVQPENSECLVNSLPNRA 
CcnjlRn          ITTSKQLYTVAVSCLLDREDRVPKLEQINNTRILSSKELLTTELLLLEAFSWDLCLPTPA 
Mat2bRn          IYISSDYVFDGTNPPY-TEEDIPSPLNLYGKTKLDG-----------EKAVLENNLGAAV 
Pttg1Rn          ASRKALGTVNRVT--EKLPKPVKSSKPLQSKQPTLS---------------VKKITEKST 
Eif4g1Rn         IPGQGRSTYVVPTQQYPGFYPGASPTEFGTYAGAYYQFPASVAPAPVLMNQPPQIAPKRE 
C1qtnt2Rn        DGQDGDRGDSGEEGPPGKQGPKGKAGAIGRAGPRGP----GVSGTPGKHGTPGKKGPKGK 
Gabrg2Rn         DAVPARTSLGITTVLPTIARKSVSYVTAMDLFVS--------VCFIFVFSALVEYGLPTL 
                         70        80        90       100       110       120 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VLYQVNPSSGVPGEVVHVYGWVITDRMEIFDPDVDYMESPLILEAGGDKWLTPCSLINRK 
FibrocystinBRn   VLYQVNPSSGVPGEVVHVYGWVITDRMEIFDPDVDYMESPLILEAGGDKWLTPCSLINRK 
FibrocystinAMm   VLYQVYPASGVPGEVVSVYGRVITTWLETFDPDVDYIESPLILEAREDKWLTPCSLINRQ 
FibrocystinEMm   VLYQVYPASGVPGEVVSVYGRVITTWLETFDPDVDYIESPLILEAREDKWLTPCSLINRQ 
FibrocystinBMm   VLYQVYPASGVPGEVVSVYGRVITTWLETFDPDVDYIESPLILEAREDKWLTPCSLINRQ 
FibrocystinDMm   VLYQVYPASGVPGEVVSVYGRVITTWLETFDPDVDYIESPLILEAREDKWLTPCSLINRQ 
FibrocystinCMm   VLYQVYPASGVPGEVVSVYGRVITTWLETFDPDVDYIESPLILEAREDKWLTPCSLINRQ 
KIM1Rn           LISSKCRGFSVSSVEYQANAEVIKSILMTAIVSLKRLEKAYPFFSDRK----SCNLLIRV 
CcnjlRn          HFLDYYLLASISQKDHHCHAWPTTCLRKTKECLKEYAHYFLEVTLQDHIFYKFQPSVVAA 
Mat2bRn          LRIPVLYGEVEKLEESAVTVMFDKVQFSNKSANMDHWQQRFPTHVKDVASVCRQLAEKRM 
Pttg1Rn          KTQGSAPAPDDAYPEIEKFFPFDPLDFESFDLPEEHQISLLPLNGVPLMILNEERGLEKL 
Eif4g1Rn         RKTIRIRDPNQGGKDITEEIMSGARTASTPTPPQTGGSLEPQPNGESPQVAVIIRPDDRS 
C1qtnt2Rn        KGEPGLPGPCSCGSSRAKSAFSVAVTKSYPRERLPIKFDKILMNEGGHYNASSGKFVCSV 
Gabrg2Rn         HYFVSNRKPSKDKDKKKKNPLLRMFSFKAPTIDIRPRSATIQMNNATHLQERDEEYGYEC 
                        130       140       150       160 
                 =========+=========+=========+=========+ 
FibrocystinARn   TGFPIQEEHGLGTVQCRVEGSYIGSQNVSFSVFNKGRSMV 
FibrocystinBRn   TGFPIQEEHGLGTVQCRVEGSYIGSQNVSFSVFNKGRSMV 
FibrocystinAMm   TGFPIQEEHGLGNVQCRVEGDYIGSQNVSFSVFNKGRSMV 
FibrocystinEMm   TGFPIQEEHGLGNVQCRVEGDYIGSQNVSFSVFNKGRSMV 
FibrocystinBMm   TGFPIQEEHGLGNVQCRVEGDYIGSQNVSFSVFNKGRSMV 
FibrocystinDMm   TGFPIQEEHGLGNVQCRVEGDYIGSQNVSFSVFNKGRSMV 
FibrocystinCMm   TGFPIQEEHGLGNVQCRVEGDYIGSQNVSFSVFNKGRSMV 
KIM1Rn           ASFP--EVYGMGGEPVTLPCSYPESRALSFVCWGRGECAS 
CcnjlRn          ACICLQLSPYWTRDLQRVSSYSLEHLSTCIEILLVAYDNV 
Mat2bRn          LD-SIKGTFHWSGNEQMTKYEMACAIADAFNLPSSHLRPI 
Pttg1Rn          LH----PPSPLQKPFLPWESDPLPSPPSALSALDVELPPV 
Eif4g1Rn         QGGLPGPEHSPGTESQPSSPSPTPSPPPILEPGSESNLGV 
C1qtnt2Rn        PG-YFTYDITLANKHLAIGLVHNGQYRIRTFDANTGNHDV 
Gabrg2Rn         LD---KDCASFFCCFEDCRTGAWRHGRIHIRIAKMDSYAR 
 
 
FIGURE 5-2: CURATED PROTEIN SEQUENCES 
Sequence  alignment  of  the  curated  proteins  encoded  by  the  candidate  genes  and 
proteins encoded by Pkhd-1 in Rattus norvegicus (Rn) and Mus musculus (Mm) 
models of ARPKD. The isoforms of fibrocystin are denoted here as: A, B, C, D or E.  
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5.3.3: Phylogenetic Analysis 
 
 
FIGURE 5-3: EVOLUTIONARY RELATIONSHIPS 
The  evolutionary  relationships  of  the  proteins  encoded  by  the  candidate  genes 
(KIM1, Mat2b, Pttg1, Eif4g1, C1qtnt2, Ccnjl and Gabrg2, group C), and fibrocystin, 
the protein encoded by Pkhd-1 gene in Rattus norvegicus (Rn, group B) and Mus 
musculus (Mm, group A). Fibrocystin has isoforms denoted here as: A, B, C, D or E.  
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TABLE 5-2: COMPARISON OF THE PROTEINS, THEIR FAMILIES AND DOMAINS 
Protein  Family  Functional Domains 
Fibrocystin 
Transmembrane G-
proteins  Cell surface receptor IPT/TIG 
    Parallel beta-helix repeat 
    Pectin lyase fold/virulent factor 
    Immunoglobulin E-set 
    Signal peptide 
    Polyductin 
    Anthrax protective antigen 
    EF-Hand-1, calcium-binding site 
Methionine 
adenosyltransferase 
II# 
dTDP-4-
dehydrorhamnose 
reductase  NAD(P)-binding 
    NAD(P)-binding Rossmann-fold 
    DTDP-dehydrorhamnose dehydrogenase 
    Signal peptide 
Kidney injury 
molecule 1  Immunoglobulins  Immunoglobulin-like 
    Immunoglobulin V-set 
    Immunoglobulin-like fold 
    T-immunoglobulin and mucin domain 
    Signal peptide 
    Transmembrane region 
Gamma-aminobutyric 
acid A receptor 
gamma 2  Receptors  Neurotransmitter-gated ion-channel 
   
Neurotransmitter-gated ion-channel 
transmembrane 
Pituitary tumor-
transforming 1 
Securin sister-
chromatid separation 
inhibitor 
Pituitary tumor transforming protein 
(PTTP) 
 
Securin sister-
chromatid separation 
inhibitor metazoan   
C1q and tumor 
necrosis related 
protein 2 
Tumor necrosis factor-
like  Complement C1q protein 
    Collagen triple repeat 
Eukaryotic translation 
initiation factor 4, 
gamma 1    elF4-gamma/elF2-epsilon 
    MIF4G-like, type 3 
    Initiation factor elF4 gamma 
Cyclin J-like    Cyclin, C-terminal 
    Cyclin, N-terminal 
    Cyclin-like 
    Cyclin-related 
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5.4: Discussion 
The quantitative trait locus (QTL) on rat chromosome 10q21 controls the expression 
of ARPKD phenotypes in the LPK/SsNArc
+/+ rats. The QTL region maps to human 
chromosome 5q34-5q35 and it has therefore excluded the LPK/SsNArc
+/+ locus as a 
candidate  homolog  for  human  PKHD-1,  which  maps  to  chromosome  6p21-p12 
(Mucher et al., 1998). It has also excluded as a homolog the wpk locus, which maps 
to rat chromosomes 5q13 and the pck locus, which maps to chromosome 10q12 
(Nauta  et  al.,  2000;  Smith  et  al.,  2006a).  Furthermore,  the  QTL  region  maps  to 
mouse  chromosomes  11C  and  18B1,  and  therefore  this  has  excluded  the 
LPK/SsNArc
+/+ locus as a homolog for the bpk locus that was mapped on mouse 
chromosome 10 (Guay-Woodford, 2003; Guay-Woodford et al., 1996), the cpk locus 
that was mapped on mouse chromosome 12 (Masyuk et al., 2004) or the orpk locus 
that was mapped on mouse chromosome 14 (Lehman et al., 2008). Because there are 
different genetic loci, mutation of which cause ARPKD, it is not easy to establish 
convincing  genotype-phenotype  relationships  in  the  development  of  ARPKD  in 
different murine models. 
 
Multiple sequence alignment of the proteins encoded by the genes in the QTL region 
and fibrocystin revealed a 3% similarity between the amino acid sequences. The 3% 
sequence similarity clearly reveals lack of complete structural homology between the 
proteins (Blouin et al., 2009). Although it is not yet clear which gene in the QTL 
region  is  mutated  and  therefore  which  protein  is  highly  expressed  in  the  cystic  
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kidneys  of  the  LPK/SsNArc
+/+  rats,  the  study  has  established  that  none  of  the 
proteins encoded by the potential candidate genes is a homolog of fibrocystin, the 
causative  protein  which  is  highly  expressed  in  ARPKD  in  other  murine  models 
(Bergmann et al., 2006; Masyuk et al., 2004). The proteins do not come from the 
same family and they do not have common functional domains or motifs, except for 
signal  peptide  domain,  which  is  found  in  common  between  fibrocystin  and  the 
proteins  encoded  by  methionine  adenosyltransferase  II#  and  the  kidney  injury 
molecule. Since the type of mutation and its location in the QTL region are not 
known, it is not easy to establish the gene, which is responsible of ARPKD in the 
LPK/SsNArc
+/+ rats. However, the lack of complete structural similarity and the lack 
of common functional domains between the protein sequences do not mean lack of 
common disease processes or pathways that arise during the expression of ARPKD 
in different murine models. 
 
The  evolutionary  relationships  of  the  proteins  encoded  by  the  candidate  genes 
located  in  the  QTL  region  show  that  these  proteins  are  distantly  related  to 
fibrocystin, the protein highly expressed during the development of ARPKD (Harris, 
2009; Harris and Torres, 2009). However, the protein encoded by the kidney injury 
molecule 1 appears to be closely related to fibrocystin. Due to lack of evolutionary 
relationship  between  the  proteins  and  because  there  are  no  extra-renal  cysts,  the 
expression  of  ARPKD  in  the  LPK/SsNArc
+/+  rats  appears  to  demonstrate 
convergence of disease processes that have resulted from mutation in independent 
genomic loci which have occurred at different time points (Behboudi et al., 2002; 
Kumar and Hedges, 1998). Furthermore, the results suggest that there is not yet a  
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clear-cut linkage of gene-to-function-to-disease in the development of ARPKD in 
different murine models. 
 
Because there is a lack of significant sequence similarity, lack of common functional 
domains,  except  for  the  signal  peptide  domain,  lack  of  phylogenetic  relatedness 
between the proteins in the QTL region and fibrocystin, and there are no extra-renal 
cysts, the gene responsible for ARPKD in the LPK/SsNArc
+/+ rats may not be related 
to Pkhd-1. However, it is possible that mutation in any gene or a dysfunction of any 
regulatory elements found within the QTL region, which may include non-coding 
genomic segments (Forrest et al., 2009), can result in cellular aberrations that have 
common pathological pathways in different animal species. 
 
It was reported that rat chromosome 10 shares homology with human chromosomes 
5, 16, and 17 and mouse chromosomes 11, 16 and 17 (Gomez-Fabre et al., 2002; 
Nilsson et al., 2001). Human chromosome 5q34-q35 contains the MAT2! and mouse 
chromosomes 11C and 18B1 contain breast carcinoma amplified sequence 3 and 
Ras-like  without  CAAX2,  respectively.  These  genes  are  different  from  Pkhd-1, 
which is responsible for ARPKD in other murine models. The genes are, however, 
important in signal transduction, cell proliferation and cell differentiation (Bourne et 
al., 1990; Hoshino and Nakamura, 2002; Hoshino et al., 2005) and their mutations 
were previously linked to development of cancer in different human and rat tissues 
(Cowley et al., 1991; Garbay et al., 2000; Margolis and Skolnik, 1994). Nonetheless, 
there is not enough evidence in the present study to support or refute the suggestion 
that ARPKD inherited in the LPK/SsNArc
+/+ rats is a cancer of the kidneys.  
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Therefore, regardless of the characterization of ARPKD in several murine models 
(Guay-Woodford, 2003; Janaswami et al., 1997; Nauta et al., 2000), it is unknown 
how many genetic loci have a role in the pathogenesis of the disease, and how each 
of the murine diseases relates to various other animal models or human diseases at 
the genetic and pathological levels. As such, more research needs to be done to 
determine which genetic mutation provides complementary experimental models to 
make  us  understand  the  genetic  and  pathophysiology  of  human  ARPKD.  In  a 
broader  perspective,  however,  the  animal  models  of  the  disease  will  help  us  to 
understand the development of ARPKD, since each mutation defines a novel gene, 
which is likely to play an important role in the development of normal kidneys and 
their metabolic functions. 
 
In  conclusion,  the  proteins  encoded  by  the  candidate  genes  located  in  the  QTL 
region are not homologous to fibrocystin, the protein highly expressed during the 
development of ARPKD in other murine models (Harris and Torres, 2009; Masyuk 
et al., 2004). The lack of structural homology between the proteins is also supported 
by the lack of a close evolutionary relationship, which indicates that the proteins do 
not have a common ancestry with fibrocystin. Furthermore, there are no common 
functional  domains  or  motifs  between  the  protein  families,  except  for  the  signal 
peptide domain found between fibrocystin and methionine adenosyltransferase II# 
and kidney injury molecule 1. However, the lack of structural homology between the 
proteins  does  not  mean  that  the  proteins  do  not  share  common  functional  and 
pathological pathways in disease presentation. 
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Although  the  phenotype  of  ARPKD  in  the  LPK/SsNArc
+/+  rats  is  similar  to  the 
phenotype of ARPKD caused by mutation in Pkhd-1 in murine models, the gene 
responsible  for  the  disease  is  novel  and  it  is  still  unknown.  Even  though  rat 
chromosome 10 was previously reported to contain tumor-related genes (Kobayashi 
et al., 1995; Yeung et al., 1993), there is not enough evidence in the present study to 
confirm or refute that ARPKD inherited in the LPK/SsNArc
+/+ rats is a cancer of the 
kidneys. However, the results presented in this Chapter are in accordance with the 
hypothesis that there were no sequence similarities between the proteins encoded by 
the candidate genes and fibrocystin, the protein invariably ubiquitous in ARPKD.  
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CHAPTER VI 
General Discussion 
6.1: Discussion 
The characterization of polycystic kidney disease in the Lewis polycystic kidney rat, 
the newest model for human ARPKD has been performed. Multiple lines of evidence 
from all the experiments, throughout the study, consistently support the hypothesis 
that a recessive mutation in a single gene was responsible for the expression of PKD 
in the LPK/SsNArc
+/+ rats. In the mating experiments, the ratios 42:110 and 67:72 
for PKD:non-PKD rats do not significantly deviate from the expected ratios of 1:3 in 
the F2 and 1:1 in the BC1, respectively. These ratios are in accordance with the 
Mendelian segregation ratios for the inheritance of traits controlled by one gene and 
provide significant evidence that a recessive mutation was the cause of the disease 
phenotype.  The  gene  is  predominantly  expressed  in  the  kidneys,  the  organs 
invariably involved in this disorder. 
 
The QTL region that controls the expression of PKD was mapped to rat chromosome 
10q21,  with  a  maximum  LOD  score  of  7.9  between  markers  D10Rat43  and 
D10Rat26. All other phenotypic trait data link to the same QTL, as shown in the 
Manhattan plot (Figure 6.1).  
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FIGURE 6-1: MANHATTAN PLOT 
Negative log10 (P-value) is plotted against the 20 rat autosomes. All the phenotypic 
traits link to chromosome 10q21, shown by the highest peaks. This genetic region is 
where the recessive mutation in a single gene is located and it is responsible for the 
PKD. 
 
In this graph, the -log10 (P-Value) is plotted against the chromosomes. The QTL 
responsible for phenotypic trait variation between PKD and non-PKD rats is linked 
to rat chromosome 10q21. The study has, therefore, provided significant evidence 
that this QTL is the only genetic region responsible for the phenotypic variation. The 
QTL  has  excluded  all  genetic  loci  that  control  the  expression  of  ARPKD  in 
previously established murine models (Guay-Woodford and Desmond, 2003; Zerres 
et al., 1994). The results have also clearly shown that the locus responsible for the 
disease  is  novel  and  it  is  different  from  the  loci  that  contain  Pkhd-1,  the  gene 
responsible for ARPKD in other models of the disease. The locus does not contain  
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Nek8,  located  on  rat  chromosome  10q25,  and  mutation  of  which  was  linked  to 
development of ARPKD in other models (Smith et al., 2006a). 
 
In  previous  human  studies,  it  was  established  that  PKD  was  inherited  either  as 
ADPKD or ARPKD (Martinez and Grantham, 1995; Yoder et al., 1997). In animal 
studies, scientists used different murine models (Gattone et al., 1996; Harris and 
Torres,  2009;  Nauta  et  al.,  2000;  Rossetti  and  Harris,  2007)  to  elucidate  the 
inheritance of the disease, understand the disease phenotype and identify the genes 
involved in the development of the disease. In the present study, the LPK/SsNArc
+/+ 
rats that spontaneously developed PKD were used to determine the inheritance of the 
disease,  identify  the  chromosome  and  the  genetic  locus  that  controls  the  disease 
phenotype. 
 
The study has clearly shown that the PKD in the LPK/SsNArc
+/+ rats was a result of 
a recessive mutation in a single locus located on chromosome 10q21. The disease 
resulted in the development of numerous cysts in the renal nephrons. Accumulation 
of fluids into the cysts resulted in kidney enlargement. The presence of fluids in the 
cysts distorted the architecture of the kidneys and led to deterioration of the kidney 
functions. This is the cause of increase in systolic blood pressure, development of 
anemia and inability of the kidneys to concentrate urine and carry out homeostasis in 
all the PKD rats, as depicted in Figure 6.2.  
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FIGURE 6-2: SUMMARY: DEVELOPMENT OF ARPKD IN THE LPK/SSNARC
+/+ RATS 
The diagram shows the progression of ARPKD from mutation in chromosome 10q21 
to deterioration of kidney functions in the LPK/SsNArc
+/+ rats. 
 
Since there were no extra-renal cysts in the LPK/SsNArc
+/+ rats with PKD, which 
makes the phenotypic expression of ARPKD different from that in humans and other 
murine models, it appears that the phenotype of ARPKD in the LPK/SsNArc
+/+ rats 
highlights genetic heterogeneity that was previously described (Harris and Rossetti, 
2004). The findings of the study have, however, raised questions about the genetic 
similarity  of  ARPKD  in  different  rat  models,  since  the  QTL  that  controls  the 
phenotype of PKD in the LPK/SsNArc
+/+ rats does not contain the genes that control 
the phenotype of ARPKD in other murine models.  
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In the wpk rats, for example, ARPKD was caused by mutation in Pkhd-1, located on 
chromosome 5q13 (Nauta et al., 2000) and the human and mouse homologs were 
located on chromosome 8q22.1 and chromosome 4A1, respectively. However, there 
were no extra-renal cysts. The lack of extra-renal cysts in this model was attributed 
to the genetic background and environmental factors that altered the PKD expression 
(Cowley et al., 1996; Ogborn et al., 1998; Ogborn et al., 2000). In LPK/SsNArc
+/+ 
rats, the gene responsible for ARPKD is not known, but the QTL does not contain 
the Pkhd-1 or nek8 genes, mutations in which caused ARPKD in the murine models 
(Menezes and Onuchic, 2006; Smith et al., 2006a). It is, therefore, less likely that 
environmental factors, known to alter the disease presentation, alone can explain the 
lack of extra-renal cysts in the LPK/SsNArc
+/+ rats with the disease. More work will 
be  done  to  examine  the  effects  of  environmental  factors  on  the  expression  of 
ARPKD in the LPK/SsNArc
+/+ rats. This will reveal whether different environmental 
factors have significant effects in the expression of ARPKD in the LPK/SsNArc
+/+ 
rats. In this study, the environmental factors were kept constant, by ensuring that all 
the rats received the same lighting, ate the same food, drank the same water and 
lived in the same area space, as provided by the breeding facility. 
 
Although it is now clear that there are different genetic loci, mutations of which are 
the cause of ARPKD in different murine models, the clinical features of ARPKD in 
the LPK/SsNArc
+/+ rats are similar to that of other rat models of the disease and 
these  include:  bilaterally  enlarged  cystic  kidneys, development  of  higher  systolic 
blood pressure, development of anemia and deterioration of the kidney functions.  
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The kidneys of the LPK/SsNArc
+/+ rats eventually reached end stage renal disease by 
the twelfth week after birth. 
 
The presentation of similar disease phenotypes, resulting from mutations in different 
genetic loci in different murine models of ARPKD, presents a new perspective in the 
understanding of systems biology in the murine models of the disease. This also 
challenges  our  appreciation  of  convergence  of  common  disease  processes,  and 
especially in the development of ARPKD in different animal species. As such, a 
thorough understanding of the cellular processes, pertinent to the development of 
ARPKD  in  the  animal  species  is  required  to  set  a  baseline  for  comparison  of 
ARPKD in different animal species. 
 
In the correlation analysis, it was found that the percentage kidney/body weight of 
the rats was directly correlated with increase in systolic blood pressure, decrease in 
hematocrit and decrease in urine specific gravity (Chapter III). The findings imply 
that changes in the phenotypic traits were a consequence of cyst development in the 
kidneys,  which  resulted  from  a  recessive  mutation  in  one  gene  located  on 
LPK/SsNArc
+/+ rat chromosome 10q21. This also implies that each phenotype was 
not controlled by a mutation in independent genetic loci. Furthermore, the results of 
the linkage analysis show a causative effect resulting from the recessive mutation in 
a single genetic locus, located in chromosome 10q21. Importantly, the study shows 
that there were no significant differences in the mean values of the phenotypic trait 
data between male and female and between F2 and BC1 rats with ARPKD, except 
for the mean body weights. The lack of significant differences in the mean values of  
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the  phenotypic  trait  data  further  implies  that  there  were  no  modifier  loci  that 
significantly affected the expression of PKD in the LPK/SsNArc
+/+ rats, as was the 
case in other murine models of the disease (Bihoreau et al., 2002; Guay-Woodford et 
al., 1996; Upadhya et al., 1999). 
 
However, it appears that the current knowledge of the genetics that underlie the 
development of ARPKD in different murine models is far from complete. Given that 
there are different genetic loci associated with ARPKD in different murine models, it 
is  likely  that  there  are  many  different  genes,  mutations  of  which  are  the  cause 
ARPKD, and this suggests that PKD is actually a syndrome and not a single disease. 
However,  the  present  study  provides  an  important  insight  into  the  genetics  of 
ARPKD in the LPK/SNArc
+/+ rats. The genome-wide scan provides solid evidence 
for  linkage  of  the  phenotypic  traits  to  a  narrow  genetic  region,  23.76  cM  in 
chromosome  10q21  (Chapter  IV).  Furthermore,  the  proteins  encoded  by  the 
candidate genes in the QTL region are not similar to and they do not share common 
functional domains with fibrocystin, except for the signal peptide domain that is 
found common between fibrocystin, Methionine adenosyltransferase II# and kidney 
injury molecule 1 (Chapter V). Therefore, the results presented in this study have 
provided  invaluable  information  for  future  identification  of  the  gene  that  causes 
ARPKD and for the identification of important regulatory elements, and some non-
coding conserved elements may fall into this category.  
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During linkage analysis, the confounding factors that were taken into consideration 
were the genetic background and the environmental factors. In previous PKD studies 
in human and murine models (Bergmann et al., 2003; Lager et al., 2001; Menezes 
and  Onuchic,  2006),  genetic  and  environment  factors  significantly  affected  the 
severity of renal disease and extrarenal presentation. It may then be argued that these 
factors  also  complicated  the  presentation  of  ARPKD  in  the  LPK/SsNArc
+/+  rats. 
However, environmental factors were invariant throughout the study. Furthermore, 
the phenotypic ratios showed that recessive mutation in one gene was responsible for 
the disease presentation (Chapter III). This finding is supported by the fact that there 
are no significant differences in the mean values of the phenotypic trait data between 
male and female rats with ARPKD or between F2 and BC1 progeny with ARPKD, 
which  means  that  there  are  no  modifier  loci  that  significantly  affected  the  PKD 
presentation in the LPK/SsNArc
+/+ rats. Therefore, the results of linkage analysis 
strongly support that the QTL on chromosome 10q21 is the only principal genetic 
determinant of ARPKD in the LPK/SsNArc
+/+ rats (Chapter IV). 
 
Although an epistatic interaction between D10Rat26 and loci on chromosomes 3, 5, 
7, 11, 12, 14 and 17 was found, the interaction does not significantly alter the disease 
phenotype (Chapter III). The lack of a significant modification effect may explain 
why there are no significant differences in the mean values of the phenotypic trait 
data between male and female rats or between F2 and BC1 progeny with the disease. 
Therefore, the results of the present genetic analysis do not support the previous 
findings that genetic modifier loci influence the expression of ARPKD (Bihoreau et 
al., 2002; Guay-Woodford et al., 1996; Upadhya et al., 1999).  
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The QTL responsible for ARPKD in the LPK/SsNArc
+/+ rats on chromosome 10q21 
maps to human chromosome 5q34-q35 and to mouse chromosomes 11C and 18B1 
(Chapter  V).  In  previous  studies,  rat  chromosome  10  was  mapped  to  human 
chromosomes 5, 16 and 17 and mouse chromosomes 11, 16, and 17 (Gomez-Fabre et 
al.,  2002;  Nilsson  et  al.,  2001).  Human  chromosome  5q34-q35  contains  the 
methionine adenosyltransferase II# gene, while mouse chromosomes 11C and 18B1 
contain breast carcinoma amplified sequence 3 and Ras-like without CAAX 2 genes, 
respectively. These genes were found to control cell growth, cell proliferation and 
cell  differentiation  (Bourne  et  al.,  1990,  1991;  Hoshino  and  Nakamura,  2002; 
Hoshino  et  al.,  2005)  and  their  mutations  were  associated  with  development  of 
tumors in human liver and colon (Garbay et al., 2000; Margolis and Skolnik, 1994). 
Previously, Gratham (1990) and Harris and Watson (1997) indicated that all forms of 
PKD  shared  common  cellular  processes  with  neoplasm.  However,  there  is  not 
enough  evidence  in  the  present  study  to  support  or  refute  that  ARPKD  in  the 
LPK/SsNArc
+/+ rats is a form of neoplasm. 
 
The alignment of the protein sequences encoded by the genes in the QTL region and 
fibrocystin  to  assess  their  sequence  similarity  and  protein  domain  conservation 
(Xiong, 2006) and to find differences between the protein sequences (Jankun-Kelly 
et al., 2009) showed that the proteins were not similar and they did not have similar 
conserved domains, except for the signal peptide domain, which is found between 
fibrocystin and methionine adenosyltransferase II# and kidney injury molecule 1. 
Although  the  protein  sequences  are  not  homologous  and  they  lack  structural 
similarity,  this  does  not  mean  that  there  is  also  a  lack  of  functional  similarity.  
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However,  because  there  is  a  significant  evolutionary  divergence  between  the 
proteins, lack of sequence similarity and because the disease does not lead to the 
development of extra-renal cysts, the development of ARPKD in the LPK/SsNArc
+/+ 
rats appears to present convergence of disease processes, resulting from mutation in 
independent genomic loci that occurred at different time point. 
 
The present study has established strong evidence that a recessive mutation in one 
genetic  locus  located  in  chromosome  10q21  is  the  cause  of  ARPKD  in  the 
LPK/SsNArc
+/+ rats, and this genetic locus controls the expression of the disease 
phenotype. It has also become clear that chromosome 10q21 does not contain Pkhd-1 
or Nek8, mutation of which caused ARPKD in other murine models (Harris and 
Torres,  2009;  Smith  et  al.,  2006a).  Although  it  is  not  yet  clear  which  gene  is 
mutated, it is highly probable that the function of the mutated gene responsible of 
ARPKD in the LPK/SsNArc
+/+ may have common genetic and cellular pathways or 
regulatory elements with Pkhd-1, and therefore, disruption of the pathways or the 
regulatory elements resulted in ARPKD. 
6.2: Future Direction 
It has been established in the present study that a recessive mutation in a single gene 
located  on  rat  chromosome  10q21  controls  the  expression  of  ARPKD  in  the 
LPK/SsNArc
+/+ rats. Although several candidate genes are located in this QTL, it is 
not known which gene is responsible for the disease. As such, detailed and fine 
mapping  of  chromosome  10q21  in  the  LPK/SsNArc
+/+  rats  using  a  dense  set  of  
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markers is being undertaken using the genotype of F2 progeny. The gene will be 
identified and it will be sequenced in both the PKD and the non-PKD rats and the 
sequences compared to identify the type of mutation. This will ensure that the actual 
gene and the mutation responsible for the PKD phenotypes in the LPK/SsNArc
+/+ 
rats are identified.  
 
The most important part in the continuation of this study will be to find a treatment 
for ARPKD. Therefore, once the mutated gene is identified, mutated mRNA will be 
easily  identified  and  targeted  interference  with  the  mutant  mRNA,  using  RNA 
interference  techniques  (Agrawal  et  al.,  2003;  Leung  and  Whittaker,  2005; 
Stanislawska and Olszewski, 2005), will be carried out. RNA interference is a new 
method of genetic treatment and it will provide individualized genetic therapy. In 
recent years, however, mammalian target of rapamycin (mTOR) was used in drug 
treatment of all types of PKD using rapamycin (Abraham and Gibbons, 2007; Lang 
et al., 2007). Yet, gene therapy (Flotte and Laube, 2001; Grimm, 2009; He et al., 
2009) will provide promise in the treatment of PKD. 
6.3: General Conclusion 
Overall, the results presented in this thesis support the general hypothesis that a 
recessive mutation in a single gene was responsible for development and expression 
of ARPKD in the LPK/SsNArc
+/+ rats. This has been established through mating 
experiments,  which  showed  that  the  segregation  ratios  of  PKD:non-PKD  in  the 
LPK/SsNArc
+/+ rats followed simple Mendelian ratios of 1:3 in the F2 and 1:1 in the  
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BC1,  a  requirement  for  the  inheritance  of  traits  controlled  by  a  single  gene. 
Furthermore,  the  study  has  unveiled  strong  and  significant  evidence  for  linkage 
between  PKD  phenotypes  and  markers  located  on  chromosome  10q21  in  the 
LPK/SsNArc
+/+ rats, giving a total LOD score of 7.9 between markers D10Rat43 and 
D10Rat26. Given that there are many genetic loci involved in the development of the 
cystic kidney diseases, the PKD studied should better be described as a syndrome. 
 
Known gene products coded within this region are not associated with gene products 
that are responsible for ARPKD in other murine models. The study has, therefore, 
excluded Pkhd-1, nek8 and other genes linked to ARPKD in other murine models of 
the  disease,  as  candidate  homologs,  and  therefore  shows  that  the  mutated  gene 
responsible for ARPKD in the LPK/SsNArc
+/+ rats is novel or another mechanism, 
yet to be discovered, is responsible for ARPKD in the LPK/SsNArc
+/+ rats. Although 
all the candidate genes located in chromosome 10q21 are cancer-related and the 
findings support earlier reports that rat chromosome 10 was associated with tumor-
related genes (Watanabe et al., 1999; Yasue et al., 1992; Yeung et al., 1993), there is 
not enough evidence in this study to confirm or refute that ARPKD inherited from 
the LPK/SsNArc
+/+ rats is a cancer of the kidneys. The study has potentially revealed 
a new form of genetic origin of ARPKD. It has also opened a new opportunity to 
investigate  and  understand  the  underlying  pathways  that  are  to  be  revealed  and 
treatments that are to be discovered. Chromosome 10q21 is now the target for fine 
mapping to identify the mutated gene that causes ARPKD in the LPK/SsNArc
+/+ rats 
and  currently,  a  detailed  study  of  chromosome  10  using  the  F2  progeny  is  in 
progress.  
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Appendix A 
The genotype for chromosomes 1 to 20 of the 139 BC1 progeny using the markers 
indicated  is  shown.  The  dash  score  shows  non-informative  alleles.  In  this  table, 
genotype from progeny number 1 to 15 is shown. 
 
Chro  Marker  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15 
Chr1  D1Rat246  A  H  A  -  H  A  -  H  A  -  -  A  A  H  A 
  D1Rat256  A  A  A  A  A  A  A  H  H  H  A  A  H  A  A 
  D1Rat183  A  A  H  H  A  A  H  A  A  H  A  -  A  A  H 
  D1Rat194  A  A  A  H  H  H  A  H  A  A  A  A  A  A  A 
Chr2  D2Rat9  H  H  H  -  H  H  H  A  A  A  -  H  A  A  H 
  D2Rat136  H  A  A  A  A  H  A  A  H  H  A  H  H  A  H 
  D2Rat228  A  H  A  A  A  H  A  H  H  A  A  A  A  A  A 
  D2Rat70  H  A  A  -  A  A  A  A  A  H  H  H  A  H  - 
Chr3  D3Rat56  H  A  A  A  A  H  A  H  H  A  H  H  H  A  H 
  D3Rat193  H  A  A  A  A  H  A  H  H  A  H  H  H  H  A 
  D3Rat194  H  A  A  A  A  H  -  H  H  A  H  H  H  -  H 
  D3Rat231  H  A  A  A  A  H  A  H  H  A  H  H  H  A  H 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  A  A  A  A  A  A  H  A  H  A  H  H  H  H  H 
  D3Rat68  H  A  H  A  H  H  H  H  H  H  H  H  H  H  H 
  D3Rat132  H  A  H  A  H  H  H  H  H  H  H  H  H  H  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  A  H  A  H  A  A  H  A  H  A  -  H  A  H  H 
  D4Rat140  H  H  A  H  A  H  H  A  H  A  H  H  H  H  H 
Chr5  D5Rat125  H  H  H  A  -  H  A  A  -  A  A  A  H  H  H 
  D5Rat82  H  H  H  -  H  H  -  -  A  -  A  H  H  H  A 
  D5Rat72  H  H  H  A  A  H  A  H  H  H  A  H  H  A  A 
  D5Rat111  H  A  H  H  H  H  A  A  H  H  A  A  A  A  A 
Chr6  D6Rat46  H  A  A  A  H  H  H  H  H  A  A  H  A  H  A 
  D6Rat132  A  H  A  A  H  H  A  H  A  H  A  H  A  A  H 
  D6Rat87  H  A  A  H  H  H  A  A  A  H  A  A  A  H  H 
  D6Rat101  -  A  A  H  H  H  A  A  A  H  A  A  A  H  H 
Chr7  D7Rat36  H  H  H  H  H  H  H  H  A  A  H  A  A  A  A 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  H  H  H  H  H  H  H  H  A  A  H  A  A  A  A 
  D7Rat32  H  H  H  H  H  H  H  H  A  A  H  A  A  A  A  
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  D7Rat152  -  H  H  H  H  H  A  H  A  A  H  A  A  A  A 
  D7Rat103  H  A  H  H  A  H  A  A  A  A  A  A  H  A  H 
  D7Rat17  A  A  H  H  A  A  A  A  A  A  A  A  H  A  H 
  D7Rat3  H  A  H  H  H  H  H  A  H  H  H  A  H  A  H 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  H  A  H  H  A  A  A  A  A  A  A  A  A  A  H 
  D8Rat130  A  A  H  H  A  A  A  A  A  A  H  A  A  A  H 
  D8Rat69  A  A  H  H  H  A  A  H  A  A  H  A  A  A  H 
Chr9  D9Rat44  H  H  A  H  H  H  H  H  A  A  H  A  H  H  H 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  A  H  A  A  A  H  A  H  H  A  H  A  H  A  H 
  D9Rat75  A  H  A  A  A  H  A  A  H  A  H  A  H  H  H 
Chr10  D10Rat95  H  -  A  H  H  A  A  H  A  A  H  H  H  H  A 
  D10Rat218  H  A  H  A  H  A  A  H  A  A  H  H  A  H  A 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  H  A  H  A  H  H  H  H  A  H  H  H  A  -  A 
  D10Rat26  H  H  A  H  H  A  H  H  A  H  H  H  H  A  - 
  D10Rat12  H  A  A  A  H  H  H  H  A  H  H  H  H  A  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  A  H  H  -  H  H  A  A  A  H  A  H  H  A  A 
Chr11  D11Rat28  -  A  H  H  A  A  A  A  A  H  A  H  A  A  H 
  D11Rat93  A  A  H  H  A  A  A  H  A  H  A  A  A  H  A 
  D11Rat56  A  A  H  A  A  A  H  H  A  H  A  A  H  H  A 
  D11Rat43  A  A  H  A  A  A  H  H  A  A  A  A  H  H  A 
Chr12  D12Rat89  A  H  A  H  A  H  H  A  H  H  A  H  A  H  H 
  D12Rat28  A  H  A  H  A  H  H  A  H  H  H  H  A  H  H 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  A  A  A  A  A  H  H  H  H  H  H  H  A  A  H 
Chr13  D13Rat108  H  H  A  H  A  A  -  A  A  H  -  H  A  A  A 
  D13Rat58  H  H  H  H  H  A  H  H  H  A  A  A  H  A  H 
  D13Rat131  H  H  -  -  -  A  A  H  H  H  A  A  H  H  H 
  D13Rat86  H  H  A  H  H  A  A  H  H  H  A  A  A  H  H 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  H  A  A  H  A  A  A  H  A  A  A  H  A  A  H 
  D14Rat94  A  A  A  H  A  A  H  H  A  A  A  H  A  A  H 
  D14Rat38  A  A  A  H  A  A  H  H  A  A  H  H  A  A  A 
Chr15  D15Rat1  A  H  -  H  -  H  A  H  H  H  H  A  A  A  H 
  D15Rat17  A  A  A  A  A  A  H  A  A  H  H  A  A  A  - 
  D15Rat101  A  A  A  H  H  A  H  A  A  H  -  -  -  -  A 
  D15Rat107  A  A  -  A  A  A  H  A  A  H  H  H  A  H  A 
Chr16  D16Rat107  A  H  H  A  A  A  H  A  H  A  H  H  A  A  A 
  D16Rat53  A  H  H  A  H  A  A  A  H  A  A  -  A  A  A 
  D16Rat34  A  H  H  H  H  A  A  A  H  A  H  H  A  A  A 
  D16Rat48  A  H  H  A  H  A  A  A  H  H  H  -  H  H  A 
Chr17  D17Rat1  H  H  A  A  H  A  A  A  H  H  A  H  H  A  A 
  D17Rat17  H  A  A  A  H  A  A  -  H  H  -  -  H  A  A 
  D17Rat96  A  H  A  H  A  H  H  H  A  A  H  H  A  A  H 
  D17Rat131  H  A  H  H  H  A  A  H  H  A  A  A  H  H  A 
Chr18  D18Rat112  H  -  H  A  -  H  H  A  H  A  H  H  H  H  H 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  -  -  -  -  -  
 
 
198 
  D18Rat13  H  H  H  H  H  A  A  H  H  A  H  A  A  A  A 
  D18Rat44  H  A  H  H  H  A  A  H  H  A  H  A  A  A  A 
Chr19  D19Rat19  H  H  H  H  A  H  A  H  H  A  H  A  A  H  A 
  D19Rat11  H  H  H  H  A  H  -  A  H  A  A  A  A  H  A 
  D19Rat64  H  H  A  A  H  H  A  A  H  H  A  A  H  A  A 
  D19Rat5  A  A  A  A  H  H  A  A  H  H  A  -  H  A  H 
Chr20  D20Rat21  A  A  H  H  A  A  H  A  H  A  H  H  H  A  A 
  D20Rat10  H  A  H  H  A  A  A  A  H  A  H  A  H  A  H 
  D20Rat19  H  A  H  A  A  A  A  A  H  H  A  A  H  A  H 
  D20Rat29  H  A  H  A  A  -  A  A  H  H  A  A  H  A  H 
  LPK/SsNArc
+/+   H  H  A  A  H  H  H  H  A  H  H  H  H  A  A 
 
Genotype for BC1, from progeny number 16 to 28 
Chro  Marker  16  17  18  19  20  21  22  23  24  25  26  27  28 
Chr1  D1Rat246  A  H  A  -  H  H  A  H  H  A  -  H  A 
  D1Rat256  A  H  -  A  H  A  -  H  H  A  A  H  H 
  D1Rat183  H  H  H  H  A  -  H  H  A  A  H  A  H 
  D1Rat194  H  H  A  A  H  H  A  A  H  -  A  H  A 
Chr2  D2Rat9  H  H  H  A  A  H  H  H  H  A  H  A  H 
  D2Rat136  H  A  A  A  A  H  -  -  -  -  A  A  A 
  D2Rat228  A  A  H  A  A  H  A  H  A  H  A  A  A 
  D2Rat70  H  H  H  A  H  H  H  A  A  H  H  A  H 
Chr3  D3Rat56  A  A  A  A  H  A  A  -  A  H  H  A  A 
  D3Rat193  A  A  A  A  H  A  A  A  A  H  A  H  A 
  D3Rat194  A  A  -  A  H  A  A  -  A  H  H  H  A 
  D3Rat231  A  A  A  A  H  A  A  A  A  H  H  A  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  H  -  -  -  H  -  -  -  -  H  A  A  H 
  D3Rat68  -  A  H  H  H  A  H  H  A  A  H  H  H 
  D3Rat132  H  A  H  H  H  A  H  H  A  A  H  H  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  H  A  H  H  A  A  H  H  H  H  A  A  H 
  D4Rat140  H  H  A  A  A  A  A  A  H  A  H  A  H 
Chr5  D5Rat125  A  H  H  H  H  H  H  A  H  A  H  H  H 
  D5Rat82  A  H  H  H  -  A  H  A  H  A  H  H  H 
  D5Rat72  A  H  H  H  H  H  H  H  H  H  A  A  A 
  D5Rat111  A  A  H  H  H  H  A  A  H  A  A  A  A 
Chr6  D6Rat46  A  H  H  H  H  A  H  A  A  A  H  A  A 
  D6Rat132  H  A  H  H  H  A  A  H  A  H  H  A  A 
  D6Rat87  A  H  H  A  A  A  -  H  H  H  A  H  H 
  D6Rat101  H  A  H  H  A  -  -  H  A  H  A  A  H 
Chr7  D7Rat36  H  H  H  A  H  H  H  A  H  H  H  A  A 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  H  H  H  A  H  H  H  A  H  H  A  A  H 
  D7Rat32  H  H  H  A  H  H  H  A  H  H  A  A  H 
  D7Rat152  H  H  H  A  H  H  -  A  H  H  A  A  H 
  D7Rat103  A  -  -  A  H  H  A  H  H  H  A  A  H  
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  D7Rat17  A  H  A  A  H  H  A  H  A  H  A  A  H 
  D7Rat3  H  A  -  -  -  -  -  -  -  -  H  A  A 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  A  H  H  A  A  H  H  H  H  A  H  A  H 
  D8Rat130  H  A  H  A  H  H  H  A  H  A  H  A  H 
  D8Rat69  H  A  H  H  H  H  H  A  H  A  H  A  H 
Chr9  D9Rat44  A  A  H  A  H  H  H  A  A  H  A  H  A 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  H  H  A  H  A  H  A  -  H  A  H  A  H 
  D9Rat75  H  A  H  H  A  H  A  H  H  A  H  A  A 
Chr10  D10Rat95  H  H  H  H  H  H  H  H  A  A  H  H  A 
  D10Rat218  H  A  H  A  H  H  A  H  A  A  H  H  A 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  H  A  H  A  H  H  H  H  A  A  H  H  A 
  D10Rat26  H  A  H  H  H  H  H  H  A  H  A  H  A 
  D10Rat12  H  H  H  H  H  H  A  H  A  H  H  H  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  H  H  A  H  H  H  A  A  H  H  H  H  H 
Chr11  D11Rat28  A  H  A  H  H  H  -  H  A  H  H  H  A 
  D11Rat93  A  H  H  A  -  -  H  H  A  H  H  H  H 
  D11Rat56  A  H  H  A  H  A  H  H  H  A  H  A  H 
  D11Rat43  A  H  H  A  A  A  H  H  H  A  H  A  H 
Chr12  D12Rat89  A  H  H  A  A  -  -  H  H  H  H  H  H 
  D12Rat28  A  H  -  A  -  H  -  H  H  H  H  H  H 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  H  A  H  A  H  H  A  H  A  H  A  H  H 
Chr13  D13Rat108  H  A  -  H  A  H  H  A  H  A  H  A  H 
  D13Rat58  A  A  -  -  -  -  -  A  H  H  H  H  A 
  D13Rat131  H  A  A  H  H  H  A  A  H  H  H  H  A 
  D13Rat86  H  A  H  H  A  H  A  A  H  H  H  H  H 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  A  A  A  A  A  H  A  A  A  A  H  H  H 
  D14Rat94  A  A  -  A  A  A  A  -  H  H  H  H  H 
  D14Rat38  A  A  -  A  -  A  A  -  H  H  H  H  H 
Chr15  D15Rat1  A  H  A  H  H  H  H  H  H  H  H  H  H 
  D15Rat17  H  A  H  H  A  A  H  H  H  A  A  H  H 
  D15Rat101  -  A  H  H  H  A  A  A  A  A  A  H  H 
  D15Rat107  H  A  H  H  A  A  A  H  A  A  A  H  H 
Chr16  D16Rat107  H  H  A  A  A  A  H  H  H  A  A  A  H 
  D16Rat53  H  A  A  H  -  -  A  A  A  H  A  H  H 
  D16Rat34  H  A  A  H  -  -  -  A  A  H  H  H  H 
  D16Rat48  H  A  H  H  H  H  A  A  H  H  H  -  H 
Chr17  D17Rat1  A  A  H  A  H  A  A  A  A  H  H  A  A 
  D17Rat17  A  A  A  H  H  H  A  H  -  H  H  H  A 
  D17Rat96  A  A  H  A  A  A  H  A  H  H  A  A  A 
  D17Rat131  H  H  A  H  H  H  A  H  H  A  H  H  A 
Chr18  D18Rat112  A  A  A  H  H  H  -  H  H  H  H  A  A 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  A  H  A  A  A  A  H  H  A  A  -  H  A 
  D18Rat44  A  -  A  A  A  A  -  A  A  A  H  H  A  
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Chr19  D19Rat19  H  A  H  A  H  A  H  A  H  A  H  H  H 
  D19Rat11  H  A  H  A  H  A  H  A  A  A  H  H  A 
  D19Rat64  A  H  H  A  H  -  A  A  A  H  H  H  A 
  D19Rat5  A  H  A  A  H  H  A  A  A  H  H  H  A 
Chr20  D20Rat21  -  A  H  A  -  -  -  A  A  A  A  A  H 
  D20Rat10  H  A  A  A  A  A  A  A  A  A  H  H  H 
  D20Rat19  A  A  A  H  A  A  A  A  A  H  H  H  H 
  D20Rat29  A  A  A  H  -  A  A  A  A  H  H  H  H 
  LPK/SsNArc
+/+  A  A  H  H  H  H  H  A  A  H  A  H  A 
 
Genotype for BC1, from progeny number 29 to 41 
Chro  Marker  29  30  31  32  33  34  35  36  37  38  39  40  41 
Chr1  D1Rat246  A  A  -  A  A  -  A  H  H  H  H  A  A 
  D1Rat256  H  H  A  A  H  H  H  H  H  H  H  A  A 
  D1Rat183  H  H  A  H  H  H  H  A  A  A  A  H  H 
  D1Rat194  H  H  H  H  H  A  H  A  A  A  H  H  A 
Chr2  D2Rat9  H  H  H  H  A  A  A  H  -  A  H  A  H 
  D2Rat136  -  H  H  H  A  A  H  A  A  A  H  A  A 
  D2Rat228  H  H  A  -  A  H  H  H  H  A  H  A  A 
  D2Rat70  A  H  H  A  H  -  A  A  A  A  A  H  H 
Chr3  D3Rat56  A  A  A  H  A  H  A  H  A  A  H  H  A 
  D3Rat193  A  A  A  H  A  H  A  H  A  H  A  H  A 
  D3Rat194  A  A  A  H  A  H  -  H  A  A  H  H  A 
  D3Rat231  A  A  A  H  A  H  A  H  A  A  H  H  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  A  A  H  H  A  H  A  H  H  A  H  A  A 
  D3Rat68  H  H  H  A  H  H  A  A  H  A  A  A  A 
  D3Rat132  H  -  A  A  H  H  A  A  H  A  -  A  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  A  A  H  H  A  A  A  H  A  A  A  H  A 
  D4Rat140  H  A  A  H  H  H  A  H  A  A  A  H  H 
Chr5  D5Rat125  A  -  -  A  H  A  H  H  H  A  H  A  A 
  D5Rat82  A  A  A  A  A  A  H  H  H  A  H  A  A 
  D5Rat72  A  A  H  A  A  A  H  A  H  A  A  H  H 
  D5Rat111  A  A  H  A  H  H  A  A  A  H  H  A  A 
Chr6  D6Rat46  H  H  A  A  H  H  H  H  H  H  H  A  A 
  D6Rat132  A  H  H  A  A  A  H  H  A  A  H  A  H 
  D6Rat87  H  A  H  A  A  A  H  A  A  H  A  A  H 
  D6Rat101  A  A  H  A  A  A  H  A  A  H  H  H  H 
Chr7  D7Rat36  A  A  H  H  A  H  H  A  H  A  H  A  H 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  A  A  H  H  A  H  H  A  H  H  H  A  H 
  D7Rat32  A  A  H  H  A  H  H  A  H  H  H  A  H 
  D7Rat152  A  A  H  H  A  -  H  A  H  H  A  A  H 
  D7Rat103  H  A  H  H  H  A  H  A  H  H  A  A  A 
  D7Rat17  H  H  H  H  H  A  H  H  H  H  A  H  A 
  D7Rat3  H  H  H  A  H  H  H  A  H  A  A  H  A  
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Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  A  H  A  A  A  H  H  H  H  A  H  A  H 
  D8Rat130  A  A  A  A  A  H  H  H  H  H  A  H  A 
  D8Rat69  H  A  A  H  H  A  H  A  A  H  H  H  A 
Chr9  D9Rat44  H  A  H  A  A  A  A  H  A  H  A  H  H 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  H  A  A  H  A  H  A  A  A  H  A  A  A 
  D9Rat75  H  A  A  H  A  H  A  A  H  A  H  A  A 
Chr10  D10Rat95  A  H  A  A  A  A  H  H  A  H  A  H  H 
  D10Rat218  A  A  H  H  A  A  H  H  A  H  A  A  A 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  A  A  H  H  H  A  H  H  A  H  A  A  H 
  D10Rat26  A  A  H  A  H  A  A  H  H  H  A  A  H 
  D10Rat12  A  H  H  A  H  A  H  H  A  A  H  A  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  A  H  A  A  H  H  H  H  A  A  H  A  H 
Chr11  D11Rat28  H  H  A  H  A  A  A  A  A  H  A  A  A 
  D11Rat93  A  A  H  H  A  A  A  A  A  A  A  H  H 
  D11Rat56  H  -  A  H  H  A  A  A  A  A  A  A  H 
  D11Rat43  H  A  A  H  A  A  A  A  A  A  A  A  H 
Chr12  D12Rat89  A  A  A  H  A  A  H  A  A  H  A  A  H 
  D12Rat28  A  A  A  A  A  A  -  -  A  H  H  A  H 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  -  A  H  A  A  A  A  H  H  A  H  A  A 
Chr13  D13Rat108  A  A  H  A  H  A  A  H  H  A  H  H  H 
  D13Rat58  H  H  H  A  A  A  H  H  H  H  A  A  H 
  D13Rat131  H  A  H  A  A  A  H  H  H  H  A  A  H 
  D13Rat86  H  A  H  A  A  A  H  H  H  H  A  A  H 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  H  H  A  H  A  A  H  A  A  H  A  A  A 
  D14Rat94  H  H  A  H  A  H  H  A  A  H  H  A  A 
  D14Rat38  A  H  A  H  A  H  H  A  H  H  H  H  H 
Chr15  D15Rat1  H  H  H  H  A  A  A  A  A  A  H  H  H 
  D15Rat17  A  A  A  A  H  H  H  H  H  A  H  H  H 
  D15Rat101  A  A  H  A  A  A  A  H  A  A  H  A  H 
  D15Rat107  A  A  A  A  H  A  A  H  H  A  H  H  H 
Chr16  D16Rat107  A  H  A  H  H  A  A  A  H  H  H  H  H 
  D16Rat53  A  H  A  A  H  A  A  A  A  A  H  H  A 
  D16Rat34  A  H  A  A  A  A  H  A  A  A  H  H  A 
  D16Rat48  A  H  A  A  A  H  H  A  A  A  H  H  A 
Chr17  D17Rat1  H  A  A  A  H  H  H  H  A  A  A  A  H 
  D17Rat17  H  A  -  A  H  H  H  H  H  A  A  H  H 
  D17Rat96  A  A  A  H  A  A  A  A  H  H  H  A  A 
  D17Rat131  H  H  H  A  H  A  H  H  A  A  A  H  H 
Chr18  D18Rat112  A  A  H  H  H  H  H  A  H  A  A  A  A 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  A  A  H  H  H  H  -  H  H  H  A  A  H 
  D18Rat44  A  A  A  H  H  -  H  H  H  H  H  A  H 
Chr19  D19Rat19  A  A  H  H  A  H  H  H  H  A  A  A  A 
  D19Rat11  A  A  H  A  A  A  H  -  H  -  H  A  -  
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  D19Rat64  A  H  H  A  H  A  H  H  H  A  H  H  A 
  D19Rat5  A  H  H  A  H  A  H  H  H  A  H  H  A 
Chr20  D20Rat21  A  A  H  A  H  A  H  A  A  A  H  H  H 
  D20Rat10  A  A  H  A  H  -  H  H  -  -  A  A  H 
  D20Rat19  A  A  H  A  A  A  A  H  H  A  A  A  A 
  D20Rat29  A  A  H  A  A  A  A  H  H  A  A  A  A 
  LPK/SsNArc
+/+  A  A  H  A  H  A  A  H  H  H  A  A  H 
 
Genotype for BC1, from progeny number 42 to 54 
Chro  Marker  42  43  44  45  46  47  48  49  50  51  52  53  54 
Chr1  D1Rat246  A  -  A  H  -  A  A  H  A  H  A  H  H 
  D1Rat256  H  A  A  A  A  H  A  A  H  H  H  -  A 
  D1Rat183  H  H  H  H  A  A  A  H  H  H  A  -  A 
  D1Rat194  H  A  A  H  H  H  H  H  H  A  A  -  H 
Chr2  D2Rat9  A  H  A  A  H  H  A  H  A  A  H  H  A 
  D2Rat136  A  A  -  -  A  H  A  H  H  A  H  -  H 
  D2Rat228  H  H  H  H  A  H  A  H  H  H  H  -  H 
  D2Rat70  -  H  A  -  A  H  H  A  H  H  A  H  H 
Chr3  D3Rat56  A  A  A  H  A  H  H  A  A  H  H  -  A 
  D3Rat193  A  A  A  H  -  H  H  A  H  A  A  -  A 
  D3Rat194  A  A  -  H  -  H  H  -  A  H  H  A  A 
  D3Rat231  A  A  A  H  A  H  H  A  A  H  H  -  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  H  A  A  H  H  H  H  H  A  A  H  H  A 
  D3Rat68  H  -  H  -  H  A  -  H  H  H  H  A  H 
  D3Rat132  H  A  H  A  H  A  A  H  H  H  A  A  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  A  A  H  H  A  H  A  H  A  H  H  A  A 
  D4Rat140  H  A  H  H  A  H  H  A  A  H  H  A  H 
Chr5  D5Rat125  A  -  H  -  -  H  A  A  H  A  A  H  H 
  D5Rat82  A  A  A  A  -  -  A  A  H  A  A  H  H 
  D5Rat72  A  A  A  A  H  A  H  H  H  H  A  H  H 
  D5Rat111  H  A  H  H  H  H  H  H  H  A  A  H  H 
Chr6  D6Rat46  A  H  H  H  H  H  A  H  A  H  H  A  H 
  D6Rat132  H  H  H  A  H  A  A  H  A  A  H  A  A 
  D6Rat87  A  H  H  A  A  H  H  H  H  A  H  A  A 
  D6Rat101  H  H  H  A  A  H  H  H  H  A  H  H  A 
Chr7  D7Rat36  H  A  H  -  A  A  A  -  A  A  A  A  H 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  H  A  H  H  A  A  A  H  A  A  H  -  H 
  D7Rat32  H  A  H  H  A  A  A  H  A  A  H  A  H 
  D7Rat152  H  A  H  H  A  A  A  H  A  A  H  H  H 
  D7Rat103  A  A  A  H  A  A  H  H  -  A  H  H  H 
  D7Rat17  H  A  A  A  A  A  H  H  H  A  H  H  H 
  D7Rat3  H  -  -  -  -  A  A  H  H  H  H  A  A 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  A  A  A  A  H  H  H  A  H  A  H  A  H  
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  D8Rat130  A  H  A  A  A  H  H  A  A  H  H  A  A 
  D8Rat69  H  A  A  H  A  A  H  A  A  H  H  H  A 
Chr9  D9Rat44  A  A  A  H  A  A  H  H  A  H  A  A  H 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  -  H  A  A  H  H  H  A  H  A  A  A  H 
  D9Rat75  A  H  A  A  H  H  H  A  H  A  A  A  H 
Chr10  D10Rat95  H  H  H  A  H  A  H  H  H  H  H  A  H 
  D10Rat218  H  A  A  A  H  H  H  H  A  H  H  A  H 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  H  A  A  H  H  A  H  H  A  H  H  A  H 
  D10Rat26  A  H  A  A  A  A  -  -  -  H  H  -  H 
  D10Rat12  A  H  A  A  A  A  H  A  H  H  H  A  A 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  H  H  A  A  H  A  H  A  H  A  H  A  A 
Chr11  D11Rat28  -  -  -  -  -  H  A  A  A  A  A  -  H 
  D11Rat93  A  H  -  A  H  H  A  A  A  A  H  H  H 
  D11Rat56  H  A  H  H  A  H  H  A  -  H  A  H  H 
  D11Rat43  H  A  H  H  A  H  H  A  A  H  A  H  H 
Chr12  D12Rat89  H  A  A  H  A  A  H  H  H  A  H  A  A 
  D12Rat28  H  A  A  A  A  A  H  -  -  A  H  A  A 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  H  H  H  A  H  A  A  A  A  A  H  H  A 
Chr13  D13Rat108  A  H  A  -  A  H  A  A  H  H  A  -  - 
  D13Rat58  A  A  A  A  H  H  A  H  A  A  H  A  H 
  D13Rat131  A  A  A  -  -  A  A  A  A  A  H  A  H 
  D13Rat86  A  A  A  A  H  A  H  A  A  A  H  A  H 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  A  H  A  H  A  H  H  A  A  A  H  H  H 
  D14Rat94  A  H  A  H  A  H  H  A  A  A  H  H  A 
  D14Rat38  A  -  A  -  A  H  H  A  A  A  H  H  A 
Chr15  D15Rat1  H  H  -  -  -  A  A  A  H  H  H  A  A 
  D15Rat17  H  H  A  H  H  A  H  H  H  A  H  A  A 
  D15Rat101  H  A  A  A  H  -  -  -  -  -  -  -  - 
  D15Rat107  H  A  A  A  H  H  A  H  H  A  H  A  A 
Chr16  D16Rat107  A  H  H  A  H  H  H  H  H  A  A  A  H 
  D16Rat53  A  H  H  A  A  -  A  A  -  -  -  H  H 
  D16Rat34  H  H  H  A  -  H  A  A  A  H  A  H  H 
  D16Rat48  H  H  A  A  A  A  A  A  H  H  A  H  H 
Chr17  D17Rat1  H  H  H  A  H  A  -  H  H  H  H  H  H 
  D17Rat17  A  A  -  -  H  A  H  H  H  A  H  H  H 
  D17Rat96  H  H  -  -  -  H  H  A  A  -  A  -  A 
  D17Rat131  H  H  H  H  H  H  A  H  H  A  H  H  H 
Chr18  D18Rat112  A  A  A  A  A  -  A  H  H  A  A  A  A 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  A  H  A  A  A  H  A  A  A  A  A  -  A 
  D18Rat44  -  -  A  A  -  A  H  H  A  A  A  -  A 
Chr19  D19Rat19  A  A  H  H  H  A  H  H  A  H  A  -  H 
  D19Rat11  H  A  H  H  H  H  H  H  A  H  A  -  H 
  D19Rat64  H  H  H  H  H  H  A  H  H  H  A  -  H 
  D19Rat5  H  H  A  H  H  H  A  H  H  H  A  -  H  
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Chr20  D20Rat21  A  H  -  H  A  A  A  H  H  H  H  -  A 
  D20Rat10  A  A  A  A  H  A  H  H  H  A  H  -  A 
  D20Rat19  A  A  A  A  H  A  H  H  H  A  H  -  H 
  D20Rat29  A  A  A  -  H  A  H  H  H  A  H  -  H 
  LPK/SsNArc
+/+  H  A  H  H  A  A  A  A  A  H  H  A  H 
 
Genotype for BC1, from progeny number 55 to 67 
Chro  Marker  55  56  57  58  59  60  61  62  63  64  65  66  67 
Chr1  D1Rat246  -  A  -  -  A  H  A  H  H  H  H  A  - 
  D1Rat256  H  A  H  A  H  A  A  A  A  A  H  H  H 
  D1Rat183  H  A  H  A  H  A  A  A  A  A  H  H  A 
  D1Rat194  A  A  A  A  H  A  H  A  A  H  H  H  A 
Chr2  D2Rat9  H  A  -  -  A  H  A  H  A  A  H  A  - 
  D2Rat136  H  H  H  A  H  H  H  H  A  A  A  H  H 
  D2Rat228  H  H  A  H  H  A  A  A  A  H  A  A  A 
  D2Rat70  H  H  H  A  A  A  A  H  A  A  A  A  - 
Chr3  D3Rat56  H  A  A  A  A  A  A  A  A  A  H  H  A 
  D3Rat193  A  A  A  A  A  A  A  A  A  A  H  H  A 
  D3Rat194  A  A  A  -  A  A  A  A  A  H  H  A  - 
  D3Rat231  A  A  A  A  -  A  A  A  A  A  H  H  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  H  A  A  H  A  -  H  A  A  A  A  A  H 
  D3Rat68  H  A  A  A  H  H  H  H  H  A  H  A  H 
  D3Rat132  H  A  H  A  H  H  H  H  H  A  H  A  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  H  A  H  A  H  A  A  H  H  A  H  A  H 
  D4Rat140  H  H  H  A  H  A  A  H  H  A  A  H  H 
Chr5  D5Rat125  -  H  A  -  A  A  A  H  -  A  A  A  - 
  D5Rat82  H  H  A  H  A  A  A  H  H  A  A  A  H 
  D5Rat72  A  H  A  H  H  A  A  H  H  A  A  A  H 
  D5Rat111  A  H  A  A  A  H  H  H  -  H  H  A  H 
Chr6  D6Rat46  A  A  H  H  H  A  H  A  H  A  H  H  A 
  D6Rat132  H  A  A  H  A  H  A  H  A  H  A  A  H 
  D6Rat87  H  A  A  H  A  A  A  H  A  A  A  A  A 
  D6Rat101  H  H  A  H  A  H  A  H  A  A  H  A  A 
Chr7  D7Rat36  H  H  H  H  H  H  H  H  H  H  H  H  A 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  H  H  H  H  A  H  H  H  H  A  H  H  A 
  D7Rat32  H  H  H  H  -  H  H  H  H  A  H  H  A 
  D7Rat152  -  H  H  H  A  H  H  H  H  A  H  H  H 
  D7Rat103  -  -  H  H  H  H  H  -  A  A  H  H  H 
  D7Rat17  H  H  H  H  A  H  H  H  H  -  -  H  H 
  D7Rat3  H  H  A  H  A  A  H  H  H  H  H  H  H 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  A  A  H  A  H  H  H  H  H  A  A  -  - 
  D8Rat130  -  -  H  A  A  H  H  A  A  A  A  A  - 
  D8Rat69  A  H  H  A  A  H  H  H  H  H  H  A  A  
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Chr9  D9Rat44  H  A  A  H  A  A  A  A  A  H  H  H  - 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  -  -  H  H  A  -  -  -  H  A  A  A  H 
  D9Rat75  A  A  H  H  A  -  -  -  H  A  A  A  H 
Chr10  D10Rat95  A  A  H  A  A  H  H  H  H  H  H  A  A 
  D10Rat218  A  H  H  A  -  A  A  H  H  H  H  A  A 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  A  H  H  A  A  A  A  H  H  H  H  H  H 
  D10Rat26  A  A  A  A  A  A  H  A  A  H  H  H  H 
  D10Rat12  A  A  A  A  A  H  H  A  A  H  H  H  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  A  A  A  A  H  H  H  A  A  H  H  H  H 
Chr11  D11Rat28  H  H  H  A  H  H  -  -  H  H  -  -  - 
  D11Rat93  H  H  A  H  H  H  A  A  H  H  H  H  - 
  D11Rat56  H  H  H  H  H  H  H  A  A  A  A  H  A 
  D11Rat43  A  A  A  A  H  H  H  A  A  A  A  H  A 
Chr12  D12Rat89  A  -  H  H  -  H  H  H  H  H  H  A  H 
  D12Rat28  H  H  H  H  H  H  H  H  H  -  -  H  - 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  H  H  A  A  A  -  -  -  H  A  A  H  A 
Chr13  D13Rat108  -  -  -  -  -  -  H  H  -  A  A  -  A 
  D13Rat58  -  A  H  -  -  A  A  A  -  H  H  -  - 
  D13Rat131  A  A  A  H  A  A  A  -  A  H  H  H  H 
  D13Rat86  A  A  A  H  -  -  H  H  H  H  H  H  H 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  H  H  A  A  H  H  H  -  A  A  A  A  A 
  D14Rat94  H  A  A  A  H  H  H  A  A  H  A  A  A 
  D14Rat38  H  A  A  A  A  H  H  A  A  H  A  A  A 
Chr15  D15Rat1  A  A  A  H  H  H  H  H  H  H  A  A  H 
  D15Rat17  A  A  A  H  H  H  H  A  A  H  H  A  H 
  D15Rat101  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D15Rat107  H  H  H  H  H  H  A  A  A  A  A  A  H 
Chr16  D16Rat107  -  -  H  H  -  A  A  A  A  A  A  A  H 
  D16Rat53  A  A  A  A  A  -  H  H  H  H  A  A  H 
  D16Rat34  A  A  A  A  A  A  A  A  A  A  A  -  H 
  D16Rat48  H  A  A  H  A  A  A  A  A  A  A  A  H 
Chr17  D17Rat1  H  H  H  H  A  A  A  A  A  -  H  H  - 
  D17Rat17  H  -  A  H  H  A  A  A  A  H  H  H  H 
  D17Rat96  A  A  -  A  A  H  A  A  -  A  A  A  - 
  D17Rat131  A  A  A  H  A  A  A  A  A  H  H  H  H 
Chr18  D18Rat112  H  H  A  H  H  H  A  H  A  H  H  H  A 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  -  A  H  H  -  A  H  A  H  A  A  A  H 
  D18Rat44  A  A  H  -  A  A  H  A  H  A  A  A  H 
Chr19  D19Rat19  H  H  A  H  H  A  A  A  H  H  H  H  A 
  D19Rat11  H  A  A  H  H  A  H  A  -  H  H  -  H 
  D19Rat64  A  A  A  H  H  A  H  H  H  A  H  A  H 
  D19Rat5  A  A  A  H  H  -  H  H  A  A  H  A  H 
Chr20  D20Rat21  A  A  H  A  A  -  A  A  H  H  H  H  A 
  D20Rat10  H  A  H  A  A  H  H  H  A  H  A  H  A  
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  D20Rat19  H  A  A  A  A  H  H  H  A  H  A  H  A 
  D20Rat29  H  A  A  A  A  H  H  H  A  H  A  H  A 
  LPK/SsNArc
+/+  A  A  A  A  H  H  A  A  H  H  H  H  H 
 
Genotype for BC1, from progeny number 68 to 80 
Chro  Marker  68  69  70  71  72  73  74  75  76  77  78  79  80 
Chr1  D1Rat246  H  A  -  H  A  A  H  H  A  A  A  -  H 
  D1Rat256  H  A  H  A  H  H  H  -  A  A  H  H  H 
  D1Rat183  -  A  A  H  A  H  H  H  H  A  H  H  A 
  D1Rat194  H  H  A  H  H  A  A  H  H  A  H  H  A 
Chr2  D2Rat9  A  A  H  H  H  A  A  H  A  H  H  H  A 
  D2Rat136  H  -  A  H  H  H  A  -  A  A  A  H  H 
  D2Rat228  H  A  A  H  A  A  A  H  H  H  A  A  A 
  D2Rat70  H  -  A  H  H  H  A  H  A  H  A  H  H 
Chr3  D3Rat56  A  H  H  H  A  H  H  H  H  H  H  A  A 
  D3Rat193  A  H  H  H  A  H  H  H  H  H  H  A  A 
  D3Rat194  -  -  -  A  H  H  H  H  H  H  A  A  A 
  D3Rat231  A  H  H  H  A  H  H  H  H  H  H  A  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  -  -  -  -  H  A  A  H  H  A  H  A  H 
  D3Rat68  H  A  A  A  A  A  H  A  H  A  H  A  H 
  D3Rat132  H  A  A  A  H  A  H  A  A  A  H  A  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  A  A  H  A  H  H  H  H  H  A  H  H  H 
  D4Rat140  A  H  -  A  A  H  A  H  H  A  H  A  A 
Chr5  D5Rat125  A  H  H  A  H  A  H  H  H  H  H  H  H 
  D5Rat82  A  H  A  H  H  H  H  H  H  H  H  H  H 
  D5Rat72  A  A  A  A  A  H  H  H  A  H  H  A  H 
  D5Rat111  A  -  -  A  A  H  A  A  A  A  H  A  H 
Chr6  D6Rat46  H  A  A  A  H  H  H  A  A  H  A  A  H 
  D6Rat132  A  -  H  H  A  H  A  A  H  A  H  A  A 
  D6Rat87  H  A  H  A  A  A  H  H  A  A  H  A  A 
  D6Rat101  H  H  H  A  A  A  H  H  A  A  H  A  A 
Chr7  D7Rat36  A  -  H  -  -  H  A  A  A  A  A  -  H 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  A  A  H  H  A  H  H  A  A  A  A  A  A 
  D7Rat32  A  A  A  H  A  H  H  A  A  A  A  A  A 
  D7Rat152  A  A  -  H  A  H  H  A  A  A  A  A  A 
  D7Rat103  H  A  A  -  -  H  H  A  A  A  A  H  H 
  D7Rat17  H  A  A  A  H  H  H  H  A  A  H  H  H 
  D7Rat3  A  A  H  A  H  H  H  A  A  H  H  A  A 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  -  -  -  A  A  H  H  A  A  H  H  H  - 
  D8Rat130  -  H  A  A  A  -  H  H  -  H  H  H  H 
  D8Rat69  A  -  -  A  A  A  A  A  A  A  H  H  H 
Chr9  D9Rat44  A  H  A  A  A  A  A  A  A  H  H  H  H 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  -  -  -  
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  D9Rat110  H  H  A  H  H  A  A  A  A  H  H  H  H 
  D9Rat75  H  H  -  H  H  A  A  A  A  H  H  H  H 
Chr10  D10Rat95  H  H  H  H  A  A  H  H  H  H  A  A  H 
  D10Rat218  H  H  H  A  H  A  H  H  H  H  A  A  H 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  H  H  H  H  H  H  H  H  H  H  A  A  H 
  D10Rat26  -  H  H  -  -  -  -  -  -  H  H  A  H 
  D10Rat12  H  A  H  H  H  H  H  H  H  H  H  H  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  H  A  A  A  A  H  H  H  A  H  H  H  H 
Chr11  D11Rat28  -  -  -  H  H  H  A  A  A  A  A  A  H 
  D11Rat93  -  -  A  A  H  H  H  H  H  H  H  H  H 
  D11Rat56  A  H  A  A  A  A  A  A  H  H  H  H  A 
  D11Rat43  A  H  A  A  A  A  A  A  H  H  H  H  A 
Chr12  D12Rat89  H  -  A  H  H  H  A  A  -  H  H  -  H 
  D12Rat28  H  -  H  H  H  H  H  -  -  H  H  A  A 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  A  H  -  H  H  H  H  H  H  A  A  A  H 
Chr13  D13Rat108  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D13Rat58  -  -  -  -  A  A  A  -  -  A  A  A  H 
  D13Rat131  H  A  A  -  A  A  A  A  A  A  H  H  - 
  D13Rat86  A  A  -  H  H  H  A  -  H  A  H  H  A 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  -  H  A  H  H  -  H  -  H  -  A  A  A 
  D14Rat94  H  H  A  H  H  H  A  H  H  A  A  A  A 
  D14Rat38  H  -  A  H  H  H  A  H  H  A  A  A  A 
Chr15  D15Rat1  H  -  -  -  H  H  H  A  A  A  H  H  H 
  D15Rat17  H  H  A  H  H  A  A  A  A  A  H  H  H 
  D15Rat101  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D15Rat107  H  H  A  H  H  H  A  A  A  H  H  A  H 
Chr16  D16Rat107  H  H  H  H  H  H  H  H  A  A  H  H  H 
  D16Rat53  H  H  H  A  A  H  H  H  H  A  A  -  H 
  D16Rat34  H  -  -  A  A  A  H  H  -  A  A  A  H 
  D16Rat48  H  H  -  H  H  A  A  H  H  -  A  A  H 
Chr17  D17Rat1  -  -  -  H  H  H  H  A  A  H  H  A  A 
  D17Rat17  H  A  A  -  -  -  H  -  -  H  -  -  H 
  D17Rat96  -  -  -  -  -  -  -  A  A  A  A  A  A 
  D17Rat131  H  H  A  -  -  A  A  H  H  H  A  A  H 
Chr18  D18Rat112  A  A  H  A  H  A  H  H  H  A  A  A  A 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  A  A  H  H  H  H  H  H  H  A  H  A  H 
  D18Rat44  -  -  -  H  H  H  A  H  H  A  H  H  H 
Chr19  D19Rat19  A  H  A  -  H  A  A  A  H  A  A  A  H 
  D19Rat11  A  H  H  H  H  A  A  A  H  A  A  H  A 
  D19Rat64  A  H  H  A  A  H  A  A  H  A  H  H  A 
  D19Rat5  A  A  H  A  A  H  A  A  H  A  H  H  A 
Chr20  D20Rat21  -  A  A  -  A  H  A  H  H  H  H  H  A 
  D20Rat10  H  A  A  A  A  H  A  H  H  H  A  H  A 
  D20Rat19  H  A  A  -  A  H  A  H  A  H  A  H  A 
  D20Rat29  -  A  -  A  A  H  A  H  A  H  A  H  A  
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  LPK/SsNArc
+/+  A  H  H  A  H  H  H  A  A  A  A  A  H 
 
Genotype for BC1, from progeny number 81 to 93 
Chro  Marker  81  82  83  84  85  86  87  88  89  90  91  92  93 
Chr1  D1Rat246  H  H  A  H  A  H  H  H  H  A  A  A  - 
  D1Rat256  A  H  A  H  H  H  A  H  H  -  -  H  A 
  D1Rat183  A  H  A  H  H  H  A  H  H  -  -  H  A 
  D1Rat194  H  A  A  A  A  H  H  H  A  H  H  H  H 
Chr2  D2Rat9  H  H  H  A  A  A  A  H  H  A  A  H  H 
  D2Rat136  A  H  H  H  H  H  A  H  -  -  -  H  A 
  D2Rat228  A  H  H  A  H  H  H  H  -  A  A  H  A 
  D2Rat70  A  A  H  A  H  A  H  A  H  H  A  A  H 
Chr3  D3Rat56  A  H  H  -  A  H  H  A  H  A  H  H  H 
  D3Rat193  A  H  H  H  A  H  H  A  H  A  H  H  H 
  D3Rat194  A  H  H  H  A  H  H  A  A  -  A  A  - 
  D3Rat231  A  H  H  H  A  H  H  A  -  A  -  H  H 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  H  H  H  A  A  H  H  H  H  A  A  H  H 
  D3Rat68  H  A  H  A  A  H  H  -  H  A  -  -  - 
  D3Rat132  A  A  H  A  A  H  H  A  -  -  -  -  A 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  H  A  A  H  A  A  H  H  H  A  H  H  A 
  D4Rat140  H  A  A  H  A  A  H  H  H  A  H  H  A 
Chr5  D5Rat125  A  A  A  H  A  H  H  A  -  A  A  -  A 
  D5Rat82  A  H  H  H  A  H  H  H  H  A  A  H  A 
  D5Rat72  A  H  H  H  A  A  H  H  A  A  A  H  A 
  D5Rat111  H  H  A  A  H  A  H  H  H  H  H  H  - 
Chr6  D6Rat46  H  A  H  A  A  A  A  H  A  A  H  A  A 
  D6Rat132  A  A  H  H  A  H  H  A  H  -  -  H  H 
  D6Rat87  H  A  A  A  H  A  H  A  A  A  H  A  H 
  D6Rat101  H  A  A  A  A  A  H  A  H  H  H  A  - 
Chr7  D7Rat36  A  A  A  A  H  H  H  A  -  H  H  A  - 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  A  A  A  A  H  H  A  A  H  H  -  A  H 
  D7Rat32  A  A  A  A  H  H  H  A  H  H  A  A  H 
  D7Rat152  A  A  H  A  H  H  H  A  H  H  A  A  - 
  D7Rat103  A  H  H  H  H  H  H  H  H  H  H  H  H 
  D7Rat17  -  H  H  H  H  H  H  H  H  A  H  H  H 
  D7Rat3  A  A  H  H  H  H  H  A  A  A  A  A  H 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  A  H  A  A  A  A  H  -  H  -  -  -  - 
  D8Rat130  A  A  A  H  H  H  H  -  H  H  H  H  H 
  D8Rat69  A  A  H  A  H  H  -  A  H  H  H  H  - 
Chr9  D9Rat44  H  H  H  A  A  A  H  H  H  H  H  A  A 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  A  A  A  A  H  H  A  A  -  H  H  -  - 
  D9Rat75  A  A  A  A  H  H  A  A  A  H  H  -  -  
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Chr10  D10Rat95  H  H  A  H  H  A  H  H  A  A  H  H  H 
  D10Rat218  H  A  A  H  A  A  H  H  A  A  A  A  H 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  H  H  A  H  H  A  A  -  H  H  A  A  - 
  D10Rat26  A  A  A  H  H  -  A  -  -  H  A  -  - 
  D10Rat12  H  H  H  H  A  H  H  A  A  A  -  -  A 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  H  A  A  A  A  A  H  H  H  H  A  H  A 
Chr11  D11Rat28  -  -  A  H  A  A  A  H  H  -  -  -  - 
  D11Rat93  H  H  H  H  H  H  H  H  H  H  -  -  - 
  D11Rat56  A  H  A  H  H  H  A  A  H  H  H  H  H 
  D11Rat43  A  H  A  H  H  H  A  A  H  H  -  A  H 
Chr12  D12Rat89  A  -  H  H  A  A  H  H  H  H  H  A  A 
  D12Rat28  A  H  H  H  A  A  H  H  -  H  H  H  - 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  H  -  H  -  -  A  H  H  A  A  -  -  - 
Chr13  D13Rat108  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D13Rat58  H  H  A  H  H  H  -  -  -  -  -  -  - 
  D13Rat131  -  H  A  H  H  H  A  A  H  H  -  A  H 
  D13Rat86  A  H  H  H  H  H  A  A  H  H  H  A  H 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  A  A  H  H  H  H  H  H  A  H  -  -  A 
  D14Rat94  A  H  H  A  H  H  H  A  H  H  H  A  A 
  D14Rat38  H  H  A  A  H  H  H  A  A  A  H  A  A 
Chr15  D15Rat1  H  H  A  H  H  H  A  H  H  -  -  -  - 
  D15Rat17  H  A  A  H  H  H  H  H  A  H  H  H  H 
  D15Rat101  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D15Rat107  H  H  H  H  H  A  H  H  A  H  H  H  H 
Chr16  D16Rat107  H  H  H  A  A  A  A  -  H  A  A  -  H 
  D16Rat53  H  A  H  A  H  H  -  A  H  H  H  H  A 
  D16Rat34  H  H  H  A  A  A  H  H  -  -  -  -  - 
  D16Rat48  H  H  H  A  A  A  A  A  H  H  H  H  H 
Chr17  D17Rat1  A  H  H  H  A  A  A  A  A  H  H  A  H 
  D17Rat17  A  -  H  A  -  H  A  A  A  -  -  H  A 
  D17Rat96  H  A  A  H  A  A  H  H  -  -  -  -  - 
  D17Rat131  A  A  H  A  -  H  -  A  A  H  H  H  A 
Chr18  D18Rat112  A  H  A  H  H  A  A  H  A  A  A  H  A 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  H  H  H  H  A  H  H  A  A  -  -  -  A 
  D18Rat44  H  A  H  H  -  -  -  -  A  -  -  -  - 
Chr19  D19Rat19  H  A  H  H  H  H  H  A  -  -  -  A  A 
  D19Rat11  H  A  H  A  H  A  H  -  -  -  -  -  - 
  D19Rat64  A  A  H  A  H  A  A  H  H  A  A  A  A 
  D19Rat5  A  -  A  A  H  A  A  -  H  -  -  A  A 
Chr20  D20Rat21  H  H  H  A  A  A  H  -  H  -  -  H  H 
  D20Rat10  H  A  H  H  H  H  H  -  A  A  -  A  H 
  D20Rat19  A  A  A  H  H  H  -  H  A  H  A  A  A 
  D20Rat29  A  A  A  H  H  H  H  H  -  H  -  A  - 
  LPK/SsNArc
+/+  A  H  A  H  H  H  A  A  H  H  H  A  A 
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Genotype for BC1, from progeny number 94 to 104 
Chro  Marker  94  95  96  97  98  99  100  101  102  103  104 
Chr1  D1Rat246  -  A  A  H  A  A  H  A  -  H  H 
  D1Rat256  A  A  H  A  A  A  H  -  A  H  A 
  D1Rat183  A  -  A  A  H  H  H  H  H  A  - 
  D1Rat194  A  A  A  A  A  H  H  A  A  H  H 
Chr2  D2Rat9  -  H  A  A  H  H  H  H  A  A  H 
  D2Rat136  A  H  H  A  H  H  A  A  A  A  H 
  D2Rat228  A  A  A  A  A  A  A  H  A  A  H 
  D2Rat70  H  H  A  H  -  H  H  H  A  H  H 
Chr3  D3Rat56  H  H  H  A  H  A  A  A  A  H  A 
  D3Rat193  H  H  H  H  A  A  A  A  A  H  A 
  D3Rat194  H  H  H  -  H  A  A  -  A  H  A 
  D3Rat231  H  H  H  A  H  A  A  A  A  H  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  H  H  H  H  H  H  -  -  -  H  - 
  D3Rat68  H  H  H  H  H  -  A  H  H  H  A 
  D3Rat132  H  H  H  H  H  H  A  H  H  H  A 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  -  H  A  H  H  H  A  H  H  A  A 
  D4Rat140  H  H  H  H  H  H  H  A  A  A  A 
Chr5  D5Rat125  A  A  H  H  H  A  H  H  H  H  H 
  D5Rat82  A  H  H  H  A  A  H  H  H  -  A 
  D5Rat72  A  H  H  A  A  A  H  H  H  H  H 
  D5Rat111  A  A  A  A  A  A  A  H  H  H  H 
Chr6  D6Rat46  A  H  A  H  A  A  H  H  H  H  A 
  D6Rat132  A  H  A  A  H  H  A  H  H  H  A 
  D6Rat87  A  A  A  H  H  A  H  H  A  A  A 
  D6Rat101  A  A  A  H  H  H  A  H  H  A  - 
Chr7  D7Rat36  H  A  A  A  A  H  H  H  A  H  H 
  D7Rat63  -  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  H  A  A  A  A  H  H  H  A  H  H 
  D7Rat32  H  A  A  A  A  H  H  H  A  H  H 
  D7Rat152  H  A  A  A  A  H  H  H  A  H  H 
  D7Rat103  A  A  H  A  H  A  -  -  A  H  H 
  D7Rat17  A  A  H  A  H  A  H  A  A  H  H 
  D7Rat3  H  A  H  A  H  H  A  -  -  -  - 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  A  A  A  A  H  A  H  H  A  A  H 
  D8Rat130  H  A  A  A  H  H  A  H  A  H  H 
  D8Rat69  H  A  A  A  H  H  A  H  H  H  H 
Chr9  D9Rat44  H  A  H  H  H  A  A  H  A  H  H 
  D9Rat70  -  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  H  A  H  A  H  H  H  A  H  A  H 
  D9Rat75  H  A  H  H  H  H  A  H  H  A  H 
Chr10  D10Rat95  H  H  H  H  A  H  H  H  H  H  H 
  D10Rat218  H  H  A  H  A  H  A  H  A  H  H 
  D10Rat180  -  -  -  -  -  -  -  -  -  -  -  
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  D10Rat43  H  H  A  -  A  H  A  H  A  H  H 
  D10Rat26  H  H  H  A  -  H  A  H  H  H  H 
  D10Rat12  H  H  H  A  H  H  H  H  H  H  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  A  H  H  A  A  H  H  A  H  H  H 
Chr11  D11Rat28  A  H  A  A  H  A  H  A  H  H  H 
  D11Rat93  A  A  A  H  A  A  H  H  A  -  - 
  D11Rat56  A  A  H  H  A  A  H  H  A  H  A 
  D11Rat43  A  A  H  H  A  A  H  H  A  A  A 
Chr12  D12Rat89  A  H  A  H  H  A  H  H  A  A  - 
  D12Rat28  H  H  A  H  H  A  H  -  A  -  H 
  D12Rat36  -  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  H  H  A  A  H  H  A  H  A  H  H 
Chr13  D13Rat108  -  H  A  A  A  H  A  -  H  A  H 
  D13Rat58  A  A  H  A  H  A  A  -  -  -  - 
  D13Rat131  A  A  H  H  H  H  A  A  H  H  H 
  D13Rat86  A  A  A  H  H  H  A  H  H  A  H 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  A  H  A  A  H  A  A  A  A  A  H 
  D14Rat94  A  H  A  A  H  A  A  -  A  A  A 
  D14Rat38  H  H  A  A  A  A  A  -  A  -  A 
Chr15  D15Rat1  H  A  A  A  H  A  H  A  H  H  H 
  D15Rat17  H  A  A  A  -  H  A  H  H  A  A 
  D15Rat101  -  -  -  -  A  -  A  H  H  H  A 
  D15Rat107  H  H  A  H  A  H  A  H  H  A  A 
Chr16  D16Rat107  H  H  A  A  A  H  H  A  A  A  A 
  D16Rat53  A  -  A  A  A  H  A  A  H  -  - 
  D16Rat34  H  H  A  A  A  H  A  A  H  -  - 
  D16Rat48  H  -  H  H  A  H  A  H  H  H  H 
Chr17  D17Rat1  A  H  H  A  A  A  A  H  A  H  A 
  D17Rat17  -  -  H  A  A  A  A  A  H  H  H 
  D17Rat96  H  H  A  A  H  A  A  H  A  A  A 
  D17Rat131  A  A  H  H  A  H  H  A  H  H  H 
Chr18  D18Rat112  H  H  H  H  H  A  A  A  H  H  H 
  D18Rat96  -  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  H  A  A  A  A  A  H  A  A  A  A 
  D18Rat44  H  A  A  A  A  A  -  A  A  A  A 
Chr19  D19Rat19  H  A  A  H  A  H  A  H  A  H  A 
  D19Rat11  A  A  A  H  A  H  A  H  A  H  A 
  D19Rat64  A  A  H  A  A  A  H  H  A  H  - 
  D19Rat5  A  -  H  A  H  A  H  A  A  H  H 
Chr20  D20Rat21  H  H  H  A  A  -  A  H  A  -  - 
  D20Rat10  H  A  H  A  H  H  A  A  A  A  A 
  D20Rat19  A  A  H  A  H  A  A  A  H  A  A 
  D20Rat29  A  A  H  A  H  A  A  A  H  -  A 
  LPK/SsNArc
+/+  H  H  H  A  A  A  A  H  H  H  H 
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Genotype for BC1, from progeny number 105 to 114 
 
Chro  Marker  105  106  107  108  109  110  111  112  113  114 
Chr1  D1Rat246  H  A  -  H  A  A  A  -  A  A 
  D1Rat256  H  A  A  H  H  H  H  A  A  H 
  D1Rat183  A  A  H  A  H  H  H  A  H  H 
  D1Rat194  H  -  A  H  A  H  H  H  H  H 
Chr2  D2Rat9  H  A  H  A  H  H  H  H  H  A 
  D2Rat136  -  -  A  A  A  -  H  H  H  A 
  D2Rat228  A  H  A  A  A  H  H  A  -  A 
  D2Rat70  A  H  H  A  H  A  H  H  A  H 
Chr3  D3Rat56  A  H  H  A  A  A  A  A  H  A 
  D3Rat193  A  H  A  H  A  A  A  A  H  A 
  D3Rat194  A  H  H  H  A  A  A  A  H  A 
  D3Rat231  A  H  H  A  A  A  A  A  H  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  -  H  A  A  H  A  A  H  H  A 
  D3Rat68  A  A  H  H  H  H  H  H  A  H 
  D3Rat132  A  A  H  H  H  H  -  A  A  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  H  H  A  A  H  A  A  H  H  A 
  D4Rat140  H  A  H  A  H  H  A  A  H  H 
Chr5  D5Rat125  H  A  H  H  H  A  -  -  A  H 
  D5Rat82  H  A  H  H  H  A  A  A  A  A 
  D5Rat72  H  H  A  A  A  A  A  H  A  A 
  D5Rat111  H  A  A  A  A  A  A  H  A  H 
Chr6  D6Rat46  A  A  H  A  A  H  H  A  A  H 
  D6Rat132  A  H  H  A  A  A  H  H  A  A 
  D6Rat87  H  H  A  H  H  H  A  H  A  A 
  D6Rat101  A  H  A  A  H  A  A  H  A  A 
Chr7  D7Rat36  H  H  H  A  A  A  A  H  H  A 
  D7Rat63  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  H  H  A  A  H  A  A  H  H  A 
  D7Rat32  H  H  A  A  H  A  A  H  H  A 
  D7Rat152  H  H  A  A  H  A  A  H  H  A 
  D7Rat103  H  H  A  A  H  H  A  H  H  H 
  D7Rat17  A  H  A  A  H  H  H  H  H  H 
  D7Rat3  -  -  H  A  A  H  H  H  A  H 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  H  A  H  A  H  A  H  A  A  A 
  D8Rat130  H  A  H  A  H  A  A  A  A  A 
  D8Rat69  H  A  H  A  H  H  A  A  H  H 
Chr9  D9Rat44  A  H  A  H  A  H  A  H  A  A 
  D9Rat70  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  H  A  H  A  H  H  A  A  H  A 
  D9Rat75  H  A  H  A  A  H  A  A  H  A 
Chr10  D10Rat95  A  A  H  H  A  A  H  A  A  A  
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  D10Rat218  A  A  H  H  A  A  A  H  H  A 
  D10Rat180  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  A  A  H  H  A  A  A  H  H  H 
  D10Rat26  A  H  A  H  A  A  A  H  A  H 
  D10Rat12  A  H  H  H  H  A  H  H  A  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  H  H  H  H  H  A  H  A  A  H 
Chr11  D11Rat28  A  H  H  H  A  H  H  A  H  A 
  D11Rat93  A  H  H  H  H  A  A  H  H  A 
  D11Rat56  H  A  H  A  H  H  -  A  H  H 
  D11Rat43  H  A  H  A  H  H  A  A  H  A 
Chr12  D12Rat89  H  H  H  H  H  A  A  A  H  A 
  D12Rat28  H  H  H  H  H  A  A  A  A  A 
  D12Rat36  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  A  H  A  H  H  -  A  H  A  A 
Chr13  D13Rat108  H  A  H  A  H  A  A  H  A  H 
  D13Rat58  H  H  H  H  A  H  H  H  A  A 
  D13Rat131  H  H  H  H  A  H  A  H  A  A 
  D13Rat86  H  H  H  H  H  H  A  H  A  A 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  A  A  H  H  H  H  H  A  H  A 
  D14Rat94  H  H  H  H  H  H  H  A  H  A 
  D14Rat38  H  H  H  H  H  A  H  A  H  A 
Chr15  D15Rat1  H  H  H  H  H  H  H  H  H  A 
  D15Rat17  H  A  A  H  H  A  A  A  A  H 
  D15Rat101  A  A  A  H  H  A  A  H  A  A 
  D15Rat107  A  A  A  H  H  A  A  A  A  H 
Chr16  D16Rat107  H  A  A  A  H  A  H  A  H  H 
  D16Rat53  A  H  A  H  H  A  H  A  A  H 
  D16Rat34  A  H  H  H  H  A  H  A  A  A 
  D16Rat48  H  H  H  -  H  A  H  A  A  A 
Chr17  D17Rat1  A  H  H  A  A  H  A  A  A  H 
  D17Rat17  -  H  H  H  A  H  A  -  A  H 
  D17Rat96  H  H  A  A  A  A  A  A  H  A 
  D17Rat131  H  A  H  H  A  H  H  H  A  H 
Chr18  D18Rat112  H  H  H  A  A  A  A  H  H  H 
  D18Rat96  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  A  A  -  H  A  A  A  H  H  H 
  D18Rat44  A  A  H  H  A  A  A  A  H  H 
Chr19  D19Rat19  H  A  H  H  H  A  A  H  H  A 
  D19Rat11  A  A  H  H  A  A  A  H  A  A 
  D19Rat64  A  H  H  H  A  A  H  H  A  H 
  D19Rat5  A  H  H  H  A  A  H  H  A  H 
Chr20  D20Rat21  A  A  A  A  H  A  A  H  A  H 
  D20Rat10  A  A  H  H  H  A  A  H  A  H 
  D20Rat19  A  H  H  H  H  A  A  H  A  A 
  D20Rat29  A  H  H  H  H  A  A  H  A  A 
  LPK/SsNArc
+/+  A  H  A  H  A  A  A  H  A  H 
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Genotype for BC1, from progeny number 115 to 124 
 
Chro  Marker  115  116  117  118  119  120  121  122  123  124 
Chr1  D1Rat246  A  A  -  A  H  -  A  A  H  A 
  D1Rat256  A  H  A  A  A  A  H  A  A  A 
  D1Rat183  H  H  H  H  H  A  A  A  H  A 
  D1Rat194  A  H  A  A  H  H  H  H  H  A 
Chr2  D2Rat9  H  A  H  A  A  H  H  A  H  A 
  D2Rat136  A  A  A  -  -  A  H  A  H  H 
  D2Rat228  A  H  H  H  H  A  H  A  H  H 
  D2Rat70  H  -  H  A  -  A  H  H  A  H 
Chr3  D3Rat56  A  A  A  A  H  A  H  H  A  A 
  D3Rat193  A  A  A  A  H  -  H  H  A  A 
  D3Rat194  A  A  A  -  H  -  H  H  -  A 
  D3Rat231  A  A  A  A  H  A  H  H  A  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  A  H  A  A  H  H  H  H  H  A 
  D3Rat68  A  H  -  H  -  H  A  -  H  A 
  D3Rat132  H  H  A  H  A  H  A  A  H  A 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  A  A  A  H  H  A  H  A  H  A 
  D4Rat140  H  H  A  H  H  A  H  H  A  H 
Chr5  D5Rat125  A  A  -  H  -  -  H  A  A  H 
  D5Rat82  A  A  A  A  A  -  -  A  A  H 
  D5Rat72  H  A  A  A  A  H  A  H  H  H 
  D5Rat111  A  H  A  H  H  H  H  H  H  H 
Chr6  D6Rat46  A  A  H  H  H  H  H  A  H  A 
  D6Rat132  H  H  H  H  A  H  A  A  H  A 
  D6Rat87  H  A  H  H  A  A  H  H  H  A 
  D6Rat101  H  H  H  H  A  A  H  H  H  H 
Chr7  D7Rat36  H  H  A  H  -  A  A  A  -  H 
  D7Rat63  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  H  H  A  H  H  A  A  A  H  H 
  D7Rat32  H  H  A  H  H  A  A  A  H  H 
  D7Rat152  H  H  A  H  H  A  A  A  H  H 
  D7Rat103  A  A  A  A  H  A  A  H  H  - 
  D7Rat17  A  H  A  A  A  A  A  H  H  H 
  D7Rat3  A  H  -  -  -  -  A  A  H  H 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  H  A  A  A  A  H  H  H  A  A 
  D8Rat130  A  A  H  A  A  A  H  H  A  - 
  D8Rat69  A  H  A  A  H  A  A  H  A  H 
Chr9  D9Rat44  H  A  A  A  H  A  A  H  H  A 
  D9Rat70  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  A  -  H  A  A  H  H  H  A  - 
  D9Rat75  A  A  H  A  A  H  H  H  A  A 
Chr10  D10Rat95  H  H  H  H  A  H  A  H  H  A  
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  D10Rat218  A  H  A  A  A  H  H  H  H  H 
  D10Rat180  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  H  H  A  A  H  H  A  H  H  H 
  D10Rat26  H  A  H  A  A  A  A  -  -  A 
  D10Rat12  H  A  H  A  A  A  A  H  A  A 
  D10Rat7  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  H  H  H  A  A  H  A  H  A  A 
Chr11  D11Rat28  A  -  -  -  -  -  H  A  A  H 
  D11Rat93  H  A  H  -  A  H  H  A  A  H 
  D11Rat56  H  H  A  H  H  A  H  H  A  H 
  D11Rat43  H  H  A  H  H  A  H  H  A  A 
Chr12  D12Rat89  H  H  A  A  H  A  A  H  H  - 
  D12Rat28  H  H  A  A  A  A  A  H  -  H 
  D12Rat36  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  A  H  H  H  A  H  A  A  A  H 
Chr13  D13Rat108  H  A  H  A  -  A  H  A  A  - 
  D13Rat58  H  A  A  A  A  H  H  A  H  A 
  D13Rat131  H  A  A  A  -  -  A  A  A  A 
  D13Rat86  H  A  A  A  A  H  A  H  A  A 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  A  A  H  A  H  A  H  H  A  H 
  D14Rat94  A  A  H  A  H  A  H  H  A  A 
  D14Rat38  H  A  -  A  -  A  H  H  A  A 
Chr15  D15Rat1  H  H  H  -  -  -  A  A  A  A 
  D15Rat17  H  H  H  A  H  H  A  H  H  A 
  D15Rat101  H  H  A  A  A  H  -  -  -  - 
  D15Rat107  H  H  A  A  A  H  H  A  H  H 
Chr16  D16Rat107  H  A  H  H  A  H  H  H  H  - 
  D16Rat53  A  A  H  H  A  A  -  A  A  A 
  D16Rat34  A  H  H  H  A  -  H  A  A  A 
  D16Rat48  A  H  H  A  A  A  A  A  A  A 
Chr17  D17Rat1  H  H  H  H  A  H  A  -  H  H 
  D17Rat17  H  A  A  -  -  H  A  H  H  - 
  D17Rat96  A  H  H  -  -  -  H  H  A  A 
  D17Rat131  H  H  H  H  H  H  H  A  H  A 
Chr18  D18Rat112  A  A  A  A  A  A  -  A  H  H 
  D18Rat96  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  H  A  H  A  A  A  H  A  A  A 
  D18Rat44  H  -  -  A  A  -  A  H  H  A 
Chr19  D19Rat19  A  A  A  H  H  H  A  H  H  H 
  D19Rat11  -  H  A  H  H  H  H  H  H  A 
  D19Rat64  A  H  H  H  H  H  H  A  H  A 
  D19Rat5  A  H  H  A  H  H  H  A  H  A 
Chr20  D20Rat21  H  A  H  -  H  A  A  A  H  A 
  D20Rat10  H  A  A  A  A  H  A  H  H  A 
  D20Rat19  A  A  A  A  A  H  A  H  H  A 
  D20Rat29  A  A  A  A  -  H  A  H  H  A 
  LPK/SsNArc
+/+  H  H  A  H  H  A  A  A  A  A 
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Genotype for BC1, from progeny number 125 to 134 
 
Chro  Marker  125  126  127  128  129  130  131  132  133  134 
Chr1  D1Rat246  A  H  A  H  H  H  H  A  -  H 
  D1Rat256  H  A  A  A  A  A  H  H  H  H 
  D1Rat183  H  A  A  A  A  A  H  H  A  - 
  D1Rat194  H  A  H  A  A  H  H  H  A  H 
Chr2  D2Rat9  A  H  A  H  A  A  H  A  -  A 
  D2Rat136  H  H  H  H  A  A  A  H  H  H 
  D2Rat228  H  A  A  A  A  H  A  A  A  H 
  D2Rat70  A  A  A  H  A  A  A  A  -  H 
Chr3  D3Rat56  A  A  A  A  A  A  H  H  A  A 
  D3Rat193  A  A  A  A  A  A  H  H  A  A 
  D3Rat194  A  A  A  A  A  H  H  A  -  - 
  D3Rat231  -  A  A  A  A  A  H  H  A  A 
  D3Rat192  -  -  -  -  -  -  -  -  -  - 
  D3Rat110  A  -  H  A  A  A  A  A  H  - 
  D3Rat68  H  H  H  H  H  A  H  A  H  H 
  D3Rat132  H  H  H  H  H  A  H  A  H  H 
Chr4  D4Rat4  -  -  -  -  -  -  -  -  -  - 
  D4Rat168  -  -  -  -  -  -  -  -  -  - 
  D4Rat195  H  A  A  H  H  A  H  A  H  A 
  D4Rat140  H  A  A  H  H  A  A  H  H  A 
Chr5  D5Rat125  A  A  A  H  -  A  A  A  -  A 
  D5Rat82  A  A  A  H  H  A  A  A  H  A 
  D5Rat72  H  A  A  H  H  A  A  A  H  A 
  D5Rat111  A  H  H  H  -  H  H  A  H  A 
Chr6  D6Rat46  H  A  H  A  H  A  H  H  A  H 
  D6Rat132  A  H  A  H  A  H  A  A  H  A 
  D6Rat87  A  A  A  H  A  A  A  A  A  H 
  D6Rat101  A  H  A  H  A  A  H  A  A  H 
Chr7  D7Rat36  H  H  H  H  H  H  H  H  A  A 
  D7Rat63  -  -  -  -  -  -  -  -  -  - 
  D7Rat35  A  H  H  H  H  A  H  H  A  A 
  D7Rat32  -  H  H  H  H  A  H  H  A  A 
  D7Rat152  A  H  H  H  H  A  H  H  H  A 
  D7Rat103  H  H  H  -  A  A  H  H  H  H 
  D7Rat17  A  H  H  H  H  -  -  H  H  H 
  D7Rat3  A  A  H  H  H  H  H  H  H  A 
Chr8  D8Rat58  -  -  -  -  -  -  -  -  -  - 
  D8Rat98  H  H  H  H  H  A  A  -  -  - 
  D8Rat130  A  H  H  A  A  A  A  A  -  - 
  D8Rat69  A  H  H  H  H  H  H  A  A  A 
Chr9  D9Rat44  A  A  A  A  A  H  H  H  -  A 
  D9Rat70  -  -  -  -  -  -  -  -  -  - 
  D9Rat110  A  -  -  -  H  A  A  A  H  H 
  D9Rat75  A  -  -  -  H  A  A  A  H  H 
Chr10  D10Rat95  A  H  H  H  H  H  H  A  A  H  
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  D10Rat218  -  A  A  H  H  H  H  A  A  H 
  D10Rat180  -  -  -  -  -  -  -  -  -  - 
  D10Rat43  A  A  A  H  H  H  H  H  H  H 
  D10Rat26  A  A  H  A  A  H  H  H  H  - 
  D10Rat12  A  H  H  A  A  H  H  H  H  H 
  D10Rat7  -  -  -  -  -  -  -  -  -  - 
  D10Rat4  H  H  H  A  A  H  H  H  H  H 
Chr11  D11Rat28  H  H  -  -  H  H  -  -  -  - 
  D11Rat93  H  H  A  A  H  H  H  H  -  - 
  D11Rat56  H  H  H  A  A  A  A  H  A  A 
  D11Rat43  H  H  H  A  A  A  A  H  A  A 
Chr12  D12Rat89  -  H  H  H  H  H  H  A  H  H 
  D12Rat28  H  H  H  H  H  -  -  H  -  H 
  D12Rat36  -  -  -  -  -  -  -  -  -  - 
  D12Rat53  A  -  -  -  H  A  A  H  A  A 
Chr13  D13Rat108  -  -  H  H  -  A  A  -  A  - 
  D13Rat58  -  A  A  A  -  H  H  -  -  - 
  D13Rat131  A  A  A  -  A  H  H  H  H  H 
  D13Rat86  -  -  H  H  H  H  H  H  H  A 
Chr14  D14Rat2  -  -  -  -  -  -  -  -  -  - 
  D14Rat90  H  H  H  -  A  A  A  A  A  - 
  D14Rat94  H  H  H  A  A  H  A  A  A  H 
  D14Rat38  A  H  H  A  A  H  A  A  A  H 
Chr15  D15Rat1  H  H  H  H  H  H  A  A  H  H 
  D15Rat17  H  H  H  A  A  H  H  A  H  H 
  D15Rat101  -  -  -  -  -  -  -  -  -  - 
  D15Rat107  H  H  A  A  A  A  A  A  H  H 
Chr16  D16Rat107  -  A  A  A  A  A  A  A  H  H 
  D16Rat53  A  -  H  H  H  H  A  A  H  H 
  D16Rat34  A  A  A  A  A  A  A  -  H  H 
  D16Rat48  A  A  A  A  A  A  A  A  H  H 
Chr17  D17Rat1  A  A  A  A  A  -  H  H  -  - 
  D17Rat17  H  A  A  A  A  H  H  H  H  H 
  D17Rat96  A  H  A  A  -  A  A  A  -  - 
  D17Rat131  A  A  A  A  A  H  H  H  H  H 
Chr18  D18Rat112  H  H  A  H  A  H  H  H  A  A 
  D18Rat96  -  -  -  -  -  -  -  -  -  - 
  D18Rat13  -  A  H  A  H  A  A  A  H  A 
  D18Rat44  A  A  H  A  H  A  A  A  H  - 
Chr19  D19Rat19  H  A  A  A  H  H  H  H  A  A 
  D19Rat11  H  A  H  A  -  H  H  -  H  A 
  D19Rat64  H  A  H  H  H  A  H  A  H  A 
  D19Rat5  H  -  H  H  A  A  H  A  H  A 
Chr20  D20Rat21  A  -  A  A  H  H  H  H  A  - 
  D20Rat10  A  H  H  H  A  H  A  H  A  H 
  D20Rat19  A  H  H  H  A  H  A  H  A  H 
  D20Rat29  A  H  H  H  A  H  A  H  A  - 
  LPK/SsNArc
+/+  H  H  A  A  H  H  H  H  H  A 
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Genotype for BC1, from progeny number 135 to 139 
 
Chro  Marker  135  136  137  138  139 
Chr1  D1Rat246  A  H  H  H  H 
  D1Rat256  H  H  A  H  H 
  D1Rat183  H  H  A  H  H 
  D1Rat194  A  H  H  H  A 
Chr2  D2Rat9  A  A  A  H  H 
  D2Rat136  H  H  A  H  - 
  D2Rat228  H  H  H  H  - 
  D2Rat70  H  A  H  A  H 
Chr3  D3Rat56  A  H  H  A  H 
  D3Rat193  A  H  H  A  H 
  D3Rat194  A  H  H  A  A 
  D3Rat231  A  H  H  A  - 
  D3Rat192  -  -  -  -  - 
  D3Rat110  A  H  H  H  H 
  D3Rat68  A  H  H  -  H 
  D3Rat132  A  H  H  A  - 
Chr4  D4Rat4  -  -  -  -  - 
  D4Rat168  -  -  -  -  - 
  D4Rat195  A  A  H  H  H 
  D4Rat140  A  A  H  H  H 
Chr5  D5Rat125  A  H  H  A  - 
  D5Rat82  A  H  H  H  H 
  D5Rat72  A  A  H  H  A 
  D5Rat111  H  A  H  H  H 
Chr6  D6Rat46  A  A  A  H  A 
  D6Rat132  A  H  H  A  H 
  D6Rat87  H  A  H  A  A 
  D6Rat101  A  A  H  A  H 
Chr7  D7Rat36  H  H  H  A  - 
  D7Rat63  -  -  -  -  - 
  D7Rat35  H  H  A  A  H 
  D7Rat32  H  H  H  A  H 
  D7Rat152  H  H  H  A  H 
  D7Rat103  H  H  H  H  H 
  D7Rat17  H  H  H  H  H 
  D7Rat3  H  H  H  A  A 
Chr8  D8Rat58  -  -  -  -  - 
  D8Rat98  A  A  H  -  H 
  D8Rat130  H  H  H  -  H 
  D8Rat69  H  H  -  A  H 
Chr9  D9Rat44  A  A  H  H  H 
  D9Rat70  -  -  -  -  - 
  D9Rat110  H  H  A  A  - 
  D9Rat75  H  H  A  A  A 
Chr10  D10Rat95  H  A  H  H  A  
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  D10Rat218  A  A  H  H  A 
  D10Rat180  -  -  -  -  - 
  D10Rat43  H  A  A  -  H 
  D10Rat26  H  -  A  -  - 
  D10Rat12  A  H  H  A  A 
  D10Rat7  -  -  -  -  - 
  D10Rat4  A  A  H  H  H 
Chr11  D11Rat28  A  A  A  H  H 
  D11Rat93  H  H  H  H  H 
  D11Rat56  H  H  A  A  H 
  D11Rat43  H  H  A  A  H 
Chr12  D12Rat89  A  A  H  H  H 
  D12Rat28  A  A  H  H  - 
  D12Rat36  -  -  -  -  - 
  D12Rat53  -  A  H  H  A 
Chr13  D13Rat108  -  -  -  -  - 
  D13Rat58  H  H  -  -  - 
  D13Rat131  H  H  A  A  H 
  D13Rat86  H  H  A  A  H 
Chr14  D14Rat2  -  -  -  -  - 
  D14Rat90  H  H  H  H  A 
  D14Rat94  H  H  H  A  H 
  D14Rat38  H  H  H  A  A 
Chr15  D15Rat1  H  H  A  H  H 
  D15Rat17  H  H  H  H  A 
  D15Rat101  -  -  -  -  - 
  D15Rat107  H  A  H  H  A 
Chr16  D16Rat107  A  A  A  -  H 
  D16Rat53  H  H  -  A  H 
  D16Rat34  A  A  H  H  - 
  D16Rat48  A  A  A  A  H 
Chr17  D17Rat1  A  A  A  A  A 
  D17Rat17  -  H  A  A  A 
  D17Rat96  A  A  H  H  - 
  D17Rat131  -  H  -  A  A 
Chr18  D18Rat112  H  A  A  H  A 
  D18Rat96  -  -  -  -  - 
  D18Rat13  A  H  H  A  A 
  D18Rat44  -  -  -  -  A 
Chr19  D19Rat19  H  H  H  A  - 
  D19Rat11  H  A  H  -  - 
  D19Rat64  H  A  A  H  H 
  D19Rat5  H  A  A  -  H 
Chr20  D20Rat21  A  A  H  -  H 
  D20Rat10  H  H  H  -  A 
  D20Rat19  H  H  -  H  A 
  D20Rat29  H  H  H  H  - 
  LPK/SsNArc
+/+  H  H  A  A  H 
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Appendix B 
Complete sequence alignment of the proteins encoded by the candidate genes located 
in the QTL region on rat chromosome 10q21 and the proteins encoded by Pkhd-1 
gene, mutation of which is the cause of ARPKD in murine models of the disease. 
 
                         10        20        30        40        50        60 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ------------------------------------------------------------ 
FibrocystinBRn   MDRESEELTKEPTNSKHRVLAALSPSWPRVQPIIIKCQPLSVHLRPMLKTSHTEWRQQRR 
FibrocystinAMm   ------------------------------------------------------------ 
FibrocystinEMm   ------------------------------------------------------------ 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                         70        80        90       100       110       120 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ------------------------------------------MPAWRISLLSVELLLLAN 
FibrocystinBRn   ICLTVAESQAKPMVPPALNDSCTSRRDIKGFDHLPHYGDKWTFLARFIAWFSELLCTFLN 
FibrocystinAMm   -----------------------------------------MMLAWLVSLLSMEVLLLAK 
FibrocystinEMm   -----------------------------------------MMLAWLVSLLSMEVLLLAK 
FibrocystinBMm   -----------------------------------------MMLAWLVSLLSMEVLLLAK 
FibrocystinDMm   ------------------------------------------MLAWLVSLLSMEVLLLAK 
FibrocystinCMm   ------------------------------------------MLAWLVSLLSMEVLLLAK 
KIM1Rn           ------------------------------------------MMPPQVLISGLLLLLPAA 
CcnjlRn          -----------------------------------------MDEPWWEGRVASDVHCTLR 
Mat2bRn          -------------------------------------MVLRSLLPLRYCKEAVVLCSLLP 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ----------------------MNKAPQPTGPPPARSPGLPQPAFPPGQTAPVVFSTPQA 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ---------------------------------------MTIFKKVTTMISWVLLACALP 
                                                                              
                        130       140       150       160       170       180 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ----------------AYSSFRIEPTEGSLAGGTWITLVFDGLETSILYPNNGSQLAIDL 
FibrocystinBRn   REFSTSKCSLHMSALDAYSSFRIEPTEGSLAGGTWITLVFDGLETSILYPNNGSQLAIDL 
FibrocystinAMm   ----------------PYSSFQFEPAEGSLAGGTWITVVFDGLDRSILYPNNGSQLQIDL 
FibrocystinEMm   ----------------PYSSFQFEPAEGSLAGGTWITVVFDGLDRSILYPNNGSQLQIDL 
FibrocystinBMm   ----------------PYSSFQFEPAEGSLAGGTWITVVFDGLDRSILYPNNGSQLQIDL 
FibrocystinDMm   ----------------PYSSFQFEPAEGSLAGGTWITVVFDGLDRSILYPNNGSQLQIDL 
FibrocystinCMm   ----------------PYSSFQFEPAEGSLAGGTWITVVFDGLDRSILYPNNGSQLQIDL 
KIM1Rn           ----------------VDSFPEVHGVVGQPVTLPCTYPVSNELESVCWGRGECASDTCGQ 
CcnjlRn          EK--------------ELKLPTFRAHSPLLKSRRFFVDILTLLSRHCHLCPSARHLAIYL 
Mat2bRn          ----------------VRYLFDFQPHVIVHCAAERRPDVVESQPDAASQLNVGASGNLAK 
Pttg1Rn          -----------------MATLIFVDKDNEEPGSRLASKDGLKLGSGVKALDGKLQVSTPR 
Eif4g1Rn         TQMNTPSQPRQGGFRSLQHFYPSRAQPPSSAASRVQSAAPARPGPAPHVYPAGSQVMMIP 
Gabrg2Rn         ------------------TTEVVKTTSGDYVVMSVYFDLSRRMGYFTIQTYIPCTLIVVL 
C1qtnt2Rn        -------------CAADPMLGAFARRDFQKGGPQLVCSLPGPQGPPGPPGAPGSSGVVGR 
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                        190       200       210       220       230       240 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VNVATPALK----IPCDISPLFVDLPVVT----CQTRSLPSEAPEGLYSLEIRSG----- 
FibrocystinBRn   VNVATPALK----IPCDISPLFVDLPVVT----CQTRSLPSEAPEGLYSLEIRSG----- 
FibrocystinAMm   VSVAIPTLR----IPCDVSPAFVDLPVVT----CQTRSLPSEADAGPYSLEMRSG----- 
FibrocystinEMm   VSVAIPTLR----IPCDVSPAFVDLPVVT----CQTRSLPSEADAGPYSLEMRSG----- 
FibrocystinBMm   VSVAIPTLR----IPCDVSPAFVDLPVVT----CQTRSLPSEADAGPYSLEMRSG----- 
FibrocystinDMm   VSVAIPTLR----IPCDVSPAFVDLPVVT----CQTRSLPSEADAGPYSLEMRSG----- 
FibrocystinCMm   VSVAIPTLR----IPCDVSPAFVDLPVVT----CQTRSLPSEADAGPYSLEMRSG----- 
KIM1Rn           TLVWTDGNQ----IYQTSSRYQINAQLLQGN-ASLTIEDTYESDSGLYCCRVEMKG-WDG 
CcnjlRn          LDHFMDQYN----ITTSKQLYTVAVSCLLLASKFEDREDRVPKLEQINNTRILSSQNFSL 
Mat2bRn          EAAAIGAFL----IYISSDYVFDGTNPPY-------TEEDIPSPLNLYGKTKLDG----- 
Pttg1Rn          VGKVFGAPG----LPKASRKALGTVNRVT--------EKPVKSSKPLQSKQPTLS----- 
Eif4g1Rn         SQISYSASQGAYYIPGQGRSTYVVPTQQYPVQPGAPGFYPGASPTEFGTYAGAYYP-AQS 
Gabrg2Rn         SWVSFWINK----DAVPARTSLGITTVLTMTTLSTIARKSLPKVSYVTAMDLFVS----- 
C1qtnt2Rn        MGFPGKDGQ----DGQDGDRGDSGEEGPPGRTGNRGKQGPKGKAGAIGRAGPRGPK---- 
                              ################      ####################      
                        250       260       270       280       290       300 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   -DQLLGSPCARLLDNCTFKFSKEQTPVLYQVNPSSGVPGEVVHVYGWVITDRMEIFDPDV 
FibrocystinBRn   -DQLLGSPCARLLDNCTFKFSKEQTPVLYQVNPSSGVPGEVVHVYGWVITDRMEIFDPDV 
FibrocystinAMm   -EQVLGTPCPGSLDSCTFKFSKDQTPVLYQVYPASGVPGEVVSVYGRVITTWLETFDPDV 
FibrocystinEMm   -EQVLGTPCPGSLDSCTFKFSKDQTPVLYQVYPASGVPGEVVSVYGRVITTWLETFDPDV 
FibrocystinBMm   -EQVLGTPCPGSLDSCTFKFSKDQTPVLYQVYPASGVPGEVVSVYGRVITTWLETFDPDV 
FibrocystinDMm   -EQVLGTPCPGSLDSCTFKFSKDQTPVLYQVYPASGVPGEVVSVYGRVITTWLETFDPDV 
FibrocystinCMm   -EQVLGTPCPGSLDSCTFKFSKDQTPVLYQVYPASGVPGEVVSVYGRVITTWLETFDPDV 
KIM1Rn           VQTLTTSLQVQPENSECLVNSLPNRALISSKCRGFSVSSVEYQANAEVIKSILMTAIVSL 
CcnjlRn          TKKELLTTELLLLEAFSWDLCLPTPAHFLDYYLLASISQKDHHCHAWPTTCLRKTKECLK 
Mat2bRn          -------------EKAVLENNLGAAVLRIPVLYGEVEKLEESAVTVMFDKVQFSNKSANM 
Pttg1Rn          -----------------VKKITEKSTKTQGSAPAPDDAYPEIEKFFPFDPLDFESFDLPE 
Eif4g1Rn         VQQFPASVAPAPVLMNQPPQIAPKRERKTIRIRDPNQGGKDITEEIMSGARTASTPTPPQ 
Gabrg2Rn         ----------VCFIFVFSALVEYGTLHYFVSNRKPSKDKDKKKKNPLLRMFSFKAPTIDI 
C1qtnt2Rn        ------GVSGTPGKHGTPGKKGPKGKKGEPGLPGPCSCGSSRAKSAFSVAVTKSYPRERL 
                   ########################################################## 
                        310       320       330       340       350       360 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   DYMESPLILEAGGDKWLTPCSLINRKTGI-----CFPIQEEHGLGTVQCRVEGSYIGSQN 
FibrocystinBRn   DYMESPLILEAGGDKWLTPCSLINRKTGI-----CFPIQEEHGLGTVQCRVEGSYIGSQN 
FibrocystinAMm   DYIESPLILEAREDKWLTPCSLINRQTGS-----CFPIQEEHGLGNVQCRVEGDYIGSQN 
FibrocystinEMm   DYIESPLILEAREDKWLTPCSLINRQTGS-----CFPIQEEHGLGNVQCRVEGDYIGSQN 
FibrocystinBMm   DYIESPLILEAREDKWLTPCSLINRQTGS-----CFPIQEEHGLGNVQCRVEGDYIGSQN 
FibrocystinDMm   DYIESPLILEAREDKWLTPCSLINRQTGS-----CFPIQEEHGLGNVQCRVEGDYIGSQN 
FibrocystinCMm   DYIESPLILEAREDKWLTPCSLINRQTGS-----CFPIQEEHGLGNVQCRVEGDYIGSQN 
KIM1Rn           KRLEKAYPFFSDRK----SCNLLIRVASG-----SFP--EVYGMGGEPVTLPCSYPESRA 
CcnjlRn          EYAHYFLEVTLQDHIFYKFQPSVVAAACVGAS--RICLQLSPYWTRDLQRVSSYSLEHLS 
Mat2bRn          DHWQQRFPTHVKDVASVCRQLAEKRMLDP-------SIKGTFHWSGNEQMTKYEMACAIA 
Pttg1Rn          EHQISLLPLNGVPLMILNEERGLEKLLHLD---------PPSPLQKPFLPWESDPLPSPP 
Eif4g1Rn         TGGSLEPQPNGESPQVAVIIRPDDRSQGAAIGGRPGLPGPEHSPGTESQPSSPSPTPSPP 
Gabrg2Rn         RPRSATIQMNNATHLQERDEEYGYECLDG---------KDCASFFCCFEDCRTGAWRHGR 
C1qtnt2Rn        PIKFDKILMNEGGHYNASSGKFVCSVPGIY------YFTYDITLANKHLAIGLVHNGQYR 
                 ############################       ######################### 
                        370       380       390       400       410       420 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VSFSVFNKGRSMVHKEAWLISAKQELFLYQTYPEIHSVFPKVGSLG--GRTDITITGDFF 
FibrocystinBRn   VSFSVFNKGRSMVHKEAWLISAKQELFLYQTYPEIHSVFPKVGSLG--GRTDITITGDFF 
FibrocystinAMm   VSFSVFNKGRSMVHKEAWLISAKQELFLYQTYPEILSVFPKVGSLG--GRTDIIITGDFF 
FibrocystinEMm   VSFSVFNKGRSMVHKEAWLISAKQELFLYQTYPEILSVFPKVGSLG--GRTDIIITGDFF 
FibrocystinBMm   VSFSVFNKGRSMVHKEAWLISAKQELFLYQTYPG-------------------------- 
FibrocystinDMm   VSFSVFNKGRSMVHKEAWLISAKQELFLYQTYPVPFLTFCQSDNFCYYPDPALYINRTFF 
FibrocystinCMm   VSFSVFNKGRSMVHKEAWLISAKQELFLYQTYPG-------------------------- 
KIM1Rn           LSFVCWGRGECASDTCGQTLVWTDGNRINYRTSSRYQINAQLLQGN-------------- 
CcnjlRn          TCIEILLVAYDNVLKDAVAVKSQTLAMVPGSSSAPAQVLFQPPTYP-------------- 
Mat2bRn          DAFNLPSSHLRPITDSPVIGAQRP------------------------------------ 
Pttg1Rn          SALSALDVELPPVCYDADI----------------------------------------- 
Eif4g1Rn         PILEPGSESNLGVLSIPGDTMTTGMIPISVEESTPISCESGEPYCLS------------- 
Gabrg2Rn         IHIRIAKMDSYARIFFPTAFCLFNLVYWVSYLYL-------------------------- 
C1qtnt2Rn        IRTFDANTGNHDVASGSTILALKEGDEVWLQIFYS------------------------- 
                 #############                                                
                        430       440       450       460       470       480 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   DPSARVTIAGIPCDIRHVSPRKIECTTRAPGNGARLTAPQAGNRGLLFEVGNAVKDEELT 
FibrocystinBRn   DPSARVTIAGIPCDIRHVSPRKIECTTRAPGNGARLTAPQAGNRGLLFEVGNAVKDEELT 
FibrocystinAMm   DPSARVTIAGIPCDIRYVSPRKIECTTRAPGNEARLTAPQAGNRGLRFEVGDATKDVELT 
FibrocystinEMm   DPSARVTIAGIPCDIRYVSPRKIECTTRAPGNEARLTAPQAGNRGLRFEVGDATKDVELT  
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FibrocystinBMm   ----------IPCDIRYVSPRKIECTTRAPGNEARLTAPQAGNRGLRFEVGDATKDVELT 
FibrocystinDMm   SLFSHCTLMSIPCDIRYVSPRKIECTTRAPGNEARLTAPQAGNRGLRFEVGDATKDVELT 
FibrocystinCMm   --------------TLSLHPVFIPSLTAHP------------------------------ 
KIM1Rn           --------ASLTIDYAYVSDSGLYCCRVEMKGWDGVQTLTTSLQVQPGSNSTRTKGLAIG 
CcnjlRn          ---TLSQPPPTTLAQFQSPAQDLCLAYRDSLQAHRSGGLLSGDTGPSLHTPYPTLQPLDM 
Mat2bRn          ------------------KNAQLDCSKLETLGIGQRTPFRIGIKESLWPFLIDKRWRQTV 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         PEPTLAEPILEVEVTLSKPIPESEFSSSPLQVSTSLVPHRAETHEPNGVIPSEDLEPEVE 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        -----------------------------EQNGLFYDPYWTDSLFTGFLIYADQGDPNEV 
                                                                              
                        490       500       510       520       530       540 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   EATPGYRWQIVPNASSPSGFWSKEGRPFRARLSGFFVAPETNNYTFWIQADSQAFLRFSS 
FibrocystinBRn   EATPGYRWQIVPNASSPSGFWSKEGRPFRARLSGFFVAPETNNYTFWIQADSQAFLRFSS 
FibrocystinAMm   EATPGYRWQIVPNASSPSGFWSKEGRPFRARLSGFFVAPQTNNYTFWIQADSQASLCFSS 
FibrocystinEMm   EATPGYRWQIVPNASSPSGFWSKEGRPFRARLSGFFVAPQTNNYTFWIQADSQASLCFSS 
FibrocystinBMm   EATPGYRWQIVPNASSPSGFWSKEGRPFRQIWTQSLTSLQGK------------------ 
FibrocystinDMm   EATPGYRWQIVPNASSPSGFWSKEGRPFS------------------------------- 
FibrocystinCMm   KLALLFFWQLF------------------------------------------------- 
KIM1Rn           LSIFVLLLVLVSSLVVAS----------RKIMPGVYCSP--------------------- 
CcnjlRn          CPVPVPASLSMQMAIAAEPRHCLTASYGSSYFSGSHMFPAGCFDS--------------- 
Mat2bRn          FH---------------------------------------------------------- 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         SSTEPAPPPLSACASESLVPIAPTAQPEELLNGAPSPPAVDLSPVSEPEEQAKEVPSAAL 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                        550       560       570       580       590       600 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SEEPRMKVEVASIAVGTADWFDSWEQNGNEGSWQQKTNKLELQGGAKYYLEAEQHGIAPS 
FibrocystinBRn   SEEPRMKVEVASIAVGTADWFDSWEQNGNEGSWQQKTNKLELQGGAKYYLEAEQHGIAPS 
FibrocystinAMm   SEEPRTKVEVASVGVGTADWFDSWEQIGNEGSWHQKTTKLELQGGAKYYLEAEQHGIAPS 
FibrocystinEMm   SEEPRTKVEVASVGVGTADWFDSWEQIGNEGSWHQKTTKLELQGGAKYYLEAEQHGIAPS 
FibrocystinBMm   ---------------FSKVVMLPWESVN--------------------FVSLDFLGVACV 
FibrocystinDMm   ----------------------PWESVN--------------------FVSLDFLGVACV 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ASIVSPTPPVAPSDTSAAQEEEIEEDEDEDGEAESEKGGEDLPLDSTPVPAQLSQNLEVA 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                        610       620       630       640       650       660 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   RGMRIAVQIHNTWLNPDVVNTYLLEKHQIRAQAQRLPEIQVLNMSGKGNFFLTWGNVSSQ 
FibrocystinBRn   RGMRIAVQIHNTWLNPDVVNTYLLEKHQIRAQAQRLPEIQVLNMSGKGNFFLTWGNVSSQ 
FibrocystinAMm   RGMRIGVQIHNTWLNPDVVNTYLLEKHQIRARAQRLPEIQVLHVSGKGNFFLTWGNVSSQ 
FibrocystinEMm   RGMRIGVQIHNTWLNPDVVNTYLLEKHQIRARAQRLPEIQVLHVSGKGNFFLTWGNVSSQ 
FibrocystinBMm   R----------------------------------------------------------- 
FibrocystinDMm   R----------------------------------------------------------- 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         AAPQVAVSVPKRRRKIKELNKKEAVGDLLDAFKEVDPAVPEVENQPPTGSNPSPESEGSA 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                        670       680       690       700       710       720 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   PVPANATAQQIQTIIEELLVVKCNLVPLSARVLLWLGFEQGLDGSRSDGVLTSSTEPFCG 
FibrocystinBRn   PVPANATAQQIQTIIEELLVVKCNLVPLSARVLLWLGFEQGLDGSRSDGVLTSSTEPFCG 
FibrocystinAMm   PVPANATAQQIQTTIEELLVVKCNLAPFSAHVLLRLGFEQGLEGSRSDGVRTSSTEPFCG 
FibrocystinEMm   PVPANATAQQIQTTIEELLVVKCNLAPFSAHVLLRLGFEQGLEGSRSDGVLTSSTEPFCG 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------  
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Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ALPQPEEAEETWDSKEDKIHNAENIQPGEQKYEYKSDQWKPLNLEEKKRYDREFLLGFQF 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                        730       740       750       760       770       780 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   RFSLGQLRHLILSPGAVSKGYQLDRYPYLCFAYRGHMNRTLDMTVSFLFGFQNVMKNITC 
FibrocystinBRn   RFSLGQLRHLILSPGAVSKGYQLDRYPYLCFAYRGHMNRTLDMTVSFLFGFQNVMKNITC 
FibrocystinAMm   RFSLGQLGHLILIPEAADKGYQLDRYPYLCLAYRGHMNKTLDMTVSFLFGFQTIMKNITC 
FibrocystinEMm   RFSLGQLGHLILIPEAADKGYQPDRYPYLCLAYRGHMNKTLDMTVSFLFGFQNIMKNITC 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         IFASMQKPEGLPHITDVVLDKANKTPLRSLDPSRLPGINCGPDFTPSFANLGRPTLSSRG 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                        790       800       810       820       830       840 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   DWSLMEPHPESWHFTCNNLWDTCVRHSEELQSSLANTPLLVHRIDIFPVVPEADLLYVDE 
FibrocystinBRn   DWSLMEPHPESWHFTCNNLWDTCVRHSEELQSSLANTPLLVHRIDIFPVVPEADLLYVDE 
FibrocystinAMm   DWSLTDPHPESWQFTCINLWDTCLCHSEDIQSSLANTPLLAHRIDIRPVVPEAGLLYVDE 
FibrocystinEMm   DWSLTNPHPESWQFTCINLWDTCLCHSEDLQSSLANTPLLVHRIDIRPVVPEAGLLYVDE 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         PPRGGPGGELPRGPAGLGPRRSQQGPRKETRKIISSVIMTEDIKLNKAEKAWKPSSKRTA 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                        850       860       870       880       890       900 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   IILADTNVTVSQADSGVARPGGNVVESVSVVGVPPVYSIASWMAGCGSELPLITACYVPT 
FibrocystinBRn   IILADTNVTVSQADSGVARPGGNVVESVSVVGVPPVYSIASWMAGCGSELPLITACYVPT 
FibrocystinAMm   IILADTNVTVSQADSGRACPGGNVVESVSVVGVPPVYSISSWLAGCGSELPLITACSVST 
FibrocystinEMm   IILADTNVTVSQADSGRACPGGNVVESVSVVGVPPVYSISSWLAGCGSELPLITACSVST 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ADKDRGEEDADGSKTQDLFRRVRSILNKLTPQMFQQLMKQVTQLAIDTEERLKGVIDLIF 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                        910       920       930       940       950       960 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   QGTGEGSELIEVTAKRLQRTSPPLGGHFSLHLSDTVIPDVPVHVSARQLHKLLQDNADES 
FibrocystinBRn   QGTGEGSELIEVTAKRLQRTSPPLGGHFSLHLSDTVIPDVPVHVSARQLHKLLQDNADES 
FibrocystinAMm   EGTGDGSELIEVTAQRLQRTSPPLGGHFFLYLSDTVIPDVPVRMSARQLHKLLQDSADES 
FibrocystinEMm   EGTGDGSELIEVTAQRLQRTSPPLGGHFFLYLSDTVIPDVPVRMSARQLHKLLQDSADES 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         EKAISEPNFSVAYANMCRCLMALKVPTTEKPTVTVNFRKLLLNRCQKEFEKDKDDDEVFE 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
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                        970       980       990      1000      1010      1020 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   TSGYLNADDFIVTKDQNSCYEHVWTLSWTTQIGDLPNFIRVSDQNLTGLNPTITARVVYD 
FibrocystinBRn   TSGYLNADDFIVTKDQNSCYEHVWTLSWTTQIGDLPNFIRVSDQNLTGLNPTITARVVYD 
FibrocystinAMm   TSGYLNAGDFTVTEDLNSCYEHVWTLSWTTQTGDLPNFIRVSDQNLTGVNPTVTARVVYD 
FibrocystinEMm   TSGYLNAGDFTVTEDLNSCYEHVWTLSWTTQTGDLPNFIRVSDQNLTGVNPTVTARVVYD 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         KKQKEMDEAATAEERGRLKEELEEARDIARRRSLGNIKFIGELFKLKMLTEAIMHDCVVK 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1030      1040      1050      1060      1070      1080 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   GGVFLGPILGDTLATANQQTQVTVQVNDIPAHCSGSCSFQYQRASTPSVDCVWYSLGSDV 
FibrocystinBRn   GGVFLGPILGDTLATANQQTQVTVQVNDIPAHCSGSCSFQYQRASTPSVDCVWYSLGSDV 
FibrocystinAMm   GGVFLGPIFGDMLATANQQTQVAVQVNDIPAYCSGSCSFQYQQESTPSVDHVWYSLGSDV 
FibrocystinEMm   GGVFLGPIFGDMLATANQQTQVAVQVNDIPAYCSGSCSFQYQQESTPSVDHVWYSLGSDV 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         LLKNHDEESLECLCRLLTTIGKDLDFAKAKPRMDQYFNQMEKIIKEKKTSSRIRFMLQDV 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1090      1100      1110      1120      1130      1140 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   NLLVHFTGNGFPRDAQFLQVTVINTSCEVIFSNETNVACELALLPVGVHRVFMLVRPSGL 
FibrocystinBRn   NLLVHFTGNGFPRDAQFLQVTVINTSCEVIFSNETNVACELALLPVGVHRVFMLVRPSGL 
FibrocystinAMm   NLLVHFTGTGFPRDTQFLQVTVNKTSCEVLFSNETNVACELALLPVGVHQIFMLVIPSGL 
FibrocystinEMm   NLLVHFTGTGFPRDTQFLQVTVNKTSCEVLFSNETNVACELALLPVGVHQIFMLVIPSGL 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         LDLRQSNWVPRRGDQGPKTIDQIHKEAEMEEHREHIKVQQLMAKGGDKRRGGPPGPPVNR 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1150      1160      1170      1180      1190      1200 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ALNASGEGLFLRVEPRLDAVEPSTGAEIG---GWWVTLRGSSLEAVSLVLFGTRSCVIDV 
FibrocystinBRn   ALNASGEGLFLRVEPRLDAVEPSTGAEIGNVGGATLCTCPLKLETVSSVVSGIGACPWDG 
FibrocystinAMm   AVHASGEDLLLHVEPRLDAVEPSTAAEIG---GRWVTLRGSSLEGVSLVLFGTQSCVIDA 
FibrocystinEMm   AVNASGEDLLLHVEPRLDAVEPSTAAEIG---GRWVTLRGSSLEGVSLVLFGTQSCVIDA 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         GLPLVDDGGWNTVPISKGSRPIDTSRLTKITKPGSIDSNNQLFAPGGRLSWGKGSSGGSG 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1210      1220      1230      1240      1250      1260 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   IRSNSQQIQCKVPPRGKDGYTVNVTVINGDHSTVLARAFTYVSSLNPVIVSLSRNRSNIA 
FibrocystinBRn   SQVGSIIVGCLIPPLAGVGVRLKETHASPSHTVVKGVSFTYVGALGDKLLELCRNKCTIL 
FibrocystinAMm   IRSNSQQIQCKVPPRGKDGYTVNVTVISGDHSTVLARAFTYVSSLNPVIVSLSRNRSSIA 
FibrocystinEMm   IRSNSQQIQCKVPPRGKDGYTVNVTVISGDHSTVLARAFTYVSSLNPVIVSLSRNRSSIA  
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FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         AKPSDTASEATRPATLNRFSALQQTLPVENTDNRRVVQRSSLSRERGEKAGDRGDRLERS 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1270      1280      1290      1300      1310      1320 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   G--GEILFLGMTLMVNYTDLNVQIYIQNTSAQVLAKTAWGLEVLLPPLLPGIYVISAFIN 
FibrocystinBRn   DTGGEILFLGMTLMVNYTDLNVQIYIQNTSAQVLAKTAWGLEVLLPPLLPGIYVISAFIN 
FibrocystinAMm   G--GEILFLGMSLLVNYTDLDVQIHVQDTSAQVLSQTAWGLEVVLPPLVPGIHVISAFIN 
FibrocystinEMm   G--GEILFLGMSLLVNYTDLDVQIHVQDTSAQVLSQTAWGLEVVLPPLVPGIHAISAFIN 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ERGGDRGDRLDRARTPATKRSFSKEVEERSRERPSQPEGLRKAASLTEDRGRDPVKREAT 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1330      1340      1350      1360      1370      1380 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   GISIRSQGVDLHIQYLTEVFSMEPCSGSLLGGTILRLSGAGLGRDPALIRVLVDNRPCDT 
FibrocystinBRn   GISIRSQGVDLHIQYLTEVFSMEPCSGSLLG----------------------------- 
FibrocystinAMm   GVSIRSQGVDLYIQYLTEVFSVEPCSGSLLGGTLLSLLGTGLGRDPALIRVLVDNHPCDI 
FibrocystinEMm   GVSIRSQGVDLYIQYLTEVFSVEPCSGSLLGGTLLNLLGTGLGRDPALIRVLVDNHPCDI 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         LPPVSPPKAALAVDEVERKS---------------------------------------- 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1390      1400      1410      1420      1430      1440 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VKLTEVNIWCETPRVLLPPRADVLTVPASVEIWAGNT------SFVGKAFIFTYEAAATP 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   VNLTEVNIWCETPPAVLPPRADVLTVLASVEIWAGNTSFFHGPSLVGKGFTFTYEAAATP 
FibrocystinEMm   VNLTEVNIWCETPPAVLPPRADVLTVPASVEIWAGNTSFFHGPSLVGKGFTFTYEAAATP 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1450      1460      1470      1480      1490      1500 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VVTAMWGELMNNSVRFYVEGNNLSDSVILLGSLKCDLQVQLFGDNMNLSGCSLLLHSLEA 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   VVTAMWGEFRNNSVRFYVEGSNISDSVILLGSLKCELEVQFFGDSMNLSGCFFPLHSLEA 
FibrocystinEMm   VVTAMWGEFRNNSVRFYVEGSNISDSVILLGSLKCELEVQFFGDSMNLFGCFFPLHSLEA 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------  
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Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1510      1520      1530      1540      1550      1560 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   GVYALQVRHKRMGFANMSAVPQKFELSPQIIDIFPTHGSIYGGTVLTVKGTAFRSRRRSV 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   GVYTLQVRHKRMGFANMSVVPQKFELSPQIIAIFPTHGSKCGGTVLTVKGMAFSSRKRSV 
FibrocystinEMm   GVYTLQVRHKRMGFANMSVVPQKFELSPQIIAIFPTHGSKCGGTVLTVKGMAFSSRKRSV 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1570      1580      1590      1600      1610      1620 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   HVDLSGPFTCVILSLGDHTVLCQTKFVGDQFSETSLALNITVLVNGLTSKCEGNCTLFLE 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   HVDISGPFACMILSLEDHTVLCQTRFVGDQFSEASLALNITVLVNGLTSKCKGNCTLFIE 
FibrocystinEMm   HVDISGPFACMILSLEDHTVLCQTRFVGDQFSEASLALNITVLVNGLTSKCKGNCTLFIE 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1630      1640      1650      1660      1670      1680 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   EAATPIVDALTISISGSLTTVLMRGQRLGS-AGEPTAFVDGQLLCHTTFFNTSYVACQMR 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   EAATPIVDALTISISGSLTMVLMRGRRLATTADEPIAFVDDQLPCHTTFFNTSHVACQIR 
FibrocystinEMm   EAATPNVDALTISISGSLTMVLMRGRRLATTADEPIAFVDDQLPCHTTFFNTSHVACQIR 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1690      1700      1710      1720      1730      1740 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   DLAPGFHYLSAVRTSAGYACLNSVSRNFFVVPQVFDYFPKDFSIHGGSLLTIKGTTLRGW 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   DLAPGFHYLSAVHTSAGYACLNSVSRNFFIVPQVLDYFPKDFSIHGGSLLTIKGTALRGW 
FibrocystinEMm   DLAPGFHYLSAVHTSAGYACLNSVSRNFFIVPQVLDYFPKDFSIHGGSLLMIKGTALRGW 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
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                       1750      1760      1770      1780      1790      1800 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   KTTFVYVGQQACLTVNISSEFIQCIVPAGNGSAALEIDVDGVLYHMGFVDYSSIFTPELL 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   KATVVYVGRQACLTVNFSSDFIQCIVPAGNGSAALEIDVNGVLYHIGLVDYSSIFTPELL 
FibrocystinEMm   KATVVYVGRQACLTVNISSDFIQCIVPAGNGSAALEIDVDGVLYHIGLVDYSSIFTPELL 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1810      1820      1830      1840      1850      1860 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SVSRSHDILTFTVARISGAANVDILIGTSPCLDVAGNRTILRCMVPLLPAGEYAVTGYDH 
FibrocystinBRn   ------------------------------------------------------------ 
FibrocystinAMm   SVSRSQDILTFTVARISGAANVDIFIGTSPCLGVAGNRTVLQCMVPLLPAGEYLVTGYDH 
FibrocystinEMm   SVSRSQDILTFTVARISGAANVDIFIGTSPCLGVAGNRTVLQCMVPLLPAGEYLVTGYDH 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1870      1880      1890      1900      1910      1920 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SRGWVSSTLILVLRATVTSVTENYGCLGGRLLHVLGAGFSPGNISAAVCGAPCQVLANAT 
FibrocystinBRn   -------------------------CLGGRLLHVLGAGFSPGNISAAVCGAPCQVLANAT 
FibrocystinAMm   SRGWASSTLILVLRATVTSVTKNYGCLGGRLLHVLGAGFSPGNISAAVCGAPCQVLANAT 
FibrocystinEMm   SRGWASSTLILVLRATVTSVTKNYGCLGGRLLHVLGAGFSPGNISAAVCGAPCQVLANAT 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         -------KAIIEEYLHLNDMKEAVQCVQELASPSLLFIFVRLGIESTLERSTIAREHMGR 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1930      1940      1950      1960      1970      1980 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VSAFSCLVLPLDASLAFLCNLRHAEDSCGVSRPTYLQCDLTVSVGMERLPGSWPYVYLCE 
FibrocystinBRn   VSAFSCLVLPLDASLAFLCNLRHAEDSCGVSRPTYLQCDLTVSVGMERLPGSWPYVYLCE 
FibrocystinAMm   VSAFSCLVLPLHVSLAFLCDLRHAEDSCKVRSSTYLRCDLTVSMGTERLPGSWPYVYLCE 
FibrocystinEMm   VSAFSCLVLPLDVSLAFLCDLRHAEDSCKVRSSTYLQCDLTVSMGTERLPGSWPYVYLCE 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         LLHQLLCAGHLSTAQYYQGLYETLELAEDMEIDIPHVWLYLAELITPILQEDGVPMGELF 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       1990      2000      2010      2020      2030      2040 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ESSQGLFVP---DHQIFLSFSGLFLSPKVERDEVLIYNSSCNITMETEAEMECGTPNQPI 
FibrocystinBRn   ESSQGLFVP---DHQIFLSFSGLFLSPKVERDEVLIYNSSCNITMETEAEMECGTPNQPI 
FibrocystinAMm   ESSLCLFEPDHWTESVFPSFSGLFLSPKVERDEVLIYNSSCNITMETEAEMECEMPNQPI 
FibrocystinEMm   ESSLCLFEPDHWTESVFPSFSGLFLSPKVERDEVLIYNSSCNITMETEAEMECEMPNQPI  
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FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         REITKPLRPMGKATSLLLEILGLLCKSMGPKKVGMLWREAGLSWREFLAEGQDVGSFVAE 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2050      2060      2070      2080      2090      2100 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   TAKITEIQKSRGQNTQGNFSFQFCRRWSRPHSWFPHRVPQDGDNVTVETSHLLLLDANTS 
FibrocystinBRn   TAKITEIQKSRGQNTQGNFSFQFCRRWSRPHSWFPHRVPQDGDNVTVETSHLLLLDANTS 
FibrocystinAMm   TAKITEIQKSWGQNTQGNFSFQFCRRWSRPHSWFPQRVPHDGDSVTVETGHLLLLDANTS 
FibrocystinEMm   TAKITEIQKSWGQNTQGNFSFQFCRRWSRPHSWFPQRVPHDGDSVTVETGHLLLLDANTS 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         KKVEYTLGEESEAPGQRALAFEELRRQLEKLLKDGGSNQRVFDWIEANLNEQQIASNTLV 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2110      2120      2130      2140      2150      2160 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   LLNSLHIKGGKLIFMEPGPIDLRAHSILITDGGELHIGSEDKPFQGKARIKLYGSVHSTS 
FibrocystinBRn   LLNSLHIKGGKLIFMEPGPIDLRAHSILITDGGELHIGSEDKPFQGKARIKLYGSVHSTS 
FibrocystinAMm   FLNSLHIKGGKLIFMDPGPIELRAHSILITDGGELHIGSEEKPFQGKARIKIYGSVHSTP 
FibrocystinEMm   FLNSLHIKGGKLIFMDPGPIELRAHSILITDGGELHIGSEEKPFQGKARIKIYGSVHSTP 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         RALMTTVCYSAIIFETPLRVDVQVLKVRARLLQKYLSDEQKELQALYALQALVVTLEQPA 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2170      2180      2190      2200      2210      2220 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   FFPYGVKFLAVRNGTLSLHGSVPEVTFTYLRAAACAGDTVLALEEAVAWHPGDEAVISSG 
FibrocystinBRn   FFPYGVKFLAVRNGTLSLHGSVPEVTFTYLRAAACAGDTVLALEEAVAWHPGDEAVISSG 
FibrocystinAMm   FFPYGVKFLAVRNGTLSLHGSVPEVTVTYLQAAAHAGDKVLTLGEAVDWKPGDEAVITSG 
FibrocystinEMm   FFPYGVKFLAVRNGTLSLHGSVPEVTVTYLQAAAHAGDKVLTLGEAVDWKPGDEAVITSG 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         NLLRMFFDALYDEDVVKEDAFYSWESSKDPAEQQGKGVALKSVTAFFNWLREAEDEESDH 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2230      2240      2250      2260      2270      2280 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ATVEGAEATEEVVVVETVHDADLHLRNPLRYSYNFTENWVTGVNHILKATVALLSRNIIV 
FibrocystinBRn   ATVEGAEATEEVVVVETVHDADLHLRNPLRYSYNFTENWVTGVNHILKATVALLSRNIIV 
FibrocystinAMm   MTVAGAEA-TEVVVVETVHNADLHLRNPLRYSYDFRENWVAGENPILKPTVALLSRNIII 
FibrocystinEMm   MTVAGAEA-TEVVVVETVHNADLHLRNPLRYSYDFRENWVAGENPILKPTVALLSRNIII 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------  
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Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         N----------------------------------------------------------- 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2290      2300      2310      2320      2330      2340 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   QGNLTLERVKLLDSCQEAGAAEGNLKHCLYSKSEKMLGARNLGARVIIQSFPEEPSLVKL 
FibrocystinBRn   QGNLTLERVKLLDSCQEAGAAEGNLKHCLYSKSEKMLGARNLGARVIIQSFPEEPSLVKL 
FibrocystinAMm   QGNFTLERVKLLNSCQEANTAKGNLKHCLYSKSEKMLGARDLGARVIIQSFPEEPSFVKL 
FibrocystinEMm   QGNFTLERVKLLNSCQEANTAKGNLKHCLYSKSEKMLGARDLGARVIIQSFPEEPSFVKL 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2350      2360      2370      2380      2390      2400 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   KGVQFRDLGQAFHKHLSSLTLVGAMRGSYLHSCSMWGSFSRGLSIHRTWGLKVENNIFYK 
FibrocystinBRn   KGVQFRDLGQAFHKHLSSLTLVGAMRGSYLHSCSMWGSFSRGLSIHRTWGLKVENNIFYK 
FibrocystinAMm   KGVQFRDLGQAFHKHLSSLALVGAMRGSYIQSCSVWNSFSRGLSMHRTWGLKVDSNVFYK 
FibrocystinEMm   KGVQFRDLGQAFHKHLSSLALVGAMRGSYIQSCSVWNSFSRGLSMHRTWGLKVDSNVFYK 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2410      2420      2430      2440      2450      2460 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   IVGHALLVGSYMDRSFSTSEAVIGRKNGWWEEGSMIRNNVIINVSGAEGLSSSEMLAPAG 
FibrocystinBRn   IVGHALLVGSYMDRSFSTSEAVIGRKNGWWEEGSMIRNNVIINVSGAEGLSSSEMLAPAG 
FibrocystinAMm   IVGHALLLGSYLDGRFSTSETVTGRKNGWWEQGSTIRNNVIISVSAAEGLSGSEMLAPAG 
FibrocystinEMm   IVGHALLLGSYLDGRFSTSETVTGRKNGWWEQGSTIRNNVIISVSAAEGLSGSEMLAPAG 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2470      2480      2490      2500      2510      2520 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   IYTFSPTSAIEGNRVCAAGYGYVLHLVTSQTVQAPLLSFNWNTAHSCTRYGLLVYPEFQP 
FibrocystinBRn   IYTFSPTSAIEGNRVCAAGYGYVLHLVTSQTVQAPLLSFNWNTAHSCTRYGLLVYPEFQP 
FibrocystinAMm   IYTFSPTNVMEGNRVCAAGYGYVFHLVTSQTLQAPLLSFNWNTAHSCTRYGLLVYPKFQP 
FibrocystinEMm   IYTFSPTNVMEGNRVCAAGYGYVFHLVTSQTLQAPLLSFNWNTAHSCTRYGLLVYPKFQP 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
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                       2530      2540      2550      2560      2570      2580 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   PWNNDTGFTLFQNFMVWGSAGGAQIFRSNNLHLRNFQVYACRDFGIDILESDTNTLVTDS 
FibrocystinBRn   PWNNDTGFTLFQNFMVWGSAGGAQIFRSNNLHLRNFQVYACRDFGIDILESDTNTLVTDS 
FibrocystinAMm   PWNNDTGFTLFQNFMVWGSAGGAQIFRSNNLHLKNFQVYACRDFGIDILESDANTLITDS 
FibrocystinEMm   PWNNDTGFTLFQNFMVWGSAGGAQIFRSNNLHLKNFQVYACRDFGIDILESDANTLITDS 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2590      2600      2610      2620      2630      2640 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   FLLGHFTHEGSLCMSVGIKTPKRWGLTISNTTFVNFDLNCVAIRTCSGCSQGQGGFPVKT 
FibrocystinBRn   FLLGHFTHEGSLCMSVGIKTPKRWGLTISNTTFVNFDLNCVAIRTCSGCSQGQGGFPVKT 
FibrocystinAMm   FLLGHFTHKGSLCMSAGIKTPQRWELTISNTTFVNFDGNCVAIRTCSGCFQGQGGYTVKT 
FibrocystinEMm   FLLGHFTHKGSLCMSAGIKTPQRWELTISNTTFVNFDGNCVAIRTCSGCFQGQGGYTVKT 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2650      2660      2670      2680      2690      2700 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   RQLKFVNSSNLVAFPFPHAAVLQDLDGSLSGKNGSHVLASMETLSDTCLTNASFSQIVSG 
FibrocystinBRn   RQLKFVNSSNLVAFPFPHAAVLQDLDGSLSGKNGSHVLASMETLSDTCLTNASFSQIVSG 
FibrocystinAMm   RQLKFVNSSNLVAFPFPHAAVLEDLDGSLSGKNGSHVLASMETLSDTCLTNASFSQIVPG 
FibrocystinEMm   RQLKFVNSSNLVAFPFPHAAVLEDLDGSLSGKNGSHVLASMETLSDTCLTNASFSQIVPG 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2710      2720      2730      2740      2750      2760 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SVCGEAVLFHRMSIGLAKSLDVPKNLTMTDIRNRTITINYVDDTLSNSYGWMALLLDQET 
FibrocystinBRn   SVCGEAVLFHRMSIGLAKSLDVPKNLTMTDIRNRTITINYVDDTLSNSYGWMALLLDQET 
FibrocystinAMm   SVCGEAVLFHRMSIALANSLDVPKNLTITDISNKTITVNYVEDTLSNYYGWMALLLDQET 
FibrocystinEMm   SVCGEAVLFHRMSIALANSLDVPKNLTITDISNKTITVNYVEDTLSNYYGWMALLLDQET 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2770      2780      2790      2800      2810      2820 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   YLLQFEGPWTDGSLQYSATFDNFAPGNYLLLMHRDLLPYPDILLRCGSRVGQSLPSHPLP 
FibrocystinBRn   YLLQFEGPWTDGSLQYSATFDNFAPGNYLLLMHRDLLPYPDILLRCGSRVGQSLPSHPLP 
FibrocystinAMm   YSLQFESPWMNRSLQYSATFDSFAPGNYLLIMHRDLPPYPDILLRCGSQVGHSLPFHPLP 
FibrocystinEMm   YSLQFESPWMNRSLQYSATFDSFAPGNYLLIMHRDLPPYPDILLRCGSQVGHSLPFHPLP  
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FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2830      2840      2850      2860      2870      2880 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SRDGACDWFFHRQLRQLTYLVSGEGQVHVFLQVKHGAPPTVSASTSVSESALKWSLPETW 
FibrocystinBRn   SRDGACDWFFHRQLRQLTYLVSGEGQVHVFLQVKHGAPPTVSASTSVSESALKWSLPETW 
FibrocystinAMm   SQDRACDWFFNRQLRQLTYLVSGEGQVKVFLQLKPGVPPSVSASTSVPESASRWSLPETW 
FibrocystinEMm   SQDRACDWFFNRQLRQLTYLVSGEGQVKVFLQLKPGVPPSVSASTSVPESASRWSLPETW 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2890      2900      2910      2920      2930      2940 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   QDVEKGWGGYNHTIPGPGDDVLILPNKTVLVDTDLPVLRCLYVMGTLEFPVDRSNVLSVA 
FibrocystinBRn   QDVEKGWGGYNHTIPGPGDDVLILPNKTVLVDTDLPVLRCLYVMGTLEFPVDRSNVLSVA 
FibrocystinAMm   QDVEKGWGGYNHTIPGPGDDVLILPNKTVLVDTDLPVLRCLYVMGTLEFPVDRSNVLSVA 
FibrocystinEMm   QDVEKGWGGYNHTIPGPGDDVLILPNKTVLVDTDLPVLRCLYVMGTLEFPVDRSNVLSVA 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       2950      2960      2970      2980      2990      3000 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   CLLIAGGELKVGTLENPLGKDQRLLILLRASEEIFCDRFDGIRVDPGTIGVYGKLRLHSA 
FibrocystinBRn   CLLIAGGELKVGTLENPLGKDQRLLILLRASEEIFCDRFDGIRVDPGTIGVYGKLRLHSA 
FibrocystinAMm   CLLIAGGELKVGTLENPLEKDQRLLIFLRASEEVVCDYFEGIHVDPGTIGVYGKLRLHSA 
FibrocystinEMm   CLLIAGGELKVGTLENPLEKDQRLLIFLRASEEVVCDYFEGIHVDPGTIGVYGKLRLHSA 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3010      3020      3030      3040      3050      3060 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   YPKKSWVHLGADIAPGNERIIVHNAVDWQPHDKIVLSSSSYEPHEAEVLTVKEVKDHHIR 
FibrocystinBRn   YPKKSWVHLGADIAPGNERIIVHNAVDWQPHDKIVLSSSSYEPHEAEVLTVKEVKDHHIR 
FibrocystinAMm   YPKKSWVHLGADIAPGNERIIVHNAVDWQPHDTIVLSSSSYEAHEAEVLTVKEVKGHHIR 
FibrocystinEMm   YPKKSWVHLGADIAPGNERIIVHNAVDWQPHDTIVLSSSSYEAHEAEVLTVKEVKGHHIR 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------  
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Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3070      3080      3090      3100      3110      3120 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   IYERLKHRHIGSAHTLEDSRQICLAAEVGLLTRNIRIQSDSSCRGRLLVGSFRKSSGEEF 
FibrocystinBRn   IYERLKHRHIGSAHTLEDSRQICLAAEVGLLTRNIRIQSDSSCRGRLLVGSFRKSSGEEF 
FibrocystinAMm   IYERLKHRHIGSTHTMEDGQQVHLAAEVGLLTRNIRIQPDSSCRGRLLVGSFRKSSGEDF 
FibrocystinEMm   IYERLKHRHIGSTHTMEDGQQVHLAAEVGLLTRNIRIQPDSSCRGRLLVGSFRKSSGEDF 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3130      3140      3150      3160      3170      3180 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SGILQLLNVEIQNMGSPLYASIEFTGVSAGSWVISSTVHQSCTVGIHASSSRGMVLNDNI 
FibrocystinBRn   SGILQLLNVEIQNMGSPLYASIEFTGVSAGSWVISSTVHQSCTVGIHASSSRGMVLNDNI 
FibrocystinAMm   SGVLQLLNVEIQNMGLPLYSSIEFTGVSAGSWVISSTVHQSCSVGIHASSSHGVILTDNV 
FibrocystinEMm   SGVLQLLNVEIQNMGLPLYSSIEFTGVSAGSWVISSTVHQSCSVGIHASSSHGVILTDNV 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3190      3200      3210      3220      3230      3240 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VFGTKGHGIDVEGQNYSLTNNLVILSMQSANSLPWVAGIKVNYAEDIILHGNVVAGSERL 
FibrocystinBRn   VFGTKGHGIDVEGQNYSLTNNLVILSMQSANSLPWVAGIKVNYAEDIILHGNVVAGSERL 
FibrocystinAMm   VFGTNGHGIDVEGQNYSLTNNLVILTMQSANSSPWVAGIKVNYAEDIILHGNVVAGSERL 
FibrocystinEMm   VFGTNGHGIDVEGQNYSLTNNLVILTMQSANSSPWVAGIKVNYAEDIILHGNVVAGSERL 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3250      3260      3270      3280      3290      3300 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   GFHVRGHGCSSEVLWSDNVVHSSLHGIHLYKKREPNNCTGVSGFLAFKNFDYGAMVQTEN 
FibrocystinBRn   GFHVRGHGCSSEVLWSDNVVHSSLHGIHLYKKREPNNCTGVSGFLAFKNFDYGAMVQTEN 
FibrocystinAMm   GFHVGGHGCSSEVLWSDNVVHSSLHGLHLYKKHESNNCTGVSGFMAFKNFDYGAMVQTEN 
FibrocystinEMm   GFHVGGHGCSSEVLWSDNVVHSSLHGLHLYKKHESNNCTGVSGFMAFKNFDYGAMVQTEN 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
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                       3310      3320      3330      3340      3350      3360 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SVDIQNITLVDNTVGLLAISYVSSAPLRSGSTLQITLRNSVIVATSSSFDCIQDRKAPQS 
FibrocystinBRn   SVDIQNITLVDNTVGLLAISYVSSAPLRSGSTLQITLRNSVIVATSSSFDCIQDRKAPQS 
FibrocystinAMm   SVDIQNITLVDNTVGLLAITYVSSALLSSVSTVQITLRNSVIVATSSSFDCIHDRKAPQS 
FibrocystinEMm   SVDIQNITLVDNTVGLLAITYVSSALLSSVSTVQITLRNSVIVATSSSFDCIHDRKAPQS 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3370      3380      3390      3400      3410      3420 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ANWTSTDRAPSNPRGGRIGILWPVSASEPNGWPQEPWHKVRGGHSVPGIMKLQDVTFSSF 
FibrocystinBRn   ANWTSTDRAPSNPRGGRIGILWPVSASEPNGWPQEPWHKVRGGHSVPGIMKLQDVTFSSF 
FibrocystinAMm   ANWTSTDRAPSNPRGGRIGILWPVSASEPNAWPQEPWHKVRSRHSVPGIMKLQDVTFSSF 
FibrocystinEMm   ANWTSTDRAPSNPRGGRIGILWPVSASEPNAWPQEPWHKVRSRHSVPGIMKLQDVTFSSF 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3430      3440      3450      3460      3470      3480 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   VKSCYSDDLDVCILTNEHSTGIMYPITAERTRMLKIKDKNKFYFLPLQSGKDLVGTICPA 
FibrocystinBRn   VKSCYSDDLDVCILTNEHSTGIMYPITAERTRMLKIKDKNKFYFLPLQSGKDLVGTICPA 
FibrocystinAMm   VKSCYSNDLDVCILPNEYSTGVMYPITAERTRMLGIKDKNKFYFPVLQSSKDLVGTICPT 
FibrocystinEMm   VKSCYSNDLDVCILPNEYSTGVMYPITAERTRMLGIKDKNKFYFPVLQSSKDLVGTICPT 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3490      3500      3510      3520      3530      3540 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SSDCEIPRKYLFTDLDGRTLGLSPPVSVFPRIEEGWTGSFFNTGIFREEQKCTFRAMIQG 
FibrocystinBRn   SSDCEIPRKYLFTDLDGRTLGLSPPVSVFPRIEEGWTGSFFNTGIFREEQKCTFRAMIQG 
FibrocystinAMm   -LVCEYPRKYLFTDLDGRTLGLPPPVSVFPRTEEEWTGSFLNTGIFREEQKCTFRAMNQG 
FibrocystinEMm   -LVCEYPRKYLFTDLDGRTLGLPPPVSVFPRTEEEWTGSFLNTGIFREEQKCTFRAMNQG 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3550      3560      3570      3580      3590      3600 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   FFCKQTEHAVLILDNVDVTWTIPKFYPLVSITNGFVDTFSIVKDSGLCFPTSSPSTFYSI 
FibrocystinBRn   FFCKQTEHAVLILDNVDVTWTIPKFYPLVSITNGFVDTFSIVKDSGLCFPTSSPSTFYSI 
FibrocystinAMm   FFCKQTEHAVLILDNVDATWTIPKSHPLVSVTNGFVDTFSIVKDSDLCPPTSSLSTFYSI 
FibrocystinEMm   FFCKQTEHAVLILDNVDATWTIPKSHPLVSVTNGFVDTFSIVKDSDLCPPTSSLSTFYSI  
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FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3610      3620      3630      3640      3650      3660 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   LPTRQMTKVCFPERTPPFLHFFLLANRRASKLILAVFYNEIQSPYVFLDKSFIPPTPVES 
FibrocystinBRn   LPTRQMTKVCFPERTPPFLHFFLLANRRASKLILAVFYNEIQSPYVFLDKSFIPPTPVES 
FibrocystinAMm   LPTRQMTKVCFPEQTPPFLRFLLLGNQRASKLILAVFYNEIQSPHVFLDKSFIPPTPLES 
FibrocystinEMm   LPTRQMTKVCFPEQTPPFLRFLLLGNQRASKLILAVFYNEIQSPHVFLDKSFIPPTPLES 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3670      3680      3690      3700      3710      3720 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   AFSLLDEPVGANYFDIMNNLLYVVLQGEEAVEIRSSVSIHLALTVTFSVLEKGWEKAVLE 
FibrocystinBRn   AFSLLDEPVGANYFDIMNNLLYVVLQGEEAVEIRSSVSIHLALTVTFSVLEKGWEKAVLE 
FibrocystinAMm   AFSLLAEPSGANYFDIMNNLLYVVLQGEEPVEIHSSVSIHLALTVTFSVLEKGWERAMLE 
FibrocystinEMm   AFSLLAEPSGANYFDIMNNLLYVVLQGEEPVEIHSSVSIHLALTVTFSVLEKGWERAMLE 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3730      3740      3750      3760      3770      3780 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SLRGFFQIDQNQIRLTLEMPGNKETLKAIANSEGKRKRSCPTVTCAVPSSRYVQRRPLMA 
FibrocystinBRn   SLRGFFQIDQNQIRLTLEMPGNKETLKAIANSEGKRKRSCPTVTCAVPSSRYVQRRPLMA 
FibrocystinAMm   SLSDFFQIDPNQIRLTLEMPGNKETLEAIANSERKRKRNCPSVTCGGPSIRYGQRRPLMA 
FibrocystinEMm   SLSDFFQIDPNQIRLTLEMPGNKETLEAIANSERKRKRNCPSVTCGGPSIRYGQRRPLMA 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3790      3800      3810      3820      3830      3840 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   EMASFTITPATTLETFSKVIVFEIGDLPNARDSEFIQSLPSNRLQKLAHQVITAQQTGVL 
FibrocystinBRn   EMASFTITPATTLETFSKVIVFEIGDLPNARDSEFIQSLPSNRLQKLAHQVITAQQTGVL 
FibrocystinAMm   EMTSLKITPATTLETFSKVIVIEVGDLPNIRNSEPIQSLPSNRLQRLVNQVITAQQTGAL 
FibrocystinEMm   EMTSLKITPATTLETFSKVIVIEVGDLPNIRNSEPIQSLPSNRLQRLVNQVITAQQTGAL 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------  
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Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3850      3860      3870      3880      3890      3900 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   ENVLGMTVGALLVAQSEGVTGYRNASSLITGNQIYTRPSVVSILVQPSDGEVGIELPIQP 
FibrocystinBRn   ENVLGMTVGALLVAQSEGVTGYRNASSLITGNQIYTRPSVVSILVQPSDGEVGIELPIQP 
FibrocystinAMm   ENVLGMTVGALLVTQSKGVTGYRNASSLITGNLIYTRPSELSILVQPSDGEVGIELPVQP 
FibrocystinEMm   ENVLGMTVGALLVTQSKGVTGYRNASSLITGNLIYTRPSELSILVQPSDGEVGIELPVQP 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3910      3920      3930      3940      3950      3960 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   RLIFLDEKNERVEALGLPSEPWIISVSLEGTSESMLKGCTQAETQDGYVTFSRLAVLTSG 
FibrocystinBRn   RLIFLDEKNERVEALGLPSEPWIISVSLEGTSESMLKGCTQAETQDGYVTFSRLAVLTSG 
FibrocystinAMm   RLVFLDEKNERVESLGLPSEPWIISVSLEGASESVLKGCTLAETRDGYVTFSRLAVLISG 
FibrocystinEMm   RLVFLDEKNERVESLGLPSEPWIISVSLEGASESVLKGCTLAETRDGYVTFSRLAVLISG 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       3970      3980      3990      4000      4010      4020 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   SNWHLVFTVTFPPGTNLTARSKTFAVLPVAGKERSTIILALSLCSVASWVALSCLICCWF 
FibrocystinBRn   SNWHLVFTVTFPPGTNLTARSKTFAVLPVAGKERSTIILALSLCSVASWVALSCLICCWF 
FibrocystinAMm   SNWHLFFTVISPPGTNFTARSRTFVVLPVASKERSTIILALSLCSVASWVALSCLVCCWF 
FibrocystinEMm   SNWHLFFTVISPPGTNFTARSRTFVVLPVASKERSTIILALSLCSVASWVALSCLVCCWF 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       4030      4040      4050      4060      4070      4080 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   KKSKTRKIKPEDISESQAKEQKKNTHISSKPRELQVKTAKEDAMMGEDMRMKVMEGRQNQ 
FibrocystinBRn   KKSKTRKIKPEDISESQAKEQKKNTHISSKPRELQVKTAKEDAMMGEDMRMKVMEGRQNQ 
FibrocystinAMm   KKSKTRKIKPEDISESQAKEQKKNTHNSSKPRGLQAKTAKENTLMGEDMRMKVMQGMQSQ 
FibrocystinEMm   KKSKTRKIKPEDISESQAKEQKKNTHNSSKPRGLQAKTAKENTLMGEDMRMKVMQGMQSQ 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
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                       4090      4100      4110      4120      4130      4140 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   FSQHSMDGVSKRKVSRRAVPEERTATPALKIPRTTCVPGALPQQLTLPEPGNWQEAQQQL 
FibrocystinBRn   FSQHSMDGVSKRKVSRRAVPEERTATPALKIPRTTCVPGALPQQLTLPEPGNWQEAQQQL 
FibrocystinAMm   FPQHSMDGVSKRKVSRLAVTEERTTTPAPKIPRITCVPGSLAQQLTLQEPGNWQEAQQQL 
FibrocystinEMm   FPQHSMDGVSKRKVSRLAVTEERTTTPAPKIPRITCVPGSLAQQLTLQEPGNWQEAQQQL 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       4150      4160      4170      4180      4190      4200 
                 =========+=========+=========+=========+=========+=========+ 
FibrocystinARn   LRYQLAGRDQLLLLCPDLRQERQQGQEPSQLNKGSGRCMGLSQEKATCVPTETFCLHTAP 
FibrocystinBRn   LRYQLAGRDQLLLLCPDLRQERQQGQEPSQLNKGSGRCMGLSQEKATCVPTETFCLHTAP 
FibrocystinAMm   LRYQLAGRNQLLLLRPDLRQERKQGQEPSQLDKGSDCTG-LSQEKATCIPTETFSLHTAP 
FibrocystinEMm   LRYQLAGRNQLLLLRPDLRQERKQGQEPSQLDKGSDCTG-LSQEKATCIPTETFSLHTAP 
FibrocystinBMm   ------------------------------------------------------------ 
FibrocystinDMm   ------------------------------------------------------------ 
FibrocystinCMm   ------------------------------------------------------------ 
KIM1Rn           ------------------------------------------------------------ 
CcnjlRn          ------------------------------------------------------------ 
Mat2bRn          ------------------------------------------------------------ 
Pttg1Rn          ------------------------------------------------------------ 
Eif4g1Rn         ------------------------------------------------------------ 
Gabrg2Rn         ------------------------------------------------------------ 
C1qtnt2Rn        ------------------------------------------------------------ 
                                                                              
                       
                 ===== 
FibrocystinARn   PETIQ 
FibrocystinBRn   PETIQ 
FibrocystinAMm   PETIQ 
FibrocystinEMm   PETIQ 
FibrocystinBMm   ----- 
FibrocystinDMm   ----- 
FibrocystinCMm   ----- 
KIM1Rn           ----- 
CcnjlRn          ----- 
Mat2bRn          ----- 
Pttg1Rn          ----- 
Eif4g1Rn         ----- 
Gabrg2Rn         ----- 
C1qtnt2Rn        ----- 
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